AP900708-0017 <DOCNO>
The <NA>
study <NA>
by <NA>
the <NA>
Physician_Insurers_Association_of_America <ORGANIZATION>
found <NA>
that <NA>
in <NA>
69_percent <PERCENT>
of <NA>
cases <NA>
where <NA>
claims <NA>
were <NA>
paid <NA>
because <NA>
breast <NA>
cancer <NA>
diagnosis <NA>
was <NA>
delayed, <NA>
the <NA>
patient <NA>
had <NA>
discovered <NA>
the <NA>
lump. <NA>
The <NA>
study, <NA>
released <NA>
at <NA>
the <NA>
association's <NA>
annual <NA>
meeting <NA>
in <NA>
May <DATE>
, <NA>
was <NA>
discussed <NA>
by <NA>
members <NA>
of <NA>
the <NA>
study <NA>
committee <NA>
in <NA>
telephone <NA>
interviews <NA>
last <NA>
week. <NA>
Nearly <NA>
70_percent <PERCENT>
of <NA>
the <NA>
cases <NA>
involved <NA>
women <NA>
under <NA>
age <NA>
50, <NA>
and <NA>
40_percent <PERCENT>
were <NA>
filed <NA>
by <NA>
women <NA>
under <NA>
40. <NA>
This <NA>
was <NA>
the <NA>
case <NA>
for <NA>
55_percent <PERCENT>
of <NA>
the <NA>
women. <NA>
The <NA>
second <NA>
most <NA>
common <NA>
reason, <NA>
found <NA>
in <NA>
35_percent <PERCENT>
of <NA>
cases, <NA>
was <NA>
that <NA>
mammogram <NA>
reports <NA>
were <NA>
negative. <NA>
In <NA>
14_percent <PERCENT>
, <NA>
mammograms <NA>
were <NA>
inconclusive. <NA>
Sylvan <NA>
H. <NA>
Eisman <NA>
,_a_distinguished_professor_emeritus_of_clinical_medicine_at_the_<ORGANIZATION>University_of_Pennsylvania_School_of_Medicine </PERSON>
, <NA>
who <NA>
directed <NA>
the <NA>
study. <NA>
The <NA>
American_Medical_Association <ORGANIZATION>
had <NA>
no <NA>
comment <NA>
on <NA>
the <NA>
findings. <NA>
``It's <NA>
foolish <NA>
not <NA>
to <NA>
do <NA>
it <NA>
(a <NA>
biopsy) <NA>
if <NA>
there's <NA>
reasonable <NA>
cause <NA>
of <NA>
suspicion,'' <NA>
Eisman <PERSON>
said. <NA>
The <NA>
study <NA>
also <NA>
found <NA>
that <NA>
family <NA>
history <NA>
was <NA>
unknown <NA>
in <NA>
37_percent <PERCENT>
of <NA>
the <NA>
cases, <NA>
though <NA>
women <NA>
with <NA>
a <NA>
family <NA>
history <NA>
of <NA>
breast <NA>
cancer <NA>
are <NA>
at <NA>
higher <NA>
risk <NA>
of <NA>
getting <NA>
the <NA>
disease <NA>
themselves. <NA>
The <NA>
American_Cancer_Society <ORGANIZATION>
recommends <NA>
a <NA>
mammogram <NA>
for <NA>
women <NA>
at <NA>
around <NA>
age <NA>
35 <NA>
and <NA>
regular <NA>
mammograms <NA>
every <NA>
one <NA>
or <NA>
two <NA>
years <NA>
beginning <NA>
at <NA>
age <NA>
40 <NA>
and <NA>
annually <NA>
after <NA>
age <NA>
50. <NA>
The <NA>
cancer <NA>
society <NA>
estimates <NA>
that <NA>
breast <NA>
cancer <NA>
will <NA>
be <NA>
diagnosed <NA>
in <NA>
142,000 <NA>
women <NA>
in <NA>
the <NA>
United_States <LOCATION>
this <NA>
year <NA>
and <NA>
will <NA>
cause <NA>
43,000 <NA>
deaths. <NA>
SJMN91-06171168 <DOCNO>
This <NA>
year, <NA>
about <NA>
175,000 <NA>
women <NA>
across <NA>
the <NA>
United_States <LOCATION>
will <NA>
contract <NA>
the <NA>
disease, <NA>
while <NA>
about <NA>
44,500 <NA>
women <NA>
and <NA>
300 <NA>
men <NA>
(it <NA>
is <NA>
possible <NA>
but <NA>
rare <NA>
for <NA>
men <NA>
to <NA>
contract <NA>
the <NA>
disease) <NA>
will <NA>
die <NA>
from <NA>
it. <NA>
; <NA>
According <NA>
to <NA>
the <NA>
latest <NA>
( <NA>
1988 <DATE>
) <NA>
figures <NA>
released <NA>
by <NA>
the <NA>
Northern_California_Cancer_Center <ORGANIZATION>
's <NA>
Bay <NA>
Area <NA>
Cancer <NA>
Registry, <NA>
there <NA>
were <NA>
789 <NA>
cases <NA>
of <NA>
breast <NA>
cancer <NA>
in <NA>
Santa_Clara_County <LOCATION>
. <NA>
In <NA>
Alameda_County <LOCATION>
there <NA>
were <NA>
782 <NA>
and <NA>
in <NA>
San_Mateo_County <LOCATION>
441.; <NA>
The <NA>
American <NA>
Cancer <NA>
Society <NA>
says <NA>
those <NA>
most <NA>
at <NA>
risk <NA>
are <NA>
women <NA>
over <NA>
50, <NA>
those <NA>
with <NA>
a <NA>
family <NA>
history <NA>
of <NA>
breast <NA>
cancer <NA>
and <NA>
women <NA>
who <NA>
have <NA>
never <NA>
had <NA>
children <NA>
or <NA>
who <NA>
had <NA>
their <NA>
first <NA>
child <NA>
after <NA>
age <NA>
30.; <NA>
The <NA>
five-year <NA>
survival <NA>
rate <NA>
for <NA>
localized <NA>
breast <NA>
cancer <NA>
is <NA>
91 <NA>
percent. <NA>
; <NA>
The <NA>
American_Cancer_Society <ORGANIZATION>
recommends <NA>
these <NA>
guidelines <NA>
for <NA>
breast <NA>
cancer <NA>
detection:; <NA>
(check) <NA>
Women <NA>
age <NA>
20 <NA>
and <NA>
over <NA>
should <NA>
perform <NA>
a <NA>
self-examination <NA>
every <NA>
month. <NA>
FBIS3-22640 <DOCNO>
Language: <NA>
English <FÊP=105>
Article <NA>
Type:CSO <NA>
[Text] <NA>
Varanasi <LOCATION>
, <NA>
Jan <NA>
28 <NA>
-- <NA>
There <NA>
are <NA>
about <NA>
1.7 <NA>
million <NA>
cancer <NA>
patients <NA>
in <NA>
India <LOCATION>
and <NA>
about <NA>
30,000 <NA>
to <NA>
35,000 <NA>
people <NA>
die <NA>
annually <NA>
from <NA>
this <NA>
disease, <NA>
a <NA>
medical <NA>
expert <NA>
warned <NA>
today. <NA>
Kohli <NA>
,_Deputy_Director_General,_<ORGANIZATION>Ministry_of_Health </PERSON>
told <NA>
the <NA>
first <NA>
international <NA>
conference <NA>
of <NA>
the <NA>
Indian_Association_of_Alliative_Care <ORGANIZATION>
here <NA>
that <NA>
cancer <NA>
is <NA>
no <NA>
longer <NA>
a <NA>
problem <NA>
of <NA>
developed <NA>
countries <NA>
but <NA>
a <NA>
matter <NA>
of <NA>
concern <NA>
for <NA>
developing <NA>
countries <NA>
also. <NA>
In <NA>
India <LOCATION>
, <NA>
breast, <NA>
cervix <NA>
and <NA>
uterus <NA>
cancer <NA>
was <NA>
most <NA>
common <NA>
in <NA>
women <NA>
while <NA>
men <NA>
were <NA>
more <NA>
prone <NA>
to <NA>
mouth, <NA>
larynx <NA>
and <NA>
lung <NA>
cancer. <NA>
Considering <NA>
this, <NA>
the <NA>
Union_Government <ORGANIZATION>
had <NA>
chalked <NA>
out <NA>
a <NA>
plan <NA>
of <NA>
action <NA>
for <NA>
prevention <NA>
of <NA>
cancer <NA>
at <NA>
an <NA>
early <NA>
stage, <NA>
prevention <NA>
of <NA>
tobacco <NA>
intake <NA>
in <NA>
any <NA>
form, <NA>
early <NA>
diagnosis <NA>
of <NA>
cancer <NA>
specially <NA>
in <NA>
cervic, <NA>
breast <NA>
and <NA>
mouth. <NA>
She <NA>
said <NA>
that <NA>
it <NA>
was <NA>
most <NA>
unfortunate <NA>
that <NA>
most <NA>
of <NA>
the <NA>
cancer <NA>
patients <NA>
in <NA>
India <LOCATION>
reported <NA>
at <NA>
a <NA>
very <NA>
advanced <NA>
stage <NA>
in <NA>
hospitals <NA>
and <NA>
regional <NA>
cancer <NA>
centres, <NA>
rendering <NA>
the <NA>
therapy <NA>
ineffective. <NA>
She <NA>
suggested <NA>
that <NA>
since <NA>
there <NA>
were <NA>
more <NA>
advanced <NA>
cancer <NA>
cases <NA>
in <NA>
India <LOCATION>
, <NA>
Palliative <NA>
therapy <NA>
should <NA>
be <NA>
provided <NA>
to <NA>
such <NA>
patients <NA>
effectively. <NA>
In <NA>
India <LOCATION>
, <NA>
30_percent <PERCENT>
of <NA>
the <NA>
cancer <NA>
cases <NA>
could <NA>
not <NA>
be <NA>
treated <NA>
with <NA>
active <NA>
therapy <NA>
and <NA>
"we <NA>
could <NA>
provide <NA>
only <NA>
palliative <NA>
therapy <NA>
in <NA>
such <NA>
cases," <NA>
The <NA>
Union_Government <ORGANIZATION>
had <NA>
started <NA>
producing <NA>
oral <NA>
morphine <NA>
in <NA>
collaboration <NA>
with <NA>
the <NA>
World_Health_Organisation <ORGANIZATION>
directly <NA>
to <NA>
10 <NA>
identified <NA>
regional <NA>
cancer <NA>
centres. <NA>
Pain <NA>
could <NA>
be <NA>
minimised <NA>
in <NA>
80 <NA>
to <NA>
98_percent <PERCENT>
of <NA>
cancer <NA>
cases <NA>
if <NA>
right <NA>
drug <NA>
in <NA>
right <NA>
dose <NA>
and <NA>
at <NA>
right <NA>
time <NA>
was <NA>
given, <NA>
she <NA>
said. <NA>
AP880726-0024 <DOCNO>
The <NA>
gene <NA>
was <NA>
the <NA>
first <NA>
of <NA>
a <NA>
new <NA>
group <NA>
of <NA>
anti-cancer <NA>
genes <NA>
that <NA>
normally <NA>
protect <NA>
against <NA>
cancer <NA>
but <NA>
allow <NA>
cancer <NA>
to <NA>
appear <NA>
when <NA>
defective, <NA>
said <NA>
Ray_White <PERSON>
of <NA>
the <NA>
Howard_Hughes_Medical_Institute <ORGANIZATION>
at <NA>
the <NA>
University_of_Utah <ORGANIZATION>
in <NA>
Salt_Lake_City <LOCATION>
. <NA>
The <NA>
findings <NA>
that <NA>
the <NA>
gene <NA>
is <NA>
linked <NA>
to <NA>
breast <NA>
cancer <NA>
and <NA>
so-called <NA>
small-cell <NA>
lung <NA>
cancer <NA>
suggest <NA>
that <NA>
it <NA>
and <NA>
other <NA>
anti-cancer <NA>
genes <NA>
could <NA>
play <NA>
a <NA>
major <NA>
role <NA>
in <NA>
many <NA>
types <NA>
of <NA>
human <NA>
cancer, <NA>
White <NA>
told <NA>
genetics <NA>
students <NA>
at <NA>
the <NA>
Jackson_Laboratory <ORGANIZATION>
in <NA>
Bar_Harbor <LOCATION>
on <NA>
Monday <DATE>
. <NA>
Identifying <NA>
those <NA>
genes <NA>
and <NA>
determining <NA>
how <NA>
they <NA>
go <NA>
wrong <NA>
does <NA>
not <NA>
mean <NA>
cancer <NA>
will <NA>
then <NA>
be <NA>
eliminated, <NA>
White <ORGANIZATION>
said. <NA>
White <NA>
and <NA>
Webster_Cavenee <PERSON>
at <NA>
the <NA>
Ludwig_Institute_for_Cancer_Research <ORGANIZATION>
in <NA>
Montreal <LOCATION>
were <NA>
among <NA>
the <NA>
scientists <NA>
who <NA>
made <NA>
that <NA>
initial <NA>
discovery <NA>
and <NA>
learned <NA>
how <NA>
the <NA>
gene <NA>
worked. <NA>
More <NA>
recently, <NA>
researchers <NA>
at <NA>
the <NA>
University_of_California <ORGANIZATION>
, <NA>
San_Francisco <LOCATION>
, <NA>
led <NA>
by <NA>
Wen-Hwa_Lee <PERSON>
and <NA>
Eva_Lee <PERSON>
, <NA>
have <NA>
found <NA>
that <NA>
the <NA>
gene <NA>
is <NA>
defective <NA>
in <NA>
certain <NA>
breast <NA>
cancer <NA>
cells <NA>
grown <NA>
in <NA>
the <NA>
laboratory. <NA>
About <NA>
the <NA>
same <NA>
time, <NA>
Frederic_Kaye <PERSON>
and <NA>
colleagues <NA>
at <NA>
the <NA>
National_Cancer_Institute-Navy_Medical_Oncology_Branch <ORGANIZATION>
reported <NA>
seeing <NA>
retinoblastoma <NA>
gene <NA>
defects <NA>
in <NA>
small-cell <NA>
lung <NA>
cancer <NA>
cells <NA>
in <NA>
the <NA>
laboratory. <NA>
Retinoblastoma <NA>
affects <NA>
perhaps <NA>
1,000 <NA>
Americans <NA>
annually, <NA>
but <NA>
small-cell <NA>
lung <NA>
cancer <NA>
strikes <NA>
30,000 <NA>
people <NA>
in <NA>
the <NA>
United_States <LOCATION>
every <NA>
year, <NA>
and <NA>
breast <NA>
cancer <NA>
strikes <NA>
130,000. <NA>
He <NA>
said <NA>
Monday <DATE>
he <NA>
has <NA>
now <NA>
shown <NA>
that <NA>
this <NA>
anti-cancer <NA>
gene <NA>
plays <NA>
a <NA>
role <NA>
in <NA>
the <NA>
much <NA>
more <NA>
common <NA>
non-inherited <NA>
form <NA>
of <NA>
colon <NA>
cancer <NA>
that <NA>
is <NA>
another <NA>
one <NA>
of <NA>
the <NA>
country's <NA>
leading <NA>
cancer <NA>
killers. <NA>
Bert_Vogelstein <PERSON>
of <NA>
the <NA>
Johns_Hopkins_University_School_of_Medicine <ORGANIZATION>
in <NA>
Baltimore <LOCATION>
also <NA>
has <NA>
identified <NA>
several <NA>
other <NA>
genetic <NA>
defects <NA>
associated <NA>
with <NA>
colon <NA>
cancer. <NA>
``You <NA>
can <NA>
look <NA>
at <NA>
these <NA>
genetic <NA>
alterations <NA>
as <NA>
the <NA>
causes <NA>
of <NA>
cancer <NA>
_ <NA>
just <NA>
as <NA>
you <NA>
can <NA>
look <NA>
at <NA>
bacteria <NA>
as <NA>
the <NA>
causes <NA>
of <NA>
infection,'' <NA>
Vogelstein <PERSON>
said <NA>
in <NA>
a <NA>
telephone <NA>
interview. <NA>
FT941-1421 <DOCNO>
Striking <NA>
regional <NA>
variations <NA>
are <NA>
revealed <NA>
by <NA>
the <NA>
first <NA>
atlas <NA>
of <NA>
cancer <NA>
incidence <NA>
in <NA>
England <LOCATION>
and <NA>
Wales <LOCATION>
, <NA>
published <NA>
yesterday, <NA>
Clive_Cookson <PERSON>
writes. <NA>
The <NA>
atlas, <NA>
commissioned <NA>
by <NA>
the <NA>
Cancer_Research_Campaign <ORGANIZATION>
, <NA>
shows <NA>
that <NA>
lung <NA>
cancer, <NA>
the <NA>
most <NA>
common <NA>
form <NA>
of <NA>
the <NA>
disease <NA>
in <NA>
men, <NA>
is <NA>
much <NA>
more <NA>
prevalent <NA>
in <NA>
the <NA>
north <NA>
than <NA>
in <NA>
the <NA>
south. <NA>
Dr <NA>
Isabel_Silva <PERSON>
and <NA>
Dr <NA>
Anthony_Swerdlow <PERSON>
of <NA>
the <NA>
London_School_of_Hygiene_and_Tropical_Medicine <ORGANIZATION>
analysed <NA>
information <NA>
about <NA>
3m <NA>
new <NA>
cancer <NA>
patients <NA>
between <NA>
1968 <DATE>
and <NA>
1985 <DATE>
to <NA>
give <NA>
a <NA>
county-by-county <NA>
variation <NA>
in <NA>
cancer <NA>
risks. <NA>
Malignant <NA>
melanoma, <NA>
the <NA>
most <NA>
virulent <NA>
skin <NA>
cancer, <NA>
has <NA>
a <NA>
strong <NA>
south/north <NA>
gradient <NA>
- <NA>
someone <NA>
living <NA>
on <NA>
the <NA>
south <NA>
coast <NA>
is <NA>
three <NA>
times <NA>
more <NA>
likely <NA>
to <NA>
suffer <NA>
than <NA>
someone <NA>
in <NA>
northern_England <LOCATION>
. <NA>
The <NA>
fact <NA>
that <NA>
southern <NA>
women <NA>
have <NA>
fewer <NA>
children <NA>
on <NA>
average <NA>
may <NA>
be <NA>
a <NA>
partial <NA>
explanation, <NA>
Drs <NA>
Silver <NA>
and <NA>
Swerdlow <PERSON>
say, <NA>
because <NA>
they <NA>
have <NA>
higher <NA>
levels <NA>
of <NA>
the <NA>
hormones <NA>
related <NA>
to <NA>
these <NA>
cancers. <NA>
Atlas <NA>
of <NA>
Cancer_Incidence_in_England_&amp;_Wales <ORGANIZATION>
. <NA>
Oxford_University_Press <ORGANIZATION>
. <NA>
AP890524-0044 <DOCNO>
The <NA>
findings <NA>
were <NA>
presented <NA>
Tuesday <DATE>
by <NA>
Oliver <NA>
W. <NA>
Press <NA>
of_the_<ORGANIZATION>University_of_Washington </PERSON>
to <NA>
the <NA>
annual <NA>
meeting <NA>
of <NA>
the <NA>
American_Society_of_Clinical_Oncology <ORGANIZATION>
. <NA>
Bruce <NA>
Cheson <NA>
of_the_<ORGANIZATION>National_Cancer_Institute </PERSON>
. <NA>
Donald <NA>
S. <NA>
Kaufman <NA>
of_<ORGANIZATION>Massachusetts_General_Hospital </PERSON>
reported <NA>
preliminary <NA>
evidence <NA>
that <NA>
a <NA>
combination <NA>
of <NA>
three <NA>
drugs <NA>
followed <NA>
by <NA>
radiation <NA>
can <NA>
eliminate <NA>
bladder <NA>
cancer. <NA>
Alexander <NA>
Paterson <NA>
of_<ORGANIZATION>Cross_Cancer_Institute </PERSON>
in <NA>
Edmonton <LOCATION>
, <NA>
Alberta <LOCATION>
, <NA>
has <NA>
found <NA>
that <NA>
those <NA>
who <NA>
relapse <NA>
often <NA>
carry <NA>
multiple <NA>
copies <NA>
of <NA>
an <NA>
abnormal <NA>
gene, <NA>
known <NA>
as <NA>
an <NA>
oncogene, <NA>
inside <NA>
their <NA>
tumors. <NA>
Jude <NA>
Children's <NA>
Research <NA>
Hospital <NA>
in_<LOCATION>Memphis </ORGANIZATION>
, <NA>
Tenn. <LOCATION>
, <NA>
said <NA>
a <NA>
review <NA>
shows <NA>
that <NA>
about <NA>
two-thirds <NA>
of <NA>
all <NA>
youngsters <NA>
with <NA>
acute <NA>
lymphocytic <NA>
leukemia, <NA>
the <NA>
most <NA>
common <NA>
childhood <NA>
cancer, <NA>
can <NA>
now <NA>
be <NA>
cured. <NA>
James <NA>
D. <NA>
Levine <NA>
of_<ORGANIZATION>New_England_Deaconess_Hospital </PERSON>
in <NA>
Boston <LOCATION>
said <NA>
a <NA>
new <NA>
treatment <NA>
can <NA>
overcome <NA>
low <NA>
levels <NA>
of <NA>
white <NA>
blood <NA>
cells, <NA>
which <NA>
are <NA>
a <NA>
common <NA>
side <NA>
effect <NA>
of <NA>
treatment <NA>
with <NA>
the <NA>
drug <NA>
AZT <NA>
in <NA>
AIDS <NA>
patients. <NA>
Gregory <NA>
Wolf <NA>
of_the_<ORGANIZATION>University_of_Michigan </PERSON>
said <NA>
a <NA>
combination <NA>
of <NA>
chemotherapy <NA>
and <NA>
radiation <NA>
shows <NA>
promise <NA>
of <NA>
allowing <NA>
doctors <NA>
to <NA>
avoid <NA>
removing <NA>
the <NA>
voicebox <NA>
in <NA>
victims <NA>
of <NA>
advanced <NA>
throat <NA>
cancer. <NA>
Harinder <NA>
Garewal <NA>
of_the_<ORGANIZATION>Veterans_Administration_Medical_Center </PERSON>
in <NA>
Tucson <LOCATION>
said <NA>
initial <NA>
studies <NA>
suggest <NA>
that <NA>
a <NA>
nutrient <NA>
called <NA>
beta <NA>
carotene <NA>
can <NA>
reverse <NA>
precancerous <NA>
growths <NA>
in <NA>
the <NA>
mouth. <NA>
WSJ910425-0087 <DOCNO>
"It's <NA>
a <NA>
valuable <NA>
new <NA>
tool <NA>
for <NA>
diagnosing <NA>
prostate <NA>
cancer, <NA>
an <NA>
area <NA>
where <NA>
we're <NA>
not <NA>
doing <NA>
very <NA>
well," <NA>
says <NA>
William_J._Catalona <PERSON>
, <NA>
chief <NA>
of <NA>
urologic <NA>
surgery <NA>
at <NA>
Washington_University_School_of_Medicine <ORGANIZATION>
and <NA>
Barnes_Hospital <ORGANIZATION>
, <NA>
Moreover, <NA>
some <NA>
studies <NA>
based <NA>
on <NA>
autopsies <NA>
show <NA>
that <NA>
more <NA>
than <NA>
30% <PERCENT>
of <NA>
men <NA>
over <NA>
50 <NA>
have <NA>
evidence <NA>
of <NA>
prostate <NA>
cancer <NA>
that <NA>
remains <NA>
latent <NA>
and <NA>
never <NA>
causes <NA>
clinical <NA>
problems. <NA>
"The <NA>
detection <NA>
of <NA>
such <NA>
tumors <NA>
exposes <NA>
these <NA>
patients <NA>
to <NA>
the <NA>
risks <NA>
of <NA>
treatment <NA>
without <NA>
any <NA>
potential <NA>
for <NA>
benefit," <NA>
Gerald_W._Chodak <PERSON>
and <NA>
Glenn_S._Gerber <PERSON>
of <NA>
the <NA>
University_of_Chicago_School_of_Medicine <ORGANIZATION>
said <NA>
last <NA>
month <NA>
in <NA>
the <NA>
Journal <NA>
of <NA>
the <NA>
National_Cancer_Institute <ORGANIZATION>
. <NA>
About <NA>
100,000 <NA>
cases <NA>
of <NA>
prostate <NA>
cancer <NA>
are <NA>
diagnosed <NA>
in <NA>
the <NA>
U.S. <LOCATION>
each <NA>
year, <NA>
and <NA>
about <NA>
30,000 <NA>
men <NA>
die <NA>
annually <NA>
of <NA>
the <NA>
disease. <NA>
In <NA>
the <NA>
study, <NA>
it <NA>
missed <NA>
20% <PERCENT>
of <NA>
the <NA>
cancers <NA>
that <NA>
were <NA>
present <NA>
and <NA>
showed <NA>
false <NA>
positives <NA>
in <NA>
16% <PERCENT>
of <NA>
cases <NA>
-- <NA>
a <NA>
significant <NA>
error <NA>
rate <NA>
that <NA>
lends <NA>
support <NA>
to <NA>
those <NA>
who <NA>
say <NA>
the <NA>
evidence <NA>
doesn't <NA>
back <NA>
up <NA>
a <NA>
broad <NA>
screening <NA>
effort. <NA>
Nearly <NA>
2,000 <NA>
men <NA>
were <NA>
included <NA>
in <NA>
the <NA>
study, <NA>
financed <NA>
in <NA>
part <NA>
by <NA>
Hybritech_Inc. <ORGANIZATION>
, <NA>
a <NA>
San_Diego <LOCATION>
, <NA>
Calif. <LOCATION>
, <NA>
company <NA>
that <NA>
makes <NA>
the <NA>
blood <NA>
test. <NA>
Researchers <NA>
took <NA>
blood <NA>
tests <NA>
of <NA>
1,653 <NA>
healthy <NA>
men <NA>
over <NA>
50, <NA>
with <NA>
no <NA>
evidence <NA>
of <NA>
cancer <NA>
or <NA>
benign <NA>
prostate <NA>
disease, <NA>
and <NA>
measured <NA>
levels <NA>
of <NA>
prostate-specific <NA>
antigen, <NA>
or <NA>
PSA <ORGANIZATION>
, <NA>
a <NA>
protein <NA>
produced <NA>
by <NA>
prostate <NA>
cells. <NA>
The <NA>
researchers <NA>
found <NA>
that <NA>
92% <PERCENT>
of <NA>
the <NA>
1,653 <NA>
men <NA>
in <NA>
the <NA>
study <NA>
had <NA>
normal <NA>
PSA <ORGANIZATION>
levels; <NA>
6% <PERCENT>
, <NA>
or <NA>
107 <NA>
men, <NA>
had <NA>
mildly <NA>
elevated <NA>
levels; <NA>
and <NA>
2% <PERCENT>
, <NA>
or <NA>
30, <NA>
had <NA>
high <NA>
levels. <NA>
Overall, <NA>
112 <NA>
men <NA>
had <NA>
biopsies, <NA>
of <NA>
whom <NA>
37, <NA>
or <NA>
33% <PERCENT>
had <NA>
cancer. <NA>
A <NA>
high <NA>
PSA <ORGANIZATION>
level <NA>
was <NA>
a <NA>
major <NA>
predictor <NA>
of <NA>
cancer: <NA>
22% <PERCENT>
of <NA>
men <NA>
with <NA>
mildly <NA>
elevated <NA>
levels, <NA>
and <NA>
67% <PERCENT>
of <NA>
those <NA>
with <NA>
high <NA>
levels, <NA>
had <NA>
cancer. <NA>
Men <NA>
with <NA>
elevated <NA>
PSA <ORGANIZATION>
but <NA>
no <NA>
cancer <NA>
had <NA>
benign <NA>
prostate <NA>
disease <NA>
or <NA>
inflammation <NA>
of <NA>
the <NA>
gland. <NA>
Ultrasound <NA>
alone <NA>
missed <NA>
43% <PERCENT>
, <NA>
they <NA>
said. <NA>
The <NA>
National_Cancer_Institute <ORGANIZATION>
plans <NA>
a <NA>
major <NA>
study <NA>
of <NA>
the <NA>
effectiveness <NA>
of <NA>
screening <NA>
and <NA>
early <NA>
treatment, <NA>
but <NA>
results <NA>
won't <NA>
be <NA>
known <NA>
until <NA>
late <NA>
in <NA>
the <NA>
next <NA>
decade. <NA>
AP890728-0022 <DOCNO>
Smoking <NA>
among <NA>
American <NA>
men <NA>
has <NA>
been <NA>
dropping <NA>
since <NA>
the <NA>
early <NA>
1950s <DATE>
, <NA>
but <NA>
federal <NA>
researchers <NA>
say <NA>
women <NA>
kept <NA>
taking <NA>
up <NA>
the <NA>
habit <NA>
into <NA>
the <NA>
next <NA>
decade <NA>
and <NA>
are <NA>
now <NA>
paying <NA>
the <NA>
price <NA>
with <NA>
higher <NA>
rates <NA>
of <NA>
lung <NA>
cancer. <NA>
Edward <NA>
J. <NA>
Sondik <NA>
,_a_<ORGANIZATION>National_Cancer_Institute </PERSON>
specialist <NA>
who <NA>
helped <NA>
prepare <NA>
a <NA>
federal <NA>
health <NA>
report <NA>
on <NA>
smoking <NA>
and <NA>
cancer. <NA>
The <NA>
Atlanta-based <NA>
Centers_for_Disease_Control <ORGANIZATION>
reported <NA>
Thursday <DATE>
that <NA>
lung <NA>
cancer <NA>
deaths <NA>
increased <NA>
15_percent <PERCENT>
in <NA>
the <NA>
United_States <LOCATION>
between <NA>
1979 <DATE>
and <NA>
1986 <DATE>
, <NA>
to <NA>
a <NA>
rate <NA>
of <NA>
about <NA>
50 <NA>
deaths <NA>
per <NA>
100,000 <NA>
people. <NA>
More <NA>
men <NA>
than <NA>
women <NA>
die <NA>
of <NA>
lung <NA>
cancer <NA>
_ <NA>
about <NA>
74 <NA>
deaths <NA>
per <NA>
100,000 <NA>
for <NA>
males <NA>
in <NA>
1986 <DATE>
, <NA>
compared <NA>
to <NA>
27 <NA>
per <NA>
100,000 <NA>
for <NA>
women. <NA>
Between <NA>
1979 <DATE>
and <NA>
1986 <DATE>
, <NA>
the <NA>
lung <NA>
cancer <NA>
death <NA>
rate <NA>
for <NA>
women <NA>
jumped <NA>
44_percent <PERCENT>
, <NA>
while <NA>
the <NA>
rate <NA>
for <NA>
men <NA>
was <NA>
up <NA>
just <NA>
7_percent <PERCENT>
. <NA>
The <NA>
CDC <ORGANIZATION>
said <NA>
male <NA>
smoking <NA>
has <NA>
been <NA>
on <NA>
the <NA>
decline <NA>
since <NA>
the <NA>
early <NA>
1950s <DATE>
, <NA>
but <NA>
smoking <NA>
among <NA>
women <NA>
peaked <NA>
at <NA>
about <NA>
1965 <DATE>
. <NA>
The <NA>
recent <NA>
dropoff <NA>
in <NA>
smoking <NA>
among <NA>
women <NA>
_ <NA>
from <NA>
32_percent <PERCENT>
in <NA>
1965 <DATE>
to <NA>
27_percent <PERCENT>
in <NA>
1987 <DATE>
studies <NA>
_ <NA>
isn't <NA>
nearly <NA>
as <NA>
sharp <NA>
as <NA>
the <NA>
drop <NA>
in <NA>
smoking <NA>
by <NA>
men <NA>
_ <NA>
from <NA>
50_percent <PERCENT>
to <NA>
32_percent <PERCENT>
. <NA>
``The <NA>
men <NA>
are <NA>
in <NA>
a <NA>
very <NA>
significant <NA>
downward <NA>
trend, <NA>
while <NA>
the <NA>
women <NA>
_ <NA>
a <NA>
lot <NA>
of <NA>
them <NA>
were <NA>
taking <NA>
up <NA>
smoking <NA>
(in <NA>
the <NA>
1950s <DATE>
and <NA>
'60s),'' <NA>
Sondik <PERSON>
said. <NA>
Statistically, <NA>
the <NA>
CDC <ORGANIZATION>
reported, <NA>
peaks <NA>
in <NA>
smoking <NA>
seem <NA>
to <NA>
be <NA>
followed <NA>
by <NA>
peaks <NA>
in <NA>
lung <NA>
cancer <NA>
deaths <NA>
about <NA>
35 <NA>
years <NA>
later. <NA>
``The <NA>
burden <NA>
of <NA>
lung <NA>
cancer <NA>
and <NA>
other <NA>
smoking-related <NA>
chronic <NA>
diseases <NA>
(such <NA>
as <NA>
bronchitis <NA>
and <NA>
emphysema) <NA>
will <NA>
be <NA>
substantially <NA>
higher <NA>
... <NA>
for <NA>
many <NA>
decades <NA>
because <NA>
of <NA>
the <NA>
long <NA>
latency <NA>
periods <NA>
between <NA>
exposure <NA>
to <NA>
tobacco <NA>
and <NA>
onset <NA>
of <NA>
these <NA>
diseases,'' <NA>
the <NA>
CDC <ORGANIZATION>
said. <NA>
The <NA>
CDC <ORGANIZATION>
noted <NA>
that <NA>
lung <NA>
cancer <NA>
already <NA>
has <NA>
passed <NA>
breast <NA>
cancer <NA>
as <NA>
the <NA>
most <NA>
common <NA>
cause <NA>
of <NA>
cancer <NA>
death <NA>
among <NA>
women. <NA>
While <NA>
almost <NA>
half <NA>
of <NA>
all <NA>
Americans <NA>
who <NA>
ever <NA>
took <NA>
up <NA>
smoking <NA>
have <NA>
quit, <NA>
the <NA>
CDC <ORGANIZATION>
said, <NA>
more <NA>
than <NA>
50 <NA>
million <NA>
people <NA>
in <NA>
the <NA>
United_States <LOCATION>
continue <NA>
to <NA>
smoke. <NA>
In <NA>
1986 <DATE>
, <NA>
the <NA>
last <NA>
year <NA>
statistics <NA>
are <NA>
available, <NA>
85,050 <NA>
men <NA>
died <NA>
of <NA>
lung <NA>
cancer <NA>
in <NA>
the <NA>
United_States <LOCATION>
, <NA>
compared <NA>
to <NA>
40,461 <NA>
women, <NA>
the <NA>
CDC <ORGANIZATION>
said. <NA>
The <NA>
lung <NA>
cancer <NA>
death <NA>
rates <NA>
are <NA>
about <NA>
the <NA>
same <NA>
for <NA>
white <NA>
females <NA>
and <NA>
black <NA>
females <NA>
_ <NA>
27.4 <NA>
per <NA>
100,000 <NA>
for <NA>
white <NA>
women <NA>
and <NA>
26.4 <NA>
for <NA>
black <NA>
women <NA>
in <NA>
1986 <DATE>
. <NA>
The <NA>
highest <NA>
lung <NA>
cancer <NA>
death <NA>
rate <NA>
among <NA>
the <NA>
states <NA>
in <NA>
1986 <DATE>
was <NA>
in <NA>
Alaska <LOCATION>
, <NA>
with <NA>
148 <NA>
such <NA>
deaths <NA>
for <NA>
a <NA>
rate <NA>
of <NA>
70.5 <NA>
per <NA>
100,000 <NA>
people. <NA>
The <NA>
lowest <NA>
was <NA>
in <NA>
Utah <LOCATION>
, <NA>
with <NA>
275 <NA>
such <NA>
deaths, <NA>
or <NA>
a <NA>
rate <NA>
of <NA>
24.3. <NA>
AP890309-0132 <DOCNO>
The <NA>
number <NA>
of <NA>
older <NA>
women <NA>
getting <NA>
mammograms <NA>
increased <NA>
noticeably <NA>
after <NA>
Nancy_Reagan <PERSON>
's <NA>
breast <NA>
cancer <NA>
diagnosis, <NA>
researchers <NA>
said <NA>
Thursday <DATE>
. <NA>
A <NA>
survey <NA>
taken <NA>
in <NA>
33 <NA>
states <NA>
by <NA>
the <NA>
Centers_for_Disease_Control <ORGANIZATION>
found <NA>
that <NA>
38_percent <PERCENT>
of <NA>
women <NA>
age <NA>
50 <NA>
and <NA>
up <NA>
questioned <NA>
in <NA>
November <DATE>
and <NA>
December_1987 <DATE>
said <NA>
they <NA>
had <NA>
received <NA>
a <NA>
screening <NA>
mammogram <NA>
for <NA>
breast <NA>
cancer <NA>
within <NA>
the <NA>
previous <NA>
year. <NA>
That <NA>
was <NA>
up <NA>
nearly <NA>
half <NA>
again <NA>
from <NA>
the <NA>
26_percent <PERCENT>
the <NA>
survey <NA>
found <NA>
in <NA>
the <NA>
first <NA>
two <NA>
months <NA>
of <NA>
that <NA>
year. <NA>
Reagan <NA>
's_diagnosis_for_breast_cancer_occurred_in_<DATE>October_1987 </PERSON>
when <NA>
she <NA>
was <NA>
first <NA>
lady. <NA>
In <NA>
March,_April <DATE>
and <NA>
May <DATE>
the <NA>
American_Cancer_Society <ORGANIZATION>
conducted <NA>
a <NA>
media <NA>
campaign <NA>
to <NA>
promote <NA>
screening <NA>
for <NA>
breast <NA>
cancer. <NA>
``The <NA>
percentage <NA>
of <NA>
women <NA>
who <NA>
reported <NA>
being <NA>
screened <NA>
increased <NA>
coincident <NA>
with <NA>
the <NA>
ACS <ORGANIZATION>
... <NA>
campaign <NA>
and <NA>
again <NA>
after <NA>
the <NA>
diagnosis <NA>
of <NA>
Reagan <NA>
's_breast_cancer,''_the_<ORGANIZATION>CDC </PERSON>
said. <NA>
Data <NA>
from <NA>
the <NA>
CDC <ORGANIZATION>
survey <NA>
``suggest <NA>
that <NA>
the <NA>
media <NA>
events <NA>
and <NA>
educational <NA>
activities <NA>
were <NA>
accompanied <NA>
by <NA>
increases <NA>
in <NA>
screening <NA>
mammograms,'' <NA>
the <NA>
agency <NA>
said. <NA>
Medical <NA>
centers <NA>
in <NA>
the <NA>
United_States <LOCATION>
reported <NA>
after <NA>
She <NA>
later <NA>
was <NA>
honored <NA>
with <NA>
an <NA>
American_Cancer_Society_Courage_Award <ORGANIZATION>
for <NA>
encouraging <NA>
women <NA>
to <NA>
check <NA>
for <NA>
breast <NA>
cancer. <NA>
The <NA>
ACS <ORGANIZATION>
recommends <NA>
that <NA>
all <NA>
women <NA>
50 <NA>
or <NA>
older <NA>
have <NA>
a <NA>
mammogram <NA>
each <NA>
year, <NA>
but <NA>
studies <NA>
have <NA>
found <NA>
that <NA>
most <NA>
women <NA>
in <NA>
that <NA>
group <NA>
have <NA>
never <NA>
had <NA>
a <NA>
mammogram. <NA>
Cancer <NA>
specialists <NA>
at <NA>
the <NA>
CDC <ORGANIZATION>
and <NA>
elsewhere <NA>
say <NA>
increased <NA>
use <NA>
of <NA>
mammograms <NA>
would <NA>
increase <NA>
early <NA>
detection <NA>
of <NA>
breast <NA>
cancer, <NA>
raising <NA>
survival <NA>
rates <NA>
for <NA>
patients. <NA>
Breast <NA>
cancer, <NA>
second <NA>
to <NA>
lung <NA>
cancer <NA>
as <NA>
a <NA>
cause <NA>
of <NA>
cancer <NA>
deaths <NA>
among <NA>
women, <NA>
kills <NA>
about <NA>
40,000 <NA>
U.S. <LOCATION>
women <NA>
each <NA>
year. <NA>
LA021989-0064 <DOCNO>
THE_DISEASE <P>
Eighty_percent <PERCENT>
to <NA>
90% <PERCENT>
of <NA>
all <NA>
cancers <NA>
are <NA>
carcinomas. <NA>
<P> </P>
THE_NUMBERS <P>
<P>_For_all_cancers_combined,_the_number_of_new_cases_each_year_increased_<PERCENT>10.7% </P>
between <NA>
1973 <DATE>
and <NA>
1985 <DATE>
, <NA>
the <NA>
latest <NA>
year <NA>
for <NA>
which <NA>
statistics <NA>
are <NA>
available. <NA>
<P>_The_most_dramatic_increase_between_<DATE>1973 </P>
and <NA>
1985 <DATE>
was <NA>
for <NA>
melanoma <NA>
of <NA>
the <NA>
skin, <NA>
which <NA>
increased <NA>
60% <PERCENT>
. <NA>
<P>_The_greatest_decline_between_<DATE>1973 </P>
and <NA>
1985 <DATE>
was <NA>
for <NA>
cervical <NA>
cancer, <NA>
which <NA>
dropped <NA>
35% <PERCENT>
. <NA>
Early <NA>
detection <NA>
and <NA>
greater <NA>
use <NA>
of <NA>
Pap <ORGANIZATION>
smears <NA>
are <NA>
credited. <NA>
<P>_Lung_cancer_is_the_most_common_form_of_cancer_in_the_<LOCATION>United_States </P>
and <NA>
the <NA>
major <NA>
cause <NA>
of <NA>
cancer <NA>
death. <NA>
Among <NA>
women, <NA>
lung <NA>
cancer <NA>
incidence <NA>
increased <NA>
81% <PERCENT>
between <NA>
1973 <DATE>
and <NA>
1985 <DATE>
. <NA>
For <NA>
men, <NA>
it <NA>
increased <NA>
14.3% <PERCENT>
. <NA>
<P> </P>
THE_SURVIVAL_RATE <P>
The_rate_of_people_who_survive_cancer_and_are_disease-free_five_years_after_the_diagnosis_is_now_about_<PERCENT>50% <P>
. <NA>
Cancers <NA>
with <NA>
higher <NA>
survivability <NA>
rates <NA>
are: <NA>
testis, <NA>
90% <PERCENT>
; <NA>
colon, <NA>
54% <PERCENT>
, <NA>
and <NA>
breast, <NA>
74% <PERCENT>
. <NA>
Cancers <NA>
with <NA>
lower <NA>
rates <NA>
are: <NA>
leukemia, <NA>
31% <PERCENT>
; <NA>
lung, <NA>
13% <PERCENT>
, <NA>
and <NA>
stomach, <NA>
16% <PERCENT>
. <NA>
<P> </P>
THE_COSTS <P>
Taking_into_account_hospital_costs,_the_loss_of_job_productivity_and_the_loss_of_employable_years,_cancer_costs_about_<MONEY>$72_billion <P>
a <NA>
year <NA>
in <NA>
the <NA>
United_States <LOCATION>
. <NA>
<P>_Cancer_accounts_for_about_<PERCENT>10% </P>
of <NA>
the <NA>
cost <NA>
of <NA>
all <NA>
disease <NA>
in <NA>
the <NA>
United_States <LOCATION>
. <NA>
<P> </P>
THE_RECENT_BREAKTHROUGHS <P>
(Proteoglycans, <NA>
the <NA>
substance <NA>
that <NA>
the <NA>
La_Jolla_Cancer_Research_Foundation <ORGANIZATION>
is <NA>
working <NA>
with, <NA>
is <NA>
an <NA>
anti-oncogene. <NA>
At <NA>
UC_San_Diego_Cancer_Center <ORGANIZATION>
, <NA>
an <NA>
experimental <NA>
treatment <NA>
for <NA>
ovarian <NA>
cancer <NA>
has <NA>
shown <NA>
promise. <NA>
It <NA>
involves <NA>
administering <NA>
high <NA>
concentrations <NA>
of <NA>
cancer <NA>
drugs <NA>
through <NA>
an <NA>
abdominal <NA>
catheter <NA>
and <NA>
applying <NA>
more <NA>
directly <NA>
greater <NA>
doses <NA>
of <NA>
drugs <NA>
than <NA>
standard <NA>
intravenous <NA>
treatment <NA>
currently <NA>
allows <NA>
<P>_Sources:_Figures_are_taken_from_the_<ORGANIZATION>National_Cancer_Institute </P>
's <NA>
1988 <DATE>
"Annual <NA>
Cancer <NA>
Statistics <NA>
Review <NA>
Including <NA>
Cancer <NA>
Trends: <NA>
1950-1985" <NA>
and <NA>
the <NA>
"NCI <NA>
Fact <NA>
Book. <NA>
" <NA>
Kathryn_Phillips <PERSON>
AP890310-0065 <DOCNO>
Nancy_Reagan <PERSON>
's <NA>
triumph <NA>
over <NA>
breast <NA>
cancer <NA>
and <NA>
a <NA>
publicity <NA>
campaign <NA>
about <NA>
the <NA>
disease <NA>
may <NA>
have <NA>
sent <NA>
thousands <NA>
of <NA>
women <NA>
to <NA>
their <NA>
doctors <NA>
for <NA>
potentially <NA>
life-saving <NA>
mammograms, <NA>
federal <NA>
health <NA>
officials <NA>
reported. <NA>
A <NA>
survey <NA>
of <NA>
health <NA>
behavior <NA>
in <NA>
33 <NA>
states <NA>
by <NA>
the <NA>
Centers_for_Disease_Control <ORGANIZATION>
found <NA>
that <NA>
38_percent <PERCENT>
of <NA>
women <NA>
age <NA>
50 <NA>
and <NA>
older <NA>
questioned <NA>
in <NA>
November <DATE>
and <NA>
December_1987 <DATE>
said <NA>
they <NA>
had <NA>
received <NA>
a <NA>
mammogram <NA>
for <NA>
breast <NA>
cancer <NA>
within <NA>
a <NA>
year. <NA>
Those <NA>
findings, <NA>
shortly <NA>
after <NA>
the <NA>
then <NA>
first <NA>
lady's <NA>
October <DATE>
diagnosis, <NA>
marked <NA>
an <NA>
increase <NA>
of <NA>
nearly <NA>
50_percent <PERCENT>
over <NA>
the <NA>
26_percent <PERCENT>
the <NA>
survey <NA>
found <NA>
in <NA>
the <NA>
first <NA>
two <NA>
months <NA>
of <NA>
that <NA>
year. <NA>
Medical <NA>
centers <NA>
in <NA>
the <NA>
United_States <LOCATION>
reported <NA>
after <NA>
She <NA>
was <NA>
later <NA>
honored <NA>
with <NA>
an <NA>
American_Cancer_Society <ORGANIZATION>
award <NA>
for <NA>
her <NA>
efforts <NA>
to <NA>
encourage <NA>
women <NA>
to <NA>
check <NA>
for <NA>
breast <NA>
cancer. <NA>
A <NA>
springtime <NA>
media <NA>
campaign <NA>
by <NA>
the <NA>
cancer <NA>
society <NA>
promoted <NA>
screening <NA>
for <NA>
breast <NA>
cancer, <NA>
and <NA>
data <NA>
from <NA>
the <NA>
survey <NA>
``suggest <NA>
that <NA>
the <NA>
media <NA>
events <NA>
and <NA>
educational <NA>
activities <NA>
were <NA>
accompanied <NA>
by <NA>
increases <NA>
in <NA>
screening <NA>
mammograms,'' <NA>
the <NA>
CDC <ORGANIZATION>
said. <NA>
The <NA>
increases <NA>
in <NA>
mammograms <NA>
``may <NA>
be <NA>
related <NA>
to <NA>
enhanced <NA>
public <NA>
awareness <NA>
during <NA>
the <NA>
ACS <ORGANIZATION>
spring <NA>
campaign <NA>
and <NA>
after <NA>
Reagan <NA>
's_diagnosis,''_the_<ORGANIZATION>CDC </PERSON>
said, <NA>
although <NA>
the <NA>
agency <NA>
added <NA>
that <NA>
the <NA>
data <NA>
cannot <NA>
directly <NA>
prove <NA>
such <NA>
a <NA>
connection <NA>
statistically. <NA>
Overall, <NA>
in <NA>
the <NA>
CDC <ORGANIZATION>
's <NA>
1987 <DATE>
behavioral <NA>
risk <NA>
factor <NA>
survey, <NA>
29_percent <PERCENT>
of <NA>
the <NA>
women <NA>
50 <NA>
and <NA>
up <NA>
said <NA>
they <NA>
had <NA>
been <NA>
screened <NA>
for <NA>
breast <NA>
cancer <NA>
in <NA>
the <NA>
preceding <NA>
12 <NA>
months. <NA>
Cancer <NA>
specialists <NA>
at <NA>
the <NA>
CDC <ORGANIZATION>
and <NA>
elsewhere <NA>
say <NA>
increased <NA>
use <NA>
of <NA>
mammograms <NA>
would <NA>
increase <NA>
early <NA>
detection <NA>
of <NA>
breast <NA>
cancer, <NA>
raising <NA>
survival <NA>
rates <NA>
for <NA>
patients. <NA>
Aside <NA>
from <NA>
annual <NA>
mammograms <NA>
for <NA>
women <NA>
50 <NA>
and <NA>
up, <NA>
the <NA>
American_Cancer_Society <ORGANIZATION>
recommends <NA>
that <NA>
women <NA>
between <NA>
35 <NA>
and <NA>
40 <NA>
have <NA>
one <NA>
initial <NA>
mammogram, <NA>
and <NA>
that <NA>
women <NA>
40-49 <NA>
have <NA>
one <NA>
each <NA>
year <NA>
or <NA>
two. <NA>
Breast <NA>
cancer, <NA>
second <NA>
to <NA>
lung <NA>
cancer <NA>
as <NA>
a <NA>
cause <NA>
of <NA>
cancer <NA>
deaths <NA>
among <NA>
women, <NA>
kills <NA>
about <NA>
40,000 <NA>
U.S. <LOCATION>
women <NA>
each <NA>
year. <NA>
AP890927-0030 <DOCNO>
Researchers <NA>
examining <NA>
lung <NA>
cancer <NA>
tumors <NA>
discovered <NA>
a <NA>
series <NA>
of <NA>
abnormalities <NA>
in <NA>
the <NA>
so-called <NA>
p53 <NA>
anti-cancer <NA>
gene, <NA>
according <NA>
to <NA>
a <NA>
report <NA>
Tuesday <DATE>
by <NA>
John <NA>
Minna <NA>
of_the_<ORGANIZATION>National_Cancer_Institute-Navy_Medical_Oncology_Branch </PERSON>
in <NA>
Bethesda <LOCATION>
, <NA>
Md <LOCATION>
. <NA>
Defects <NA>
in <NA>
the <NA>
gene <NA>
also <NA>
have <NA>
been <NA>
linked <NA>
to <NA>
colon <NA>
cancer, <NA>
to <NA>
an <NA>
uncommon <NA>
bone <NA>
cancer <NA>
called <NA>
osteogenic <NA>
sarcoma <NA>
and <NA>
to <NA>
chronic <NA>
myelogenous <NA>
leukemia, <NA>
Minna <PERSON>
said. <NA>
``Obviously, <NA>
everybody <NA>
is <NA>
going <NA>
to <NA>
be <NA>
looking <NA>
for <NA>
it <NA>
in <NA>
everything <NA>
else,'' <NA>
Minna <PERSON>
said. <NA>
Bert_Vogelstein <PERSON>
of <NA>
Johns_Hopkins_University <ORGANIZATION>
in <NA>
Baltimore <LOCATION>
, <NA>
who <NA>
identified <NA>
p53 <NA>
abnormalities <NA>
in <NA>
colon <NA>
cancer, <NA>
said: <NA>
``From <NA>
what <NA>
I've <NA>
heard <NA>
of <NA>
That <NA>
should <NA>
be <NA>
useful <NA>
for <NA>
identifying <NA>
people <NA>
at <NA>
high <NA>
risk <NA>
of <NA>
getting <NA>
lung <NA>
cancer, <NA>
or <NA>
for <NA>
predicting <NA>
how <NA>
deadly <NA>
a <NA>
particular <NA>
case <NA>
of <NA>
lung <NA>
cancer <NA>
will <NA>
be, <NA>
Minna <PERSON>
said. <NA>
``One <NA>
thing <NA>
you <NA>
could <NA>
do <NA>
would <NA>
be <NA>
to <NA>
take <NA>
people's <NA>
tumors, <NA>
see <NA>
how <NA>
many <NA>
(genetic) <NA>
lesions <NA>
they <NA>
have, <NA>
and <NA>
determine <NA>
how <NA>
virulent <NA>
they <NA>
are,'' <NA>
Minna <PERSON>
said <NA>
Tuesday <DATE>
in <NA>
a <NA>
telephone <NA>
interview <NA>
from <NA>
Toronto <LOCATION>
, <NA>
where <NA>
he <NA>
presented <NA>
his <NA>
findings <NA>
at <NA>
the <NA>
Bristol-Myers_Cancer_Research_Symposium <ORGANIZATION>
. <NA>
Vogelstein <PERSON>
has <NA>
found <NA>
that <NA>
the <NA>
more <NA>
genetic <NA>
abnormalities <NA>
a <NA>
colon <NA>
cancer <NA>
tumor <NA>
has, <NA>
the <NA>
more <NA>
virulent <NA>
it <NA>
is, <NA>
Minna <PERSON>
said. <NA>
Minna <PERSON>
said <NA>
he <NA>
is <NA>
beginning <NA>
studies <NA>
to <NA>
determine <NA>
if <NA>
the <NA>
same <NA>
thing <NA>
is <NA>
true <NA>
in <NA>
lung <NA>
cancer. <NA>
If <NA>
the <NA>
protein <NA>
is <NA>
defective, <NA>
the <NA>
protective <NA>
effect <NA>
is <NA>
lost <NA>
and <NA>
one <NA>
step <NA>
has <NA>
been <NA>
taken <NA>
toward <NA>
the <NA>
formation <NA>
of <NA>
a <NA>
tumor, <NA>
Minna <PERSON>
explained. <NA>
Minna <PERSON>
said <NA>
that <NA>
although <NA>
only <NA>
six <NA>
genetic <NA>
abnormalities <NA>
have <NA>
so <NA>
far <NA>
been <NA>
linked <NA>
to <NA>
lung <NA>
cancer, <NA>
there <NA>
may <NA>
be <NA>
as <NA>
many <NA>
as <NA>
10 <NA>
or <NA>
20. <NA>
The <NA>
p53 <NA>
gene <NA>
is <NA>
the <NA>
second <NA>
anti-cancer <NA>
gene <NA>
to <NA>
be <NA>
carefully <NA>
studied, <NA>
Minna <PERSON>
said. <NA>
The <NA>
retinoblastoma <NA>
gene <NA>
also <NA>
was <NA>
shown <NA>
recently <NA>
to <NA>
be <NA>
important <NA>
in <NA>
lung <NA>
cancer, <NA>
Minna <PERSON>
said. <NA>
FT942-17260 <DOCNO>
The <NA>
Cancer_Research_Campaign <ORGANIZATION>
, <NA>
which <NA>
funded <NA>
the <NA>
vaccine's <NA>
development <NA>
at <NA>
Nottingham_University <ORGANIZATION>
, <NA>
said <NA>
yesterday: <NA>
'The <NA>
first <NA>
clinical <NA>
trials <NA>
indicate <NA>
impressive <NA>
results <NA>
in <NA>
patients. <NA>
' <NA>
ImClone_Systems <ORGANIZATION>
, <NA>
a <NA>
New_York <LOCATION>
biotechnology <NA>
company, <NA>
has <NA>
signed <NA>
an <NA>
exclusive <NA>
worldwide <NA>
licensing <NA>
agreement <NA>
with <NA>
the <NA>
CRC <ORGANIZATION>
for <NA>
commercial <NA>
development <NA>
of <NA>
Vaccine <NA>
105AD7, <NA>
as <NA>
it <NA>
is <NA>
known. <NA>
ImClone <ORGANIZATION>
is <NA>
a <NA>
leader <NA>
in <NA>
the <NA>
fast-growing <NA>
research <NA>
field <NA>
of <NA>
cancer <NA>
vaccines; <NA>
it <NA>
is <NA>
also <NA>
testing <NA>
vaccines <NA>
for <NA>
lung <NA>
cancer <NA>
and <NA>
melanoma. <NA>
Dr <NA>
Lindy_Durrant <PERSON>
and <NA>
Dr <NA>
Adrian_Robbins <PERSON>
, <NA>
who <NA>
developed <NA>
105AD7 <NA>
at <NA>
Nottingham <LOCATION>
, <NA>
said <NA>
it <NA>
not <NA>
only <NA>
had <NA>
the <NA>
potential <NA>
to <NA>
prevent <NA>
bowel <NA>
cancer <NA>
or <NA>
stop <NA>
the <NA>
disease <NA>
progressing, <NA>
but <NA>
also <NA>
had <NA>
the <NA>
advantage <NA>
of <NA>
producing <NA>
no <NA>
toxic <NA>
side-effects <NA>
- <NA>
unlike <NA>
conventional <NA>
treatments. <NA>
The <NA>
CRC <ORGANIZATION>
is <NA>
now <NA>
organising <NA>
a <NA>
larger <NA>
clinical <NA>
trial, <NA>
based <NA>
at <NA>
Nottingham <LOCATION>
, <NA>
with <NA>
350 <NA>
patients, <NA>
and <NA>
ImClone <ORGANIZATION>
will <NA>
carry <NA>
out <NA>
an <NA>
extensive <NA>
trial <NA>
in <NA>
the <NA>
US <LOCATION>
. <NA>
Even <NA>
if <NA>
the <NA>
new <NA>
vaccine <NA>
continues <NA>
to <NA>
perform <NA>
well, <NA>
it <NA>
is <NA>
unlikely <NA>
to <NA>
be <NA>
approved <NA>
as <NA>
a <NA>
commercial <NA>
treatment <NA>
of <NA>
bowel <NA>
cancer <NA>
before <NA>
1997 <DATE>
. <NA>
One <NA>
is <NA>
the <NA>
indirect <NA>
approach <NA>
- <NA>
immunising <NA>
people <NA>
against <NA>
viruses, <NA>
such <NA>
as <NA>
Epstein_Barr <PERSON>
, <NA>
which <NA>
are <NA>
associated <NA>
with <NA>
certain <NA>
cancers. <NA>
Only <NA>
9,000 <NA>
will <NA>
be <NA>
alive <NA>
five_years_later <DATE>
. <NA>
In <NA>
the <NA>
US <LOCATION>
, <NA>
the <NA>
disease <NA>
kills <NA>
55,000 <NA>
people <NA>
a <NA>
year. <NA>
'Bowel <NA>
cancer <NA>
is <NA>
the <NA>
second <NA>
most <NA>
common <NA>
cause <NA>
of <NA>
cancer <NA>
death <NA>
in <NA>
the <NA>
west,' <NA>
said <NA>
Prof_Gordon_McVie <PERSON>
, <NA>
CRC <ORGANIZATION>
scientific <NA>
director. <NA>
LA063090-0103 <DOCNO>
A_federal_advisory_panel_recommended_<DATE>Friday <P>
that <NA>
the <NA>
Food_and_Drug_Administration <ORGANIZATION>
reject <NA>
a <NA>
proposal <NA>
to <NA>
undertake <NA>
a <NA>
ground-breaking <NA>
U.S.-Soviet <NA>
study <NA>
of <NA>
20,000 <NA>
women <NA>
to <NA>
determine <NA>
whether <NA>
a <NA>
hormonal <NA>
drug <NA>
can <NA>
prevent <NA>
breast <NA>
cancer. <NA>
<P>_The_<ORGANIZATION>FDA </P>
's <NA>
Oncology_Drugs_Advisory_Committee <ORGANIZATION>
agreed <NA>
that <NA>
a <NA>
long-term <NA>
study <NA>
should <NA>
be <NA>
conducted <NA>
to <NA>
determine <NA>
the <NA>
effect <NA>
of <NA>
the <NA>
hormonal <NA>
drug <NA>
tamoxifen <NA>
in <NA>
preventing <NA>
breast <NA>
cancer <NA>
and <NA>
other <NA>
cancers <NA>
in <NA>
healthy <NA>
women. <NA>
<P>_But_the_panel_said_that_its_members_had_concluded_that_the_design_of_the_proposed_10-year,_<MONEY>$100-million </P>
study <NA>
of <NA>
women <NA>
in <NA>
the <NA>
United_States <LOCATION>
and <NA>
the <NA>
Soviet_Union <LOCATION>
was <NA>
flawed. <NA>
<P>_"I'm_disappointed_for_the_women_of_the_country,"_said_<PERSON>Phillip_D._Bretz </P>
, <NA>
director <NA>
of <NA>
the <NA>
Desert_Breast_Institute_in_Rancho_Mirage <ORGANIZATION>
and <NA>
one <NA>
of <NA>
the <NA>
proposed <NA>
study <NA>
leaders. <NA>
" <NA>
<P>_Although_the_recommendation_of_an_<ORGANIZATION>FDA </P>
advisory <NA>
committee <NA>
is <NA>
not <NA>
binding, <NA>
it <NA>
typically <NA>
wields <NA>
considerable <NA>
weight <NA>
in <NA>
agency <NA>
decision-making. <NA>
The <NA>
FDA <ORGANIZATION>
must <NA>
approve <NA>
the <NA>
U.S. <LOCATION>
segment <NA>
of <NA>
the <NA>
study <NA>
before <NA>
it <NA>
can <NA>
begin. <NA>
<P>_<PERSON>Bretz </P>
, <NA>
however, <NA>
said <NA>
that <NA>
the <NA>
study <NA>
was <NA>
rejected <NA>
because <NA>
he <NA>
did <NA>
not <NA>
have <NA>
the <NA>
academic <NA>
ties <NA>
of <NA>
traditional <NA>
researchers. <NA>
<P>_The_proposed_study,_endorsed_by_American_and_Soviet_cancer_specialists_in_<DATE>March </P>
, <NA>
would <NA>
involve <NA>
administration <NA>
of <NA>
tamoxifen, <NA>
an <NA>
anti-estrogen <NA>
drug <NA>
already <NA>
widely <NA>
used <NA>
in <NA>
post-surgical <NA>
breast <NA>
cancer <NA>
therapy, <NA>
to <NA>
women <NA>
considered <NA>
at <NA>
high <NA>
risk <NA>
for <NA>
breast <NA>
cancer. <NA>
<P>_It_would_be_the_first_large-scale_study_undertaken_jointly_in_the_<LOCATION>United_States </P>
and <NA>
Soviet_Union <LOCATION>
, <NA>
its <NA>
sponsors <NA>
said. <NA>
<P>_The_researchers_had_predicted_a_<PERCENT>25% </P>
reduction <NA>
in <NA>
the <NA>
incidence <NA>
of <NA>
breast <NA>
cancer <NA>
among <NA>
the <NA>
women <NA>
who <NA>
were <NA>
given <NA>
the <NA>
drug. <NA>
<P>_The_study_would_be_coordinated_by_<PERSON>Bretz </P>
; <NA>
Philip <NA>
B. <NA>
Dreisbach <NA>
,_of_the_<ORGANIZATION>Eisenhower_Medical_Center </PERSON>
in <NA>
Rancho <NA>
Mirage, <NA>
and <NA>
David <NA>
Zaridze <NA>
,_deputy_director_of_the_<ORGANIZATION>All-Union_Cancer_Research_Institute </PERSON>
in <NA>
Moscow <LOCATION>
. <NA>
<P>_"This_is_a_drug_that_is_not_risk-free,"_said_<PERSON>Cindy_Pearson </P>
, <NA>
program <NA>
director <NA>
of <NA>
the <NA>
National_Women's_Health_Network <ORGANIZATION>
. <NA>
Wendy <NA>
Schain <NA>
,_a_psychologist_with_<ORGANIZATION>Memorial_Cancer_Institute </PERSON>
in <NA>
Long_Beach <LOCATION>
and <NA>
a <NA>
former <NA>
breast <NA>
cancer <NA>
patient, <NA>
recommended <NA>
approval <NA>
of <NA>
the <NA>
study. <NA>
" <NA>
<P>_Tamoxifen_causes_cancer_in_animals_and_has_been_linked_to_stroke,_heart_disease_and_endometrial_cancer_in_women,_according_to_the_<ORGANIZATION>FDA </P>
. <NA>
<P>_<ORGANIZATION>FDA </P>
officials <NA>
said <NA>
that <NA>
a <NA>
large <NA>
study <NA>
of <NA>
a <NA>
drug <NA>
in <NA>
healthy <NA>
humans <NA>
was <NA>
"a <NA>
little <NA>
unusual," <NA>
but <NA>
not <NA>
unprecedented. <NA>
Robert <NA>
Temple <NA>
,_the_<ORGANIZATION>FDA </PERSON>
's <NA>
director <NA>
of <NA>
new <NA>
drug <NA>
evaluation. <NA>
<P>_Tamoxifen,_manufactured_by_the_British_firm_<ORGANIZATION>Imperial_Chemical_Industries </P>
and <NA>
sold <NA>
under <NA>
the <NA>
brand <NA>
name <NA>
Nolvadex, <NA>
has <NA>
been <NA>
used <NA>
for <NA>
more <NA>
than <NA>
a <NA>
decade <NA>
to <NA>
prevent <NA>
the <NA>
recurrence <NA>
of <NA>
tumors <NA>
in <NA>
women <NA>
whose <NA>
cancer <NA>
had <NA>
spread <NA>
to <NA>
the <NA>
underarm <NA>
lymph <NA>
nodes. <NA>
<P>_Recently,_the_<ORGANIZATION>FDA </P>
approved <NA>
its <NA>
use <NA>
in <NA>
the <NA>
post-surgical <NA>
treatment <NA>
of <NA>
early <NA>
breast <NA>
cancer <NA>
in <NA>
women <NA>
who <NA>
do <NA>
not <NA>
have <NA>
node <NA>
involvement. <NA>
In <NA>
this <NA>
country, <NA>
it <NA>
is <NA>
produced <NA>
and <NA>
marketed <NA>
by <NA>
ICI <ORGANIZATION>
Pharmaceuticals <NA>
of <NA>
Wilmington <LOCATION>
, <NA>
Del <LOCATION>
. <NA>
<P>_Breast_cancer_is_the_most_common_malignancy_among_women_in_the_<LOCATION>United_States </P>
and <NA>
the <NA>
second <NA>
leading <NA>
cause <NA>
of <NA>
cancer <NA>
death <NA>
among <NA>
women, <NA>
after <NA>
lung <NA>
cancer. <NA>
WSJ880715-0070 <DOCNO>
William <NA>
Harbour <NA>
and_<PERSON>Frederic_J._Kaye </PERSON>
of <NA>
the <NA>
National_Cancer_Institute <ORGANIZATION>
, <NA>
with <NA>
colleagues <NA>
Shinn-Liang_Lai <PERSON>
, <NA>
Jacqueline_Whang-Peng <PERSON>
, <NA>
Adi_F._Gazdar <PERSON>
and <NA>
John_D._Minna <PERSON>
. <NA>
The <NA>
study <NA>
in <NA>
Science <NA>
found <NA>
that <NA>
the <NA>
Rb <NA>
gene <NA>
was <NA>
structurally <NA>
damaged <NA>
in <NA>
18% <PERCENT>
of <NA>
small-cell <NA>
lung <NA>
cancer <NA>
cell <NA>
lines, <NA>
and <NA>
nonfunctional <NA>
in <NA>
a <NA>
startling <NA>
60% <PERCENT>
of <NA>
the <NA>
cell <NA>
lines. <NA>
In <NA>
contrast, <NA>
the <NA>
gene <NA>
was <NA>
found <NA>
to <NA>
be <NA>
intact <NA>
in <NA>
90% <PERCENT>
of <NA>
other <NA>
types <NA>
lung <NA>
cancer, <NA>
as <NA>
well <NA>
as <NA>
in <NA>
normal <NA>
lung <NA>
tissue. <NA>
Retinoblastoma, <NA>
while <NA>
very <NA>
rare, <NA>
is <NA>
hereditary <NA>
and <NA>
occurs <NA>
in <NA>
familial <NA>
patterns <NA>
in <NA>
40% <PERCENT>
of <NA>
all <NA>
cases. <NA>
Eva_Lee <PERSON>
of <NA>
the <NA>
University_of_California <ORGANIZATION>
at <NA>
San_Diego <LOCATION>
, <NA>
author <NA>
of <NA>
a <NA>
study <NA>
on <NA>
Rb <NA>
and <NA>
breast <NA>
cancer, <NA>
called <NA>
the <NA>
cancer <NA>
institute <NA>
study <NA>
"important" <NA>
in <NA>
further <NA>
understanding <NA>
the <NA>
oncogene's <NA>
role. <NA>
AP901130-0022 <DOCNO>
Stephen <NA>
Friend <NA>
of_<ORGANIZATION>Massachusetts_General_Hospital_Cancer_Center </PERSON>
. <NA>
For <NA>
people <NA>
who <NA>
inherit <NA>
a <NA>
mutated <NA>
p53 <NA>
gene, <NA>
he <NA>
said, <NA>
``their <NA>
chance <NA>
of <NA>
getting <NA>
a <NA>
malignancy <NA>
by <NA>
age <NA>
60 <NA>
is <NA>
90_percent <PERCENT>
. <NA>
'' <NA>
Dr. <NA>
Andrew_Feinberg <PERSON>
, <NA>
a <NA>
University_of_Michigan_Cancer_Center <ORGANIZATION>
researcher <NA>
and <NA>
co-discoverer <NA>
of <NA>
genes <NA>
related <NA>
to <NA>
a <NA>
rare <NA>
kidney <NA>
cancer, <NA>
said <NA>
the <NA>
p53 <NA>
discovery <NA>
adds <NA>
a <NA>
step <NA>
in <NA>
the <NA>
cascade <NA>
of <NA>
cell <NA>
changes <NA>
that <NA>
is <NA>
thought <NA>
to <NA>
lead <NA>
to <NA>
some <NA>
cancers. <NA>
``From <NA>
a <NA>
scientific <NA>
viewpoint, <NA>
it <NA>
is <NA>
very <NA>
important <NA>
because <NA>
it <NA>
helps <NA>
us <NA>
understand <NA>
the <NA>
sequence <NA>
of <NA>
events <NA>
that <NA>
lead <NA>
to <NA>
cancer,'' <NA>
said <NA>
Feinberg <PERSON>
. <NA>
The <NA>
Li-Fraumeni <NA>
syndrome <NA>
was <NA>
first <NA>
described <NA>
by <NA>
Frederick_P._Li <PERSON>
and <NA>
Joseph_F._Fraumeni_Jr. <PERSON>
, <NA>
both <NA>
of <NA>
the <NA>
National_Cancer_Institute <ORGANIZATION>
and <NA>
coauthors <NA>
of <NA>
the <NA>
study <NA>
in <NA>
Science. <NA>
The <NA>
syndrome <NA>
is <NA>
very <NA>
rare, <NA>
with <NA>
only <NA>
about <NA>
200 <NA>
such <NA>
families <NA>
in <NA>
the <NA>
United_States <LOCATION>
. <NA>
With <NA>
discovery <NA>
of <NA>
the <NA>
p53 <NA>
mutation, <NA>
Friend <ORGANIZATION>
said <NA>
a <NA>
screening <NA>
process <NA>
may <NA>
be <NA>
developed <NA>
to <NA>
determine <NA>
which <NA>
members <NA>
in <NA>
a <NA>
Li-Fraumeni <NA>
family <NA>
have <NA>
inherited <NA>
the <NA>
abnormal <NA>
gene. <NA>
Science <NA>
is <NA>
the <NA>
journal <NA>
of <NA>
the <NA>
American_Association <ORGANIZATION>
for <NA>
the <NA>
Advancement_of_Science <ORGANIZATION>
. <NA>
WSJ911226-0048 <DOCNO>
The <NA>
researchers <NA>
estimated <NA>
that <NA>
of <NA>
the <NA>
176,000 <NA>
women <NA>
who <NA>
develop <NA>
breast <NA>
cancer <NA>
each <NA>
year, <NA>
between <NA>
7% <PERCENT>
and <NA>
14% <PERCENT>
may <NA>
be <NA>
carrying <NA>
the <NA>
A-T <NA>
gene. <NA>
However, <NA>
"We <NA>
would <NA>
like <NA>
to <NA>
see <NA>
all <NA>
older <NA>
mammography <NA>
machines <NA>
that <NA>
give <NA>
higher <NA>
doses <NA>
of <NA>
radiation <NA>
retired <NA>
immediately" <NA>
in <NA>
favor <NA>
of <NA>
newer, <NA>
low-dose <NA>
machines, <NA>
said <NA>
medical <NA>
geneticist <NA>
Michael_Swift <PERSON>
who <NA>
headed <NA>
the <NA>
University_of_North_Carolina-Chapel_Hill <ORGANIZATION>
team <NA>
that <NA>
reported <NA>
the <NA>
new <NA>
finding <NA>
in <NA>
this <NA>
week's <NA>
New_England_Journal_of_Medicine <ORGANIZATION>
. <NA>
In <NA>
light <NA>
of <NA>
this <NA>
fact, <NA>
the <NA>
North_Carolina <LOCATION>
researchers <NA>
launched <NA>
an <NA>
effort <NA>
to <NA>
see <NA>
if <NA>
having <NA>
a <NA>
single <NA>
copy <NA>
of <NA>
the <NA>
gene <NA>
also <NA>
boosted <NA>
the <NA>
risk <NA>
of <NA>
developing <NA>
cancer, <NA>
as <NA>
some <NA>
previous <NA>
studies <NA>
had <NA>
hinted. <NA>
In <NA>
1982 <DATE>
the <NA>
researchers <NA>
began <NA>
following <NA>
the <NA>
lives <NA>
and <NA>
deaths <NA>
of <NA>
1,599 <NA>
adult <NA>
blood <NA>
relatives <NA>
of <NA>
161 <NA>
families <NA>
in <NA>
which <NA>
at <NA>
least <NA>
one <NA>
person <NA>
had <NA>
been <NA>
born <NA>
with <NA>
ataxia-telangiectasia. <NA>
In <NA>
contrast, <NA>
only <NA>
19% <PERCENT>
of <NA>
a <NA>
group <NA>
of <NA>
"control" <NA>
women <NA>
of <NA>
similar <NA>
age <NA>
and <NA>
background, <NA>
who <NA>
were <NA>
being <NA>
monitored <NA>
simultaneously, <NA>
had <NA>
been <NA>
exposed <NA>
to <NA>
such <NA>
X-rays. <NA>
They <NA>
noted <NA>
that <NA>
1.4% <PERCENT>
of <NA>
the <NA>
population <NA>
may <NA>
unwittingly <NA>
harbor <NA>
a <NA>
single <NA>
copy <NA>
of <NA>
the <NA>
A-T <NA>
gene <NA>
but <NA>
that <NA>
a <NA>
test <NA>
to <NA>
detect <NA>
it <NA>
isn't <NA>
yet <NA>
available. <NA>
"Until <NA>
that <NA>
is <NA>
possible <NA>
it <NA>
may <NA>
be <NA>
prudent <NA>
to <NA>
take <NA>
into <NA>
account <NA>
the <NA>
1% <PERCENT>
chance <NA>
that <NA>
anyone" <NA>
can <NA>
possess <NA>
a <NA>
single <NA>
A-T <NA>
gene <NA>
"and <NA>
to <NA>
take <NA>
the <NA>
most <NA>
stringent <NA>
measures <NA>
possible <NA>
to <NA>
minimize <NA>
incidental <NA>
diagnostic <NA>
X-ray <NA>
exposure <NA>
of <NA>
the <NA>
female <NA>
breast," <NA>
they <NA>
said. <NA>
SJMN91-06025221 <DOCNO>
Since <NA>
1980 <DATE>
, <NA>
the <NA>
society <NA>
said, <NA>
reported <NA>
cases <NA>
of <NA>
breast <NA>
cancer <NA>
in <NA>
the <NA>
United_States <LOCATION>
have <NA>
increased <NA>
more <NA>
than <NA>
30_percent <PERCENT>
, <NA>
making <NA>
it <NA>
the <NA>
most <NA>
common <NA>
cancer, <NA>
excluding <NA>
those <NA>
of <NA>
the <NA>
skin. <NA>
; <NA>
About <NA>
175,000 <NA>
American <NA>
women <NA>
will <NA>
develop <NA>
breast <NA>
cancer <NA>
this <NA>
year <NA>
and <NA>
nearly <NA>
45,000 <NA>
women <NA>
will <NA>
die <NA>
from <NA>
the <NA>
disease, <NA>
according <NA>
to <NA>
the <NA>
Cancer_Society <ORGANIZATION>
's <NA>
annual <NA>
projections. <NA>
Stephen <NA>
Weiss <NA>
,_president_of_the_<ORGANIZATION>Cancer_Society </PERSON>
's <NA>
Philadelphia <LOCATION>
division, <NA>
said <NA>
at <NA>
a <NA>
news <NA>
conference <NA>
called <NA>
to <NA>
announce <NA>
the <NA>
new <NA>
statistics. <NA>
; <NA>
Lawrence_Garfinkel <PERSON>
, <NA>
a <NA>
senior <NA>
consultant <NA>
in <NA>
epidemiology <NA>
and <NA>
statistics <NA>
for <NA>
the <NA>
Cancer_Society <ORGANIZATION>
, <NA>
said <NA>
the <NA>
rise <NA>
in <NA>
breast <NA>
cancer <NA>
rates <NA>
during <NA>
the <NA>
last <NA>
decade <NA>
was <NA>
in <NA>
part <NA>
because <NA>
of <NA>
an <NA>
increased <NA>
use <NA>
of <NA>
mammography, <NA>
which <NA>
has <NA>
meant <NA>
that <NA>
more <NA>
cases <NA>
are <NA>
detected. <NA>
"; <NA>
Garfinkel <PERSON>
said <NA>
he <NA>
expected <NA>
that <NA>
by <NA>
the <NA>
time <NA>
1990 <DATE>
breast <NA>
cancer <NA>
figures <NA>
were <NA>
analyzed, <NA>
a <NA>
woman's <NA>
chances <NA>
for <NA>
getting <NA>
breast <NA>
cancer <NA>
would <NA>
be <NA>
one <NA>
in <NA>
eight. <NA>
The <NA>
one-in-nine <NA>
risk <NA>
is <NA>
based <NA>
on <NA>
1987 <DATE>
breast <NA>
cancer <NA>
figures. <NA>
; <NA>
Edward_Sondik <PERSON>
, <NA>
an <NA>
official <NA>
at <NA>
the <NA>
National_Cancer_Institute <ORGANIZATION>
, <NA>
said <NA>
Thursday <DATE>
that <NA>
the <NA>
increased <NA>
risk <NA>
for <NA>
breast <NA>
cancer <NA>
calculated <NA>
by <NA>
the <NA>
Cancer_Society <ORGANIZATION>
showed <NA>
that <NA>
"basically <NA>
people <NA>
are <NA>
living <NA>
longer, <NA>
and <NA>
if <NA>
people <NA>
live <NA>
longer, <NA>
the <NA>
risk <NA>
of <NA>
disease <NA>
goes <NA>
up. <NA>
"; <NA>
Sondik <PERSON>
said <NA>
greater <NA>
use <NA>
of <NA>
mammograms, <NA>
or <NA>
breast <NA>
X-rays, <NA>
accounted <NA>
for <NA>
most <NA>
of <NA>
the <NA>
increase <NA>
because <NA>
detection <NA>
is <NA>
made <NA>
easier. <NA>
; <NA>
"(Other) <NA>
factors <NA>
that <NA>
have <NA>
been <NA>
identified <NA>
are <NA>
later <NA>
childbearing, <NA>
diet, <NA>
use <NA>
of <NA>
estrogen, <NA>
but <NA>
no <NA>
one <NA>
has <NA>
been <NA>
able <NA>
to <NA>
prove <NA>
the <NA>
actual <NA>
increases <NA>
we <NA>
are <NA>
seeing <NA>
are <NA>
related <NA>
to <NA>
these <NA>
factors," <NA>
said <NA>
Sondik <PERSON>
, <NA>
who <NA>
is <NA>
deputy <NA>
director <NA>
of <NA>
the <NA>
institute's <NA>
division <NA>
of <NA>
cancer <NA>
prevention <NA>
and <NA>
control. <NA>
; <NA>
The_National_Cancer_Institute <ORGANIZATION>
will <NA>
spend <NA>
about <NA>
$90_million <MONEY>
on <NA>
breast <NA>
cancer <NA>
research <NA>
this <NA>
year <NA>
-- <NA>
up <NA>
from <NA>
$81_million <MONEY>
in <NA>
1990 <DATE>
. <NA>
Advocacy <NA>
groups <NA>
argue <NA>
that <NA>
that <NA>
amount <NA>
is <NA>
just <NA>
a <NA>
fraction <NA>
of <NA>
the <NA>
more <NA>
than <NA>
$1_billion <MONEY>
spent <NA>
on <NA>
AIDS <NA>
research <NA>
last_year. <DATE>
; <NA>
There <NA>
are <NA>
some <NA>
acknowledged <NA>
risk <NA>
factors <NA>
for <NA>
breast <NA>
cancer, <NA>
including <NA>
having <NA>
a <NA>
family <NA>
history <NA>
of <NA>
the <NA>
disease, <NA>
delaying <NA>
childbearing <NA>
until <NA>
after <NA>
age <NA>
30 <NA>
and <NA>
having <NA>
an <NA>
early <NA>
onset <NA>
of <NA>
menstruation <NA>
or <NA>
late <NA>
onset <NA>
of <NA>
menopause. <NA>
AP891206-0071 <DOCNO>
Researchers <NA>
at <NA>
the <NA>
Pittsburgh_Cancer_Institute <ORGANIZATION>
will <NA>
conduct <NA>
a <NA>
five-year <NA>
study <NA>
of <NA>
the <NA>
rate <NA>
at <NA>
which <NA>
some <NA>
people <NA>
who <NA>
receive <NA>
transplanted <NA>
organs <NA>
develop <NA>
cancer. <NA>
In <NA>
the <NA>
process, <NA>
the <NA>
$5_million <MONEY>
study <NA>
_ <NA>
funded <NA>
by <NA>
the <NA>
National_Cancer_Institute__ <ORGANIZATION>
may <NA>
provide <NA>
clues <NA>
to <NA>
the <NA>
relationship <NA>
between <NA>
cancer <NA>
and <NA>
viruses <NA>
and <NA>
the <NA>
way <NA>
in <NA>
which <NA>
the <NA>
body <NA>
combats <NA>
those <NA>
diseases, <NA>
one <NA>
official <NA>
said <NA>
Tuesday <DATE>
. <NA>
Theresa <NA>
Whiteside <NA>
,_director_of_the_institute's_immunologic_monitoring_and_diagnostic_laboratory_and_a_professor_of_pathology_at_the_<ORGANIZATION>University_of_Pittsburgh </PERSON>
. <NA>
Whiteside <PERSON>
said <NA>
one <NA>
of <NA>
the <NA>
most <NA>
significant <NA>
aspects <NA>
of <NA>
the <NA>
study <NA>
is <NA>
that <NA>
researchers <NA>
will <NA>
be <NA>
able <NA>
to <NA>
study <NA>
a <NA>
large <NA>
group <NA>
of <NA>
people, <NA>
some <NA>
of <NA>
whom <NA>
they <NA>
know <NA>
will <NA>
develop <NA>
cancer. <NA>
It <NA>
will <NA>
build <NA>
on <NA>
observations <NA>
made <NA>
in <NA>
1975 <DATE>
by <NA>
Pittsburgh <LOCATION>
liver <NA>
transplant <NA>
pioneer <NA>
Thomas <NA>
Starzl <NA>
,_who_discovered_when_he_was_at_the_<ORGANIZATION>University_of_Colorado </PERSON>
that <NA>
2 <NA>
to <NA>
3_percent <PERCENT>
of <NA>
all <NA>
transplant <NA>
recipients <NA>
developed <NA>
cancer. <NA>
The <NA>
most <NA>
common <NA>
malignancies <NA>
diagnosed <NA>
among <NA>
those <NA>
patients <NA>
were <NA>
lymph <NA>
node <NA>
cancer, <NA>
liver <NA>
cancer <NA>
and <NA>
Kaposi <ORGANIZATION>
's <NA>
sarcoma, <NA>
a <NA>
skin <NA>
cancer <NA>
also <NA>
common <NA>
among <NA>
AIDS <NA>
patients. <NA>
Israel <NA>
Penn <NA>
,_also_found_that_the_risk_of_cancer_after_a_transplant_increased_to_<PERCENT>10_percent </PERSON>
for <NA>
patients <NA>
whose <NA>
pre-transplant <NA>
tests <NA>
showed <NA>
they <NA>
did <NA>
not <NA>
have <NA>
antibodies <NA>
to <NA>
the <NA>
Epstein_Barr <PERSON>
virus, <NA>
which <NA>
causes <NA>
mononucleosis. <NA>
About <NA>
80_percent <PERCENT>
of <NA>
those <NA>
patients <NA>
become <NA>
infected <NA>
with <NA>
the <NA>
virus <NA>
after <NA>
transplantation, <NA>
and <NA>
researchers <NA>
believe <NA>
there <NA>
is <NA>
some <NA>
correlation <NA>
between <NA>
that <NA>
and <NA>
the <NA>
development <NA>
of <NA>
cancer, <NA>
particularly <NA>
in <NA>
the <NA>
lymph <NA>
nodes. <NA>
The <NA>
return <NA>
of <NA>
cancer, <NA>
Whiteside <PERSON>
said, <NA>
must <NA>
have <NA>
something <NA>
to <NA>
do <NA>
with <NA>
a <NA>
person's <NA>
immune <NA>
system <NA>
after <NA>
transplantation <NA>
or <NA>
the <NA>
immune <NA>
defenses <NA>
within <NA>
the <NA>
liver <NA>
itself. <NA>
SJMN91-06122127 <DOCNO>
She <NA>
found <NA>
that <NA>
women <NA>
who <NA>
carried <NA>
most <NA>
of <NA>
their <NA>
weight <NA>
above <NA>
their <NA>
hips <NA>
were <NA>
60_percent <PERCENT>
more <NA>
likely <NA>
to <NA>
develop <NA>
breast <NA>
cancer <NA>
than <NA>
were <NA>
those <NA>
whose <NA>
weight <NA>
was <NA>
mostly <NA>
on <NA>
their <NA>
hips. <NA>
; <NA>
Those <NA>
at <NA>
most <NA>
risk <NA>
were <NA>
women <NA>
who <NA>
weighed <NA>
over <NA>
their <NA>
ideal <NA>
weight <NA>
and <NA>
had <NA>
a <NA>
lot <NA>
of <NA>
abdominal <NA>
fat, <NA>
said <NA>
Stark <NA>
of <NA>
the <NA>
Arizona_Cancer_Center <ORGANIZATION>
at <NA>
the <NA>
University_of_Arizona. <ORGANIZATION>
; <NA>
The <NA>
ideal <NA>
weight <NA>
for <NA>
a <NA>
5-foot-5-inch <NA>
woman <NA>
is <NA>
about <NA>
112 <NA>
pounds; <NA>
for <NA>
a <NA>
5-foot-7-inch <NA>
woman, <NA>
about <NA>
124 <NA>
pounds. <NA>
; <NA>
Women <NA>
in <NA>
the <NA>
study <NA>
who <NA>
recalled <NA>
being <NA>
obese, <NA>
or <NA>
20_percent <PERCENT>
over <NA>
their <NA>
ideal <NA>
weight, <NA>
at <NA>
the <NA>
time <NA>
of <NA>
their <NA>
first <NA>
period <NA>
had <NA>
about <NA>
a <NA>
three-fold <NA>
increased <NA>
risk <NA>
of <NA>
getting <NA>
breast <NA>
cancer. <NA>
The <NA>
American_Cancer_Society <ORGANIZATION>
recommends <NA>
that <NA>
women <NA>
with <NA>
a <NA>
family <NA>
history <NA>
of <NA>
the <NA>
disease <NA>
try <NA>
to <NA>
limit <NA>
their <NA>
fat <NA>
intake <NA>
to <NA>
about <NA>
20_percent <PERCENT>
of <NA>
their <NA>
total <NA>
calories. <NA>
; <NA>
Breast <NA>
cancer, <NA>
which <NA>
strikes <NA>
about <NA>
one <NA>
in <NA>
nine <NA>
women, <NA>
is <NA>
the <NA>
second-leading <NA>
cause <NA>
of <NA>
cancer <NA>
death <NA>
in <NA>
women <NA>
behind <NA>
lung <NA>
cancer, <NA>
according <NA>
to <NA>
the <NA>
American_Cancer_Society <ORGANIZATION>
. <NA>
AP880622-0182 <DOCNO>
Howard <NA>
Koh <NA>
of_<ORGANIZATION>Boston_University_School_of_Medicine </PERSON>
. <NA>
Dr. <NA>
Kenneth_H._Kraemer <PERSON>
, <NA>
who <NA>
directed <NA>
the <NA>
research <NA>
at <NA>
the <NA>
National_Cancer_Institute <ORGANIZATION>
, <NA>
believes <NA>
the <NA>
study <NA>
could <NA>
represent <NA>
a <NA>
step <NA>
toward <NA>
cancer <NA>
prevention. <NA>
``You <NA>
are <NA>
better <NA>
off <NA>
preventing <NA>
it <NA>
by <NA>
avoiding <NA>
the <NA>
sun <NA>
at <NA>
the <NA>
beginning,'' <NA>
Kraemer <PERSON>
said. <NA>
In <NA>
the <NA>
general <NA>
population, <NA>
these <NA>
are <NA>
the <NA>
most <NA>
common <NA>
kinds <NA>
of <NA>
cancer, <NA>
striking <NA>
about <NA>
500,000 <NA>
people <NA>
in <NA>
the <NA>
United_States <LOCATION>
each <NA>
year. <NA>
In <NA>
the <NA>
study, <NA>
published <NA>
in <NA>
Thursday <DATE>
's <NA>
New <NA>
England <NA>
Journal <NA>
of <NA>
Medicine, <NA>
five <NA>
patients <NA>
took <NA>
high <NA>
doses <NA>
of <NA>
Accutane <NA>
for <NA>
two <NA>
years. <NA>
Kraemer <PERSON>
said <NA>
high <NA>
doses <NA>
of <NA>
Accutane <NA>
could <NA>
be <NA>
warranted <NA>
for <NA>
some <NA>
people, <NA>
such <NA>
as <NA>
sailors <NA>
and <NA>
farmers, <NA>
who <NA>
have <NA>
frequent <NA>
skin <NA>
cancers <NA>
because <NA>
of <NA>
their <NA>
lifelong <NA>
exposure <NA>
to <NA>
the <NA>
sun. <NA>
Food <NA>
and <NA>
Drug <NA>
Administration <NA>
last_month_ordered_its_maker,_<PERSON>Hoffman-La_Roche </ORGANIZATION>
, <NA>
to <NA>
warn <NA>
customers <NA>
by <NA>
printing <NA>
a <NA>
picture <NA>
of <NA>
a <NA>
deformed <NA>
baby <NA>
on <NA>
the <NA>
drug's <NA>
packaging. <NA>
At <NA>
least <NA>
two <NA>
other <NA>
studies <NA>
using <NA>
Accutane <NA>
to <NA>
treat <NA>
pre-cancerous <NA>
ailments <NA>
have <NA>
been <NA>
published <NA>
over <NA>
the <NA>
last_two_years <DATE>
. <NA>
Harley <NA>
Haynes <NA>
of_<ORGANIZATION>Brigham_and_Women's_Hospital </PERSON>
in <NA>
Boston <LOCATION>
said <NA>
that <NA>
vitamin <NA>
A <NA>
drugs <NA>
similar <NA>
to <NA>
Accutane <NA>
may <NA>
someday <NA>
be <NA>
used <NA>
to <NA>
treat <NA>
other <NA>
tumors <NA>
of <NA>
epithelial <NA>
tissue, <NA>
such <NA>
as <NA>
cancers <NA>
of <NA>
the <NA>
lung, <NA>
stomach, <NA>
colon, <NA>
bladder, <NA>
cervix <NA>
and <NA>
breast. <NA>
AP891002-0293 <DOCNO>
T. <NA>
Franklin_Williams <PERSON>
, <NA>
a <NA>
geriatrics <NA>
physician, <NA>
is <NA>
director <NA>
of <NA>
the <NA>
National_Institute_on_Aging <ORGANIZATION>
, <NA>
one <NA>
of <NA>
the <NA>
13 <NA>
institutes <NA>
that <NA>
comprise <NA>
the <NA>
National_Institutes_of_Health_of_the_Department_of_Health_and_Human_Services <ORGANIZATION>
. <NA>
T. <NA>
Franklin_Williams <PERSON>
, <NA>
a <NA>
geriatrics <NA>
physician, <NA>
is <NA>
director <NA>
of <NA>
the <NA>
National_Institute_on_Aging <ORGANIZATION>
, <NA>
one <NA>
of <NA>
the <NA>
13 <NA>
institutes <NA>
that <NA>
comprise <NA>
the <NA>
National_Institutes_of_Health_of_the_Department_of_Health_and_Human_Services <ORGANIZATION>
. <NA>
FBIS4-67605 <DOCNO>
BFN <NA>
[Text] <NA>
Sofia <LOCATION>
, <NA>
March_15 <DATE>
(BTA) <NA>
-- <NA>
Associate <NA>
Professor <NA>
Khristo_Tsvetanski <PERSON>
, <NA>
a <NA>
cancer <NA>
specialist <NA>
working <NA>
with <NA>
the <NA>
National_Oncology_Centre <ORGANIZATION>
since <NA>
1970 <DATE>
, <NA>
gave <NA>
BTA <NA>
an <NA>
interview <NA>
on <NA>
the <NA>
incidence <NA>
of <NA>
cancer <NA>
in <NA>
Bulgaria <LOCATION>
. <NA>
Q: <NA>
How <NA>
does <NA>
the <NA>
cancer <NA>
incidence <NA>
in <NA>
Bulgaria <LOCATION>
compare <NA>
to <NA>
European <NA>
rates? <NA>
A: <NA>
Bulgaria <LOCATION>
ranks <NA>
in <NA>
the <NA>
medium <NA>
range <NA>
of <NA>
cancer <NA>
incidence, <NA>
according <NA>
to <NA>
figures <NA>
released <NA>
by <NA>
the <NA>
Epidemiology <NA>
Unit <NA>
of <NA>
the <NA>
National_Oncology_Centre <ORGANIZATION>
, <NA>
which <NA>
are <NA>
also <NA>
reported <NA>
to <NA>
the <NA>
World_Health_Organization <ORGANIZATION>
. <NA>
Q: <NA>
Is <NA>
cancer <NA>
incidence <NA>
in <NA>
Bulgaria <LOCATION>
on <NA>
the <NA>
increase? <NA>
A: <NA>
There <NA>
is <NA>
an <NA>
upward <NA>
trend <NA>
worldwide <NA>
and <NA>
Bulgaria <LOCATION>
is <NA>
no <NA>
exception. <NA>
In <NA>
1985 <DATE>
, <NA>
20,881 <NA>
developed <NA>
cancer, <NA>
bringing <NA>
the <NA>
total <NA>
number <NA>
of <NA>
cancer <NA>
patients <NA>
to <NA>
132,374. <NA>
The <NA>
1990 <DATE>
figures <NA>
are <NA>
22,021 <NA>
and <NA>
153,651, <NA>
respectively. <NA>
In <NA>
1992 <DATE>
, <NA>
22,956 <NA>
Bulgarians <NA>
developed <NA>
cancer, <NA>
bringing <NA>
the <NA>
total <NA>
to <NA>
139,243. <NA>
Q: <NA>
Which <NA>
types <NA>
of <NA>
cancer <NA>
are <NA>
the <NA>
most <NA>
widespread <NA>
in <NA>
Bulgaria <LOCATION>
? <NA>
Q: <NA>
Is <NA>
cancer <NA>
diagnosed <NA>
early <NA>
in <NA>
Bulgaria <LOCATION>
? <NA>
A: <NA>
Comparing <NA>
Bulgaria <LOCATION>
to <NA>
the <NA>
developed <NA>
countries, <NA>
there <NA>
is <NA>
a <NA>
lot <NA>
to <NA>
be <NA>
desired <NA>
in <NA>
this <NA>
respect. <NA>
In <NA>
1990 <DATE>
, <NA>
52.99_percent <PERCENT>
of <NA>
patients <NA>
were <NA>
diagnosed <NA>
early. <NA>
In <NA>
1992 <DATE>
their <NA>
proportion <NA>
was <NA>
48.58_percent <PERCENT>
. <NA>
Starting <NA>
from <NA>
1956 <DATE>
, <NA>
all <NA>
sexually <NA>
active <NA>
women <NA>
were <NA>
invited <NA>
to <NA>
be <NA>
screened <NA>
for <NA>
cervical <NA>
cancer. <NA>
In <NA>
1971 <DATE>
the <NA>
smear <NA>
( <NA>
Pap <ORGANIZATION>
) <NA>
test <NA>
was <NA>
introduced. <NA>
It <NA>
is <NA>
a <NA>
pity <NA>
that <NA>
screening <NA>
has <NA>
not <NA>
been <NA>
done <NA>
since <NA>
1990 <DATE>
. <NA>
WSJ891031-0047 <DOCNO>
"It's <NA>
a <NA>
super-exciting <NA>
set <NA>
of <NA>
discoveries," <NA>
says <NA>
Bert_Vogelstein <PERSON>
, <NA>
a <NA>
Johns_Hopkins_University <ORGANIZATION>
researcher <NA>
who <NA>
has <NA>
just <NA>
found <NA>
a <NA>
gene <NA>
pivotal <NA>
to <NA>
the <NA>
triggering <NA>
of <NA>
colon <NA>
cancer. <NA>
The <NA>
newly <NA>
identified <NA>
genes <NA>
differ <NA>
from <NA>
a <NA>
family <NA>
of <NA>
genes <NA>
discovered <NA>
in <NA>
the <NA>
early <NA>
1980s <DATE>
called <NA>
oncogenes. <NA>
Bill <NA>
and <NA>
Bonnie_Quinlan <PERSON>
are <NA>
among <NA>
the <NA>
first <NA>
beneficiaries <NA>
of <NA>
the <NA>
new <NA>
findings. <NA>
The <NA>
Dedham <LOCATION>
, <NA>
Mass. <LOCATION>
, <NA>
couple <NA>
knew <NA>
even <NA>
before <NA>
Bonnie <PERSON>
became <NA>
pregnant <NA>
in <NA>
1987 <DATE>
that <NA>
any <NA>
child <NA>
of <NA>
theirs <NA>
had <NA>
a <NA>
50% <PERCENT>
chance <NA>
of <NA>
being <NA>
at <NA>
risk <NA>
for <NA>
retinoblastoma, <NA>
an <NA>
eye <NA>
cancer <NA>
that <NA>
occurs <NA>
about <NA>
once <NA>
every <NA>
20,000 <NA>
births. <NA>
Because <NA>
of <NA>
the <NA>
isolation <NA>
of <NA>
the <NA>
retinoblastoma <NA>
tumor-suppressor <NA>
gene, <NA>
it <NA>
became <NA>
possible <NA>
last <NA>
January <DATE>
to <NA>
find <NA>
out <NA>
what <NA>
threat <NA>
the <NA>
Quinlan <PERSON>
baby <NA>
faced. <NA>
A <NA>
test <NA>
using <NA>
new <NA>
"genetic <NA>
probes" <NA>
showed <NA>
that <NA>
little <NA>
Will_Quinlan <PERSON>
had <NA>
not <NA>
inherited <NA>
a <NA>
damaged <NA>
retinoblastoma <NA>
supressor <NA>
gene <NA>
and, <NA>
therefore, <NA>
faced <NA>
no <NA>
more <NA>
risk <NA>
than <NA>
other <NA>
children <NA>
of <NA>
developing <NA>
the <NA>
rare <NA>
cancer. <NA>
Equally <NA>
important, <NA>
the <NA>
initial <NA>
discovery <NA>
of <NA>
the <NA>
gene <NA>
that <NA>
controls <NA>
retinal <NA>
cell <NA>
growth, <NA>
made <NA>
by <NA>
a <NA>
Boston <LOCATION>
doctor <NA>
named <NA>
Thaddeus_Dryja <PERSON>
, <NA>
has <NA>
opened <NA>
a <NA>
field <NA>
of <NA>
cancer <NA>
study, <NA>
which <NA>
in <NA>
recent <NA>
months <NA>
has <NA>
exploded. <NA>
"It <NA>
turns <NA>
out <NA>
that <NA>
studying <NA>
a <NA>
tragic <NA>
but <NA>
uncommon <NA>
tumor <NA>
made <NA>
possible <NA>
some <NA>
fundamental <NA>
insights <NA>
about <NA>
the <NA>
most <NA>
basic <NA>
workings <NA>
of <NA>
cancer," <NA>
says <NA>
Samuel_Broder <PERSON>
, <NA>
director <NA>
of <NA>
the <NA>
National_Cancer_Institute <ORGANIZATION>
. <NA>
Dryja <NA>
made_his_retinoblastoma_discovery_in_<DATE>1986 </PERSON>
. <NA>
Then <NA>
last <NA>
spring <DATE>
, <NA>
researchers <NA>
reported <NA>
finding <NA>
a <NA>
gene <NA>
called <NA>
p53 <NA>
which, <NA>
if <NA>
impaired, <NA>
turns <NA>
healthy <NA>
colon <NA>
cells <NA>
cancerous. <NA>
Right <NA>
now <NA>
about <NA>
a <NA>
dozen <NA>
laboratories, <NA>
in <NA>
the <NA>
U.S. <LOCATION>
, <NA>
Canada <LOCATION>
and <NA>
Britain <LOCATION>
, <NA>
are <NA>
racing <NA>
to <NA>
unmask <NA>
other <NA>
suspected <NA>
tumor-suppressing <NA>
genes. <NA>
The <NA>
story <NA>
of <NA>
tumor-suppressor <NA>
genes <NA>
goes <NA>
back <NA>
to <NA>
the <NA>
1970s <DATE>
, <NA>
when <NA>
a <NA>
pediatrician <NA>
named <NA>
Alfred_G._Knudson_Jr. <PERSON>
proposed <NA>
that <NA>
retinoblastoma <NA>
stemmed <NA>
from <NA>
two <NA>
separate <NA>
genetic <NA>
defects. <NA>
Then, <NA>
a <NA>
scientific <NA>
team <NA>
led <NA>
by <NA>
molecular <NA>
geneticist <NA>
Webster_Cavenee <PERSON>
, <NA>
then <NA>
at <NA>
the <NA>
University_of_Utah <ORGANIZATION>
, <NA>
found <NA>
the <NA>
answer. <NA>
Knudson <NA>
,_now_at_<ORGANIZATION>Fox_Chase_Cancer_Research_Center </PERSON>
in <NA>
Philadelphia <LOCATION>
. <NA>
But <NA>
in <NA>
Baltimore <LOCATION>
, <NA>
Vogelstein <NA>
,_a_young_molecular_biologist_at_<ORGANIZATION>Johns_Hopkins_Medical_School </PERSON>
, <NA>
believed <NA>
His <NA>
was <NA>
one <NA>
of <NA>
two <NA>
research <NA>
teams <NA>
in <NA>
1984 <DATE>
to <NA>
report <NA>
dual <NA>
chromosome <NA>
losses <NA>
for <NA>
a <NA>
rare <NA>
childhood <NA>
cancer <NA>
of <NA>
the <NA>
kidney <NA>
called <NA>
Wilm <PERSON>
's <NA>
tumor. <NA>
Vogelstein <NA>
next_turned_his_attention_to_colon_cancer,_the_second_biggest_cancer_killer_in_the_<LOCATION>U.S. </PERSON>
after <NA>
lung <NA>
cancer. <NA>
Vogelstein <NA>
and_a_doctoral_student,_<PERSON>Eric_Fearon </PERSON>
, <NA>
began <NA>
months <NA>
of <NA>
tedious <NA>
and <NA>
often <NA>
frustrating <NA>
probing <NA>
of <NA>
the <NA>
chromosomes <NA>
searching <NA>
for <NA>
signs <NA>
of <NA>
genetic <NA>
damage. <NA>
"It <NA>
was <NA>
the <NA>
confirming <NA>
evidence <NA>
we <NA>
all <NA>
needed <NA>
that <NA>
{gene} <NA>
losses <NA>
were <NA>
critical <NA>
to <NA>
the <NA>
development <NA>
of <NA>
a <NA>
common <NA>
tumor," <NA>
says <NA>
Ray_White <PERSON>
at <NA>
Howard_Hughes_Medical_Institute <ORGANIZATION>
in <NA>
Salt_Lake_City <LOCATION>
. <NA>
For <NA>
months <NA>
the <NA>
Johns_Hopkins <PERSON>
researchers, <NA>
using <NA>
gene <NA>
probes, <NA>
experimentally <NA>
crawled <NA>
down <NA>
the <NA>
length <NA>
of <NA>
chromosome <NA>
17, <NA>
looking <NA>
for <NA>
the <NA>
smallest <NA>
common <NA>
bit <NA>
of <NA>
genetic <NA>
material <NA>
lost <NA>
in <NA>
all <NA>
tumor <NA>
cells. <NA>
Such <NA>
a <NA>
piece <NA>
of <NA>
DNA <ORGANIZATION>
would <NA>
probably <NA>
constitute <NA>
a <NA>
gene. <NA>
When <NA>
they <NA>
found <NA>
it <NA>
last_winter <DATE>
, <NA>
His <NA>
doubts <NA>
stemmed <NA>
from <NA>
the <NA>
fact <NA>
that <NA>
several_years_earlier <DATE>
a <NA>
Princeton_University <ORGANIZATION>
researcher, <NA>
Arnold_Levine <PERSON>
, <NA>
had <NA>
found <NA>
in <NA>
experiments <NA>
with <NA>
mice <NA>
that <NA>
a <NA>
gene <NA>
called <NA>
p53 <NA>
could <NA>
transform <NA>
normal <NA>
cells <NA>
into <NA>
cancerous <NA>
ones. <NA>
Levine <NA>
had_said_the_p53_gene_caused_cancer_by_promoting_growth,_whereas_the_<PERSON>Johns_Hopkins </PERSON>
scientists <NA>
were <NA>
looking <NA>
for <NA>
a <NA>
gene <NA>
that <NA>
suppressed <NA>
growth. <NA>
Despite <NA>
that, <NA>
when <NA>
the <NA>
Johns_Hopkins <PERSON>
scientists <NA>
compared <NA>
the <NA>
gene <NA>
they <NA>
had <NA>
found <NA>
in <NA>
the <NA>
human <NA>
cancer <NA>
cells <NA>
with <NA>
the <NA>
The <NA>
discovery <NA>
"suddenly <NA>
puts <NA>
an <NA>
obscure <NA>
gene <NA>
right <NA>
in <NA>
the <NA>
cockpit <NA>
of <NA>
cancer <NA>
formation," <NA>
says <NA>
Robert_Weinberg <PERSON>
, <NA>
a <NA>
leader <NA>
in <NA>
cancer-gene <NA>
research <NA>
at <NA>
Whitehead_Institute <ORGANIZATION>
in <NA>
Cambridge <LOCATION>
, <NA>
Mass <LOCATION>
. <NA>
Researchers <NA>
in <NA>
Edinburgh <LOCATION>
, <NA>
Scotland <LOCATION>
, <NA>
have <NA>
found <NA>
that <NA>
in <NA>
23 <NA>
of <NA>
38 <NA>
breast <NA>
tumors, <NA>
one <NA>
copy <NA>
of <NA>
chromosome <NA>
17 <NA>
was <NA>
mutated <NA>
at <NA>
the <NA>
spot <NA>
where <NA>
gene <NA>
p53 <NA>
lies. <NA>
In <NA>
a <NA>
report <NA>
out <NA>
last <NA>
week, <NA>
John_Minna <PERSON>
and <NA>
colleagues <NA>
at <NA>
the <NA>
National_Cancer_Institute <ORGANIZATION>
say <NA>
that <NA>
about <NA>
half <NA>
the <NA>
cells <NA>
taken <NA>
from <NA>
lung <NA>
cancer <NA>
tissue <NA>
they <NA>
tested <NA>
are <NA>
missing <NA>
this <NA>
gene. <NA>
At <NA>
the <NA>
same <NA>
time, <NA>
the <NA>
Johns_Hopkins <PERSON>
team <NA>
and <NA>
others <NA>
are <NA>
rushing <NA>
to <NA>
pinpoint <NA>
other <NA>
tumor-suppressor <NA>
genes. <NA>
Ray <NA>
White <NA>
in <NA>
Utah <LOCATION>
and <NA>
Walter_Bodmer <PERSON>
, <NA>
a <NA>
researcher <NA>
in <NA>
Great_Britain <LOCATION>
, <NA>
are <NA>
close <NA>
to <NA>
finding <NA>
another <NA>
gene <NA>
involved <NA>
with <NA>
some <NA>
types <NA>
of <NA>
colon <NA>
cancer, <NA>
thought <NA>
to <NA>
be <NA>
on <NA>
chromosome <NA>
5. <NA>
Already <NA>
two <NA>
major <NA>
pharmaceutical <NA>
companies, <NA>
the <NA>
Squibb <ORGANIZATION>
unit <NA>
of <NA>
Bristol-Myers_Squibb_Co. <ORGANIZATION>
and <NA>
Hoffmann-La_Roche_Inc. <ORGANIZATION>
, <NA>
are <NA>
collaborating <NA>
with <NA>
gene <NA>
hunters <NA>
to <NA>
turn <NA>
the <NA>
anticipated <NA>
cascade <NA>
of <NA>
discoveries <NA>
into <NA>
predictive <NA>
tests <NA>
and, <NA>
maybe, <NA>
new <NA>
therapies. <NA>
Minna <NA>
of_the_<ORGANIZATION>National_Cancer_Institute </PERSON>
, <NA>
"We're <NA>
witnessing <NA>
the <NA>
discovery <NA>
of <NA>
one <NA>
of <NA>
the <NA>
most <NA>
important <NA>
steps <NA>
in <NA>
the <NA>
genesis <NA>
of <NA>
cancer. <NA>
AP901221-0008 <DOCNO>
Researchers <NA>
in <NA>
California <LOCATION>
and <NA>
Utah <LOCATION>
report, <NA>
in <NA>
studies <NA>
published <NA>
today, <NA>
new <NA>
advances <NA>
toward <NA>
isolating <NA>
the <NA>
gene <NA>
linked <NA>
to <NA>
a <NA>
susceptibility <NA>
to <NA>
breast <NA>
cancer <NA>
in <NA>
some <NA>
families. <NA>
Mary-Claire_King <PERSON>
, <NA>
leader <NA>
of <NA>
a <NA>
laboratory <NA>
group <NA>
at <NA>
the <NA>
University_of_California <ORGANIZATION>
, <NA>
Berkeley <LOCATION>
, <NA>
said <NA>
her <NA>
studies <NA>
have <NA>
narrowed <NA>
the <NA>
search <NA>
for <NA>
the <NA>
breast <NA>
cancer <NA>
gene <NA>
to <NA>
a <NA>
specific <NA>
chromosome. <NA>
Comparing <NA>
the <NA>
work <NA>
to <NA>
a <NA>
needle-in-a-haystack <NA>
quest, <NA>
King <PERSON>
said <NA>
in <NA>
an <NA>
interview, <NA>
``We're <NA>
now <NA>
at <NA>
the <NA>
point <NA>
of <NA>
knowing <NA>
the <NA>
handful <NA>
of <NA>
hay <NA>
in <NA>
which <NA>
this <NA>
needle <NA>
lies, <NA>
as <NA>
opposed <NA>
to <NA>
having <NA>
to <NA>
search <NA>
through <NA>
the <NA>
whole <NA>
haystack. <NA>
'' <NA>
A <NA>
research <NA>
group <NA>
at <NA>
the <NA>
University_of_Utah_Health_Sciences_Center <ORGANIZATION>
, <NA>
meanwhile, <NA>
reported <NA>
finding <NA>
that <NA>
proliferative <NA>
breast <NA>
disease, <NA>
a <NA>
condition <NA>
known <NA>
to <NA>
be <NA>
a <NA>
precursor <NA>
of <NA>
breast <NA>
cancer, <NA>
has <NA>
been <NA>
found <NA>
to <NA>
be <NA>
inherited <NA>
in <NA>
some <NA>
families. <NA>
Mark <NA>
H. <NA>
Skolnick <NA>
of_the_<LOCATION>Utah </PERSON>
group. <NA>
Skolnick <PERSON>
and <NA>
King <PERSON>
said <NA>
their <NA>
studies <NA>
could <NA>
lead <NA>
eventually <NA>
to <NA>
tests <NA>
enabling <NA>
women <NA>
with <NA>
known <NA>
breast <NA>
cancer <NA>
risks, <NA>
based <NA>
on <NA>
their <NA>
family <NA>
histories, <NA>
to <NA>
be <NA>
treated <NA>
even <NA>
before <NA>
the <NA>
smallest <NA>
of <NA>
tumors <NA>
have <NA>
formed. <NA>
``The <NA>
long-term <NA>
goal <NA>
of <NA>
this <NA>
kind <NA>
of <NA>
work <NA>
is <NA>
to <NA>
try <NA>
to <NA>
develop <NA>
diagnostic <NA>
techniques <NA>
that <NA>
will <NA>
allow <NA>
the <NA>
detection <NA>
of <NA>
aberrant <NA>
cells <NA>
in <NA>
the <NA>
breast <NA>
at <NA>
an <NA>
extremely <NA>
early <NA>
stage,'' <NA>
said <NA>
King <PERSON>
. <NA>
'' <NA>
Such <NA>
clinical <NA>
applications <NA>
of <NA>
the <NA>
two <NA>
studies, <NA>
however, <NA>
are <NA>
many <NA>
years <NA>
away, <NA>
King <PERSON>
said. <NA>
In <NA>
the <NA>
California <LOCATION>
project, <NA>
the <NA>
scientist <NA>
said <NA>
her <NA>
team <NA>
studied <NA>
more <NA>
than <NA>
400 <NA>
members <NA>
of <NA>
23 <NA>
families <NA>
with <NA>
a <NA>
total <NA>
of <NA>
146 <NA>
cases <NA>
of <NA>
breast <NA>
cancer. <NA>
By <NA>
analyzing <NA>
blood <NA>
samples <NA>
and <NA>
then <NA>
comparing <NA>
genetic <NA>
patterns, <NA>
King <PERSON>
said, <NA>
the <NA>
scientists <NA>
found <NA>
nine <NA>
families <NA>
in <NA>
which <NA>
susceptibility <NA>
to <NA>
the <NA>
early <NA>
onset <NA>
of <NA>
breast <NA>
cancer <NA>
was <NA>
linked <NA>
to <NA>
chromosome <NA>
17q, <NA>
one <NA>
of <NA>
the <NA>
46 <NA>
chromosomes <NA>
found <NA>
in <NA>
human <NA>
cells. <NA>
Families <NA>
such <NA>
as <NA>
those <NA>
studied, <NA>
where <NA>
early <NA>
breast <NA>
cancer <NA>
occurs <NA>
often, <NA>
are <NA>
``really, <NA>
really <NA>
rare,'' <NA>
said <NA>
King <PERSON>
. <NA>
``Less <NA>
than <NA>
5_percent <PERCENT>
of <NA>
breast <NA>
cancer <NA>
patients <NA>
are <NA>
in <NA>
such <NA>
families. <NA>
'' <NA>
Skolnick <PERSON>
said <NA>
his <NA>
researchers <NA>
studied <NA>
103 <NA>
women <NA>
from <NA>
20 <NA>
families <NA>
in <NA>
which <NA>
there <NA>
were <NA>
at <NA>
least <NA>
two <NA>
close <NA>
blood <NA>
relatives <NA>
with <NA>
breast <NA>
cancer. <NA>
Thirty-five <NA>
percent <NA>
of <NA>
the <NA>
women <NA>
in <NA>
families <NA>
where <NA>
breast <NA>
cancer <NA>
was <NA>
common <NA>
had <NA>
laboratory <NA>
evidence <NA>
of <NA>
proliferative <NA>
breast <NA>
disease, <NA>
or <NA>
PBD <ORGANIZATION>
, <NA>
Skolnick <PERSON>
said. <NA>
Among <NA>
women <NA>
in <NA>
the <NA>
control <NA>
study, <NA>
only <NA>
13_percent <PERCENT>
had <NA>
PBD <ORGANIZATION>
. <NA>
The <NA>
study <NA>
demonstrates <NA>
that <NA>
there <NA>
is <NA>
an <NA>
inherited <NA>
component <NA>
in <NA>
developing <NA>
PBD <ORGANIZATION>
, <NA>
he <NA>
said. <NA>
Skolnick <PERSON>
said <NA>
the <NA>
study <NA>
also <NA>
suggests <NA>
that <NA>
the <NA>
inherited <NA>
risk <NA>
for <NA>
breast <NA>
cancer, <NA>
thought <NA>
previously <NA>
to <NA>
be <NA>
a <NA>
factor <NA>
primarily <NA>
in <NA>
families <NA>
in <NA>
which <NA>
cases <NA>
develop <NA>
in <NA>
young <NA>
women <NA>
of <NA>
childbearing <NA>
age <NA>
and <NA>
in <NA>
women <NA>
who <NA>
develop <NA>
cancer <NA>
in <NA>
both <NA>
breasts, <NA>
may <NA>
also <NA>
be <NA>
a <NA>
factor <NA>
in <NA>
families <NA>
where <NA>
the <NA>
cancer <NA>
develops <NA>
only <NA>
in <NA>
older <NA>
women. <NA>
For <NA>
this <NA>
reason, <NA>
Skolnick <PERSON>
said <NA>
the <NA>
inherited <NA>
risk <NA>
of <NA>
breast <NA>
cancer <NA>
may <NA>
be <NA>
more <NA>
common <NA>
than <NA>
previously <NA>
believed. <NA>
Science, <NA>
which <NA>
published <NA>
the <NA>
studies, <NA>
is <NA>
the <NA>
journal <NA>
of <NA>
the <NA>
American_Association <ORGANIZATION>
for <NA>
the <NA>
Advancement_of_Science <ORGANIZATION>
. <NA>
WSJ911115-0022 <DOCNO>
"There <NA>
is <NA>
little <NA>
doubt <NA>
that <NA>
skin <NA>
cancer <NA>
involves <NA>
exposure <NA>
to <NA>
the <NA>
sun, <NA>
but <NA>
we <NA>
didn't <NA>
know <NA>
exactly <NA>
what <NA>
happens," <NA>
said <NA>
David_Leffell <PERSON>
, <NA>
chief <NA>
of <NA>
dermatologic <NA>
surgery <NA>
at <NA>
the <NA>
Yale <ORGANIZATION>
medical <NA>
school. <NA>
The <NA>
Yale <ORGANIZATION>
team, <NA>
aided <NA>
by <NA>
researchers <NA>
in <NA>
Boston <LOCATION>
, <NA>
New_York <LOCATION>
and <NA>
Uppsala <LOCATION>
, <NA>
Sweden <LOCATION>
, <NA>
made <NA>
the <NA>
connection <NA>
by <NA>
looking <NA>
at <NA>
cancer <NA>
cells <NA>
taken <NA>
from <NA>
24 <NA>
patients. <NA>
They <NA>
found <NA>
that <NA>
one <NA>
tiny <NA>
"hot <NA>
spot" <NA>
in <NA>
the <NA>
p53 <NA>
gene <NA>
was <NA>
altered <NA>
in <NA>
the <NA>
exact <NA>
same <NA>
manner <NA>
in <NA>
72% <PERCENT>
of <NA>
the <NA>
cases <NA>
they <NA>
studied. <NA>
"What <NA>
really <NA>
surprised <NA>
us <NA>
is <NA>
that <NA>
the <NA>
defect <NA>
was <NA>
exactly <NA>
the <NA>
kind <NA>
of <NA>
change <NA>
that <NA>
only <NA>
occurs <NA>
when <NA>
(genetic <NA>
material) <NA>
is <NA>
exposed <NA>
to <NA>
ultraviolet <NA>
light," <NA>
said <NA>
Douglas_Brash <PERSON>
, <NA>
who <NA>
led <NA>
the <NA>
research <NA>
for <NA>
the <NA>
Yale <ORGANIZATION>
group. <NA>
There <NA>
are <NA>
about <NA>
650,000 <NA>
new <NA>
cases <NA>
of <NA>
skin <NA>
cancer <NA>
in <NA>
the <NA>
U.S. <LOCATION>
every <NA>
year, <NA>
and <NA>
about <NA>
8,500 <NA>
deaths <NA>
related <NA>
to <NA>
the <NA>
disease, <NA>
making <NA>
it <NA>
the <NA>
most <NA>
common <NA>
of <NA>
all <NA>
cancers. <NA>
The <NA>
Yale <ORGANIZATION>
research, <NA>
published <NA>
today <DATE>
in <NA>
the <NA>
National <NA>
Proceedings <NA>
of <NA>
the <NA>
Academy_of_Science <ORGANIZATION>
, <NA>
involved <NA>
cancer <NA>
of <NA>
squamous <NA>
skin <NA>
cells. <NA>
AP891124-0037 <DOCNO>
John <NA>
Stehlin <NA>
,_scientific_director_at_the_<ORGANIZATION>Stehlin_Foundation_for_Cancer_Research </PERSON>
at <NA>
Houston <LOCATION>
's <NA>
Some <NA>
mice <NA>
treated <NA>
with <NA>
9-AC <NA>
are <NA>
still <NA>
alive <NA>
after <NA>
surviving <NA>
the <NA>
equivalent, <NA>
in <NA>
human <NA>
terms, <NA>
of <NA>
20 <NA>
years, <NA>
Stehlin <PERSON>
said <NA>
at <NA>
a <NA>
briefing <NA>
this <NA>
week. <NA>
'' <NA>
Colon <NA>
cancer <NA>
is <NA>
the <NA>
third <NA>
most <NA>
common <NA>
cancer <NA>
in <NA>
the <NA>
United_States <LOCATION>
with <NA>
147,000 <NA>
new <NA>
cases <NA>
reported <NA>
each <NA>
year. <NA>
Very <NA>
little <NA>
progress <NA>
has <NA>
been <NA>
made <NA>
in <NA>
colon <NA>
cancer <NA>
treatment <NA>
in <NA>
the <NA>
past <NA>
40 <NA>
years, <NA>
Stehlin <PERSON>
said. <NA>
Chemotherapy <NA>
and <NA>
immunotherapy <NA>
have <NA>
had <NA>
little <NA>
effect <NA>
and <NA>
the <NA>
use <NA>
of <NA>
the <NA>
drug <NA>
levamisole <NA>
with <NA>
5-fluorouracil <NA>
improves <NA>
the <NA>
survival <NA>
rate <NA>
in <NA>
about <NA>
15_percent <PERCENT>
of <NA>
patients, <NA>
he <NA>
said. <NA>
Monroe <NA>
Wall_of_the_<ORGANIZATION>Research_Triangle_Institute </PERSON>
in <NA>
North_Carolina <LOCATION>
isolated <NA>
camptothecin <NA>
in <NA>
the <NA>
1960s <DATE>
. <NA>
If <NA>
approved <NA>
by <NA>
the <NA>
Food_and_Drug_Administration <ORGANIZATION>
, <NA>
the <NA>
researchers <NA>
could <NA>
start <NA>
tests <NA>
on <NA>
humans <NA>
as <NA>
early <NA>
as <NA>
next <NA>
year. <NA>
Doctors <NA>
at <NA>
Johns_Hopkins_School_of_Medicine <ORGANIZATION>
in <NA>
Baltimore <LOCATION>
have <NA>
identified <NA>
camptothecin <NA>
as <NA>
a <NA>
potent <NA>
inhibitor <NA>
of <NA>
topoisomerase <NA>
I, <NA>
an <NA>
enzyme <NA>
present <NA>
in <NA>
animal <NA>
cells <NA>
which <NA>
controls <NA>
cell <NA>
division. <NA>
Studies <NA>
at <NA>
New_York_University <ORGANIZATION>
say <NA>
cancerous <NA>
colons <NA>
usually <NA>
have <NA>
more <NA>
topoisomerase <NA>
I <NA>
than <NA>
normal <NA>
colons. <NA>
FBIS4-67640 <DOCNO>
CSO <NA>
[Article:_"<PERSON>Tim_Radford <FÊP=106>
on <NA>
an <NA>
Atlas <NA>
Which <NA>
Utilises <NA>
an <NA>
18-Year <NA>
Study_To_Demonstrate_the_Geography_of_Disease:_Cancer_Map_Shows_North-South_Divide"]_[Text]_The_first_atlas_of_cancer_cases_in_<LOCATION>England </F>
and <NA>
Wales <LOCATION>
, <NA>
published <NA>
yesterday <NA>
[not <NA>
reproduced] <NA>
throws <NA>
the <NA>
geography <NA>
of <NA>
disease <NA>
into <NA>
relief <NA>
across <NA>
the <NA>
country. <NA>
More <NA>
than <NA>
70 <NA>
maps, <NA>
commissioned <NA>
by <NA>
the <NA>
Cancer_Research_Campaign <ORGANIZATION>
, <NA>
show <NA>
an <NA>
excess <NA>
of <NA>
lung <NA>
cancers <NA>
in <NA>
the <NA>
north <NA>
of <NA>
England <LOCATION>
, <NA>
of <NA>
breast <NA>
cancers <NA>
among <NA>
older <NA>
women <NA>
in <NA>
the <NA>
south, <NA>
and <NA>
as <NA>
"hot <NA>
spot" <NA>
of <NA>
stomach <NA>
cancer <NA>
in <NA>
Wales <LOCATION>
. <NA>
The <NA>
atlas <NA>
shows <NA>
a <NA>
less <NA>
easily <NA>
explained <NA>
excess <NA>
of <NA>
lip <NA>
cancer <NA>
in <NA>
East_Anglia <LOCATION>
and <NA>
of <NA>
thyroid <NA>
cancer <NA>
in <NA>
north_Wales <LOCATION>
. <NA>
It <NA>
also <NA>
reveals <NA>
Anglesey <LOCATION>
as <NA>
having <NA>
the <NA>
highest <NA>
incidence <NA>
of <NA>
penile, <NA>
cervical <NA>
and <NA>
lip <NA>
cancer <NA>
in <NA>
the <NA>
country. <NA>
"These <NA>
can <NA>
include <NA>
your <NA>
job, <NA>
where <NA>
and <NA>
how <NA>
you <NA>
live, <NA>
your <NA>
diet, <NA>
your <NA>
drinking <NA>
and <NA>
smoking <NA>
habits, <NA>
and <NA>
your <NA>
sexual <NA>
behaviour," <NA>
said <NA>
Professor <NA>
Gordon_McVie <PERSON>
of <NA>
the <NA>
Cancer_Research_Campaign <ORGANIZATION>
. <NA>
" <NA>
Mapping <NA>
of <NA>
diseases <NA>
began <NA>
in <NA>
1850 <DATE>
, <NA>
when <NA>
a <NA>
London <LOCATION>
doctor <NA>
tracked <NA>
cholera <NA>
cases <NA>
and <NA>
found <NA>
a <NA>
variation <NA>
according <NA>
to <NA>
source <NA>
of <NA>
water <NA>
supply. <NA>
The <NA>
atlas <NA>
is <NA>
supported <NA>
by <NA>
appendices <NA>
carrying <NA>
regional <NA>
and <NA>
county <NA>
information <NA>
on <NA>
abortion <NA>
rates, <NA>
air <NA>
pollution, <NA>
alcohol <NA>
consumption, <NA>
household <NA>
food <NA>
purchases, <NA>
percentages <NA>
of <NA>
residents <NA>
born <NA>
outside <NA>
Britain <LOCATION>
, <NA>
socio-economic <NA>
and <NA>
educational <NA>
status, <NA>
occupation, <NA>
venereal <NA>
disease <NA>
clinic <NA>
attendances, <NA>
and <NA>
so <NA>
on. <NA>
The <NA>
maps <NA>
were <NA>
prepared <NA>
by <NA>
Dr <NA>
Anthony_Swerdlow <PERSON>
and <NA>
Dr_Isabel_dos_Santos_Silva <PERSON>
, <NA>
of <NA>
the <NA>
London_School_of_Hygiene_and_Tropical_Medicine <ORGANIZATION>
. <NA>
They <NA>
are <NA>
based <NA>
on <NA>
records <NA>
of <NA>
an <NA>
average <NA>
176,000 <NA>
cases <NA>
of <NA>
cancers <NA>
in <NA>
each <NA>
year <NA>
between <NA>
1968 <DATE>
and <NA>
1985 <DATE>
. <NA>
Lancashire <NA>
has <NA>
63 <NA>
per <NA>
cent <NA>
more <NA>
male <NA>
lung <NA>
cancers <NA>
than <NA>
the <NA>
average <NA>
for <NA>
the <NA>
rest <NA>
of <NA>
the <NA>
country; <NA>
Montgomeryshire <ORGANIZATION>
recorded <NA>
85 <NA>
per <NA>
cent <NA>
fewer. <NA>
Caernarvonshire <NA>
and <NA>
Staffordshire <LOCATION>
showed <NA>
37 <NA>
per <NA>
cent <NA>
higher <NA>
than <NA>
average <NA>
rates <NA>
of <NA>
stomach <NA>
cancer, <NA>
the <NA>
Isle <NA>
of <NA>
Wight <NA>
35 <NA>
per <NA>
cent <NA>
lower. <NA>
Prostate <NA>
cancer <NA>
incidence <NA>
was <NA>
higher <NA>
in <NA>
Cambridgeshire <LOCATION>
and <NA>
Somerset <LOCATION>
, <NA>
lower <NA>
in <NA>
Denbighshire <LOCATION>
and <NA>
Durham <LOCATION>
. <NA>
Lung <NA>
cancer <NA>
among <NA>
women <NA>
under <NA>
45 <NA>
was <NA>
lowest <NA>
(60 <NA>
per <NA>
cent <NA>
lower) <NA>
in <NA>
Hereford <LOCATION>
and <NA>
Worcester <LOCATION>
and <NA>
highest <NA>
(74 <NA>
per <NA>
cent <NA>
higher) <NA>
in <NA>
Northumberland <LOCATION>
. <NA>
Breast <NA>
cancer <NA>
for <NA>
women <NA>
under <NA>
45 <NA>
was <NA>
highest <NA>
in <NA>
Lincolnshire <LOCATION>
(40 <NA>
per <NA>
cent) <NA>
and <NA>
lowest <NA>
in <NA>
Camarthenshire <NA>
(24 <NA>
per <NA>
cent). <NA>
The <NA>
Atlas_of_Cancer_Incidence <ORGANIZATION>
in <NA>
England <LOCATION>
and <NA>
Wales <LOCATION>
1968-1985; <NA>
Oxford_University_Press <ORGANIZATION>
; <NA>
&pound;170. <NA>
WSJ911202-0097 <DOCNO>
Tamoxifen <NA>
is <NA>
sold <NA>
in <NA>
the <NA>
U.S. <LOCATION>
as <NA>
Nolvadex <NA>
by <NA>
the <NA>
ICI_Pharmaceuticals <ORGANIZATION>
unit <NA>
of <NA>
Imperial_Chemical_Industries_PLC <ORGANIZATION>
of <NA>
Britain <LOCATION>
. <NA>
Although <NA>
tamoxifen <NA>
was <NA>
first <NA>
marketed <NA>
in <NA>
1977 <DATE>
for <NA>
treating <NA>
advanced <NA>
breast <NA>
cancer, <NA>
research <NA>
in <NA>
the <NA>
last <NA>
five <NA>
years <NA>
or <NA>
so <NA>
has <NA>
indicated <NA>
the <NA>
drug <NA>
can <NA>
prevent <NA>
breast <NA>
cancer. <NA>
The <NA>
new <NA>
evidence <NA>
on <NA>
tamoxifen's <NA>
effects <NA>
on <NA>
cholesterol, <NA>
for <NA>
example, <NA>
lends <NA>
support <NA>
to <NA>
a <NA>
suggested <NA>
large-scale <NA>
trial <NA>
in <NA>
healthy <NA>
older <NA>
women <NA>
to <NA>
see <NA>
if <NA>
the <NA>
drug <NA>
can <NA>
reduce <NA>
the <NA>
incidence <NA>
of <NA>
breast <NA>
cancer, <NA>
heart <NA>
disease <NA>
and <NA>
bone <NA>
fractures <NA>
due <NA>
to <NA>
osteoporosis, <NA>
the <NA>
weakening <NA>
of <NA>
the <NA>
bones <NA>
commonly <NA>
seen <NA>
in <NA>
women <NA>
after <NA>
menopause, <NA>
the <NA>
Wisconsin <LOCATION>
researchers <NA>
stated <NA>
in <NA>
the <NA>
report <NA>
in <NA>
the <NA>
The <NA>
researchers, <NA>
headed <NA>
by <NA>
Richard_R._Love <PERSON>
of <NA>
the <NA>
university's <NA>
Clinical_Cancer_Center <ORGANIZATION>
, <NA>
said <NA>
they <NA>
had <NA>
done <NA>
periodic <NA>
blood <NA>
tests <NA>
on <NA>
64 <NA>
women <NA>
who <NA>
were <NA>
taking <NA>
tamoxifen <NA>
in <NA>
an <NA>
experiment <NA>
to <NA>
see <NA>
if <NA>
the <NA>
drug <NA>
would <NA>
reduce <NA>
the <NA>
recurrence <NA>
of <NA>
breast <NA>
cancers. <NA>
The <NA>
mean <NA>
cholesterol <NA>
level <NA>
of <NA>
the <NA>
women <NA>
who <NA>
had <NA>
been <NA>
taking <NA>
tamoxifen <NA>
for <NA>
two <NA>
years <NA>
was <NA>
12% <PERCENT>
lower <NA>
than <NA>
that <NA>
of <NA>
the <NA>
women <NA>
who <NA>
took <NA>
the <NA>
placebo <NA>
for <NA>
two <NA>
years. <NA>
The <NA>
mean <NA>
level <NA>
of <NA>
LDL-cholesterol <NA>
was <NA>
20% <PERCENT>
lower <NA>
in <NA>
the <NA>
tamoxifen-treated <NA>
women <NA>
than <NA>
in <NA>
the <NA>
placebo-taking <NA>
women. <NA>
AP880929-0168 <DOCNO>
Federal <NA>
health <NA>
officials <NA>
said <NA>
Thursday <DATE>
that <NA>
hospitalization <NA>
rates <NA>
have <NA>
fallen <NA>
in <NA>
the <NA>
1980s <DATE>
for <NA>
four <NA>
major <NA>
types <NA>
of <NA>
cancer, <NA>
even <NA>
though <NA>
the <NA>
number <NA>
of <NA>
people <NA>
suffering <NA>
from <NA>
the <NA>
diseases <NA>
has <NA>
not <NA>
fallen <NA>
in <NA>
all <NA>
cases. <NA>
The <NA>
national <NA>
Centers_for_Disease_Control <ORGANIZATION>
reported <NA>
that <NA>
hospitalization <NA>
rates <NA>
for <NA>
breast <NA>
cancer, <NA>
lung <NA>
cancer, <NA>
colon <NA>
and <NA>
rectal <NA>
cancer, <NA>
and <NA>
cervical <NA>
cancer <NA>
all <NA>
have <NA>
declined <NA>
during <NA>
the <NA>
decade. <NA>
James <NA>
Mendlein <NA>
,_a_<ORGANIZATION>CDC </PERSON>
researcher. <NA>
``This <NA>
gives <NA>
you <NA>
just <NA>
one <NA>
measure <NA>
of <NA>
the <NA>
health <NA>
care <NA>
impact <NA>
(of <NA>
various <NA>
cancers),'' <NA>
Mendlein <PERSON>
said. <NA>
The <NA>
drop <NA>
in <NA>
hospitalization <NA>
rates <NA>
parallels <NA>
the <NA>
drop <NA>
in <NA>
the <NA>
rate <NA>
of <NA>
occurrence <NA>
of <NA>
cervical <NA>
cancer, <NA>
colorectal <NA>
cancer <NA>
and <NA>
male <NA>
lung <NA>
cancer, <NA>
Mendlein <PERSON>
said. <NA>
For <NA>
1986 <DATE>
, <NA>
the <NA>
latest <NA>
year <NA>
for <NA>
which <NA>
figures <NA>
are <NA>
available, <NA>
the <NA>
CDC <ORGANIZATION>
estimates <NA>
hospital <NA>
discharge <NA>
rates <NA>
as: <NA>
_Breast <NA>
cancer, <NA>
172 <NA>
per <NA>
100,000 <NA>
people, <NA>
down <NA>
from <NA>
a <NA>
peak <NA>
of <NA>
199 <NA>
in <NA>
1983 <DATE>
. <NA>
_Lung <NA>
cancer, <NA>
male, <NA>
142 <NA>
per <NA>
100,000, <NA>
down <NA>
from <NA>
a <NA>
peak <NA>
of <NA>
182 <NA>
in <NA>
1984 <DATE>
. <NA>
_Lung <NA>
cancer, <NA>
female, <NA>
83 <NA>
per <NA>
100,000, <NA>
down <NA>
from <NA>
a <NA>
peak <NA>
of <NA>
100 <NA>
in <NA>
1983 <DATE>
. <NA>
_Colorectal <NA>
cancer, <NA>
86 <NA>
per <NA>
100,000, <NA>
down <NA>
from <NA>
a <NA>
peak <NA>
of <NA>
92 <NA>
in <NA>
1981 <DATE>
. <NA>
_Cervical <NA>
cancer, <NA>
46 <NA>
per <NA>
100,000, <NA>
down <NA>
from <NA>
a <NA>
peak <NA>
of <NA>
89 <NA>
in <NA>
1976 <DATE>
. <NA>
A <NA>
National_Cancer_Institute <ORGANIZATION>
report <NA>
earlier <NA>
this <NA>
year <NA>
put <NA>
breast <NA>
cancer <NA>
at <NA>
its <NA>
highest <NA>
rate <NA>
in <NA>
history, <NA>
and <NA>
it <NA>
is <NA>
still <NA>
the <NA>
leading <NA>
cause <NA>
of <NA>
cancer <NA>
death <NA>
among <NA>
women. <NA>
When <NA>
studying <NA>
hospital <NA>
discharge <NA>
rates, <NA>
``incidence <NA>
or <NA>
occurrence <NA>
is <NA>
just <NA>
one <NA>
of <NA>
the <NA>
forces,'' <NA>
Mendlein <PERSON>
said. <NA>
AP890512-0042 <DOCNO>
Researchers <NA>
report <NA>
in <NA>
a <NA>
study <NA>
published <NA>
today <DATE>
that <NA>
a <NA>
gene <NA>
previously <NA>
linked <NA>
to <NA>
breast <NA>
cancer <NA>
also <NA>
can <NA>
also <NA>
be <NA>
found <NA>
in <NA>
ovarian <NA>
tumors. <NA>
Dr. <NA>
Michael_Press <PERSON>
, <NA>
a <NA>
University_of_Southern_California <ORGANIZATION>
researcher <NA>
who <NA>
participated <NA>
in <NA>
the <NA>
study, <NA>
said <NA>
the <NA>
finding <NA>
raises <NA>
the <NA>
possibility <NA>
that <NA>
diagnostic <NA>
tests <NA>
to <NA>
detect <NA>
the <NA>
gene <NA>
in <NA>
breast <NA>
and <NA>
ovarian <NA>
cancers <NA>
could <NA>
help <NA>
doctors <NA>
determine <NA>
the <NA>
precise <NA>
level <NA>
of <NA>
treatment <NA>
required <NA>
by <NA>
each <NA>
patient. <NA>
These <NA>
types <NA>
of <NA>
cancers <NA>
account <NA>
for <NA>
about <NA>
25_percent <PERCENT>
of <NA>
all <NA>
cancer <NA>
deaths <NA>
in <NA>
women. <NA>
Co-investigators <NA>
with <NA>
Press <NA>
in <NA>
the <NA>
study <NA>
were <NA>
Judith_Udove <PERSON>
of <NA>
USC <ORGANIZATION>
; <NA>
William_Godolphin <PERSON>
of <NA>
the <NA>
Vancouver_General_Hospital <ORGANIZATION>
, <NA>
Canada <LOCATION>
; <NA>
Lovell_Jones <PERSON>
, <NA>
M.D. <LOCATION>
, <NA>
of <NA>
Anderson_Hospital <ORGANIZATION>
, <NA>
Houston <LOCATION>
; <NA>
John_Holt <PERSON>
of <NA>
the <NA>
University_of_Chicago_Medical_Center <ORGANIZATION>
; <NA>
Steven_Wong <PERSON>
, <NA>
Duane_Keith <PERSON>
and <NA>
Wendy_Level_of_UCLA <ORGANIZATION>
; <NA>
Susan_Stuart <PERSON>
at <NA>
Triton_Biosciences <ORGANIZATION>
, <NA>
Alameda <LOCATION>
, <NA>
Calif. <LOCATION>
, <NA>
and <NA>
Axel_Ullrich <PERSON>
of <NA>
Genentech <ORGANIZATION>
, <NA>
South_San_Francisco <LOCATION>
, <NA>
Calif <LOCATION>
. <NA>
Science <NA>
is <NA>
the <NA>
journal <NA>
of <NA>
the <NA>
American_Association <ORGANIZATION>
for <NA>
the <NA>
Advancement_of_Science <ORGANIZATION>
. <NA>
AP890522-0155 <DOCNO>
By <NA>
shrinking <NA>
tumors <NA>
with <NA>
medicine <NA>
before <NA>
surgery, <NA>
doctors <NA>
may <NA>
be <NA>
able <NA>
to <NA>
eliminate <NA>
most <NA>
mastectomies <NA>
as <NA>
the <NA>
standard <NA>
treatment <NA>
for <NA>
breast <NA>
cancer, <NA>
a <NA>
leading <NA>
cancer <NA>
researcher <NA>
said <NA>
Monday <DATE>
. <NA>
Gianni <NA>
Bonadonna <NA>
of_the_<ORGANIZATION>National_Cancer_Institute_of_Italy </PERSON>
said <NA>
his <NA>
study <NA>
showed <NA>
that <NA>
the <NA>
new <NA>
approach <NA>
could <NA>
eliminate <NA>
the <NA>
need <NA>
for <NA>
mastectomies <NA>
in <NA>
87_percent <PERCENT>
of <NA>
women <NA>
who <NA>
otherwise <NA>
would <NA>
have <NA>
had <NA>
this <NA>
mutilating <NA>
surgery. <NA>
The <NA>
procedure <NA>
was <NA>
outlined <NA>
by <NA>
Bonadonna <PERSON>
at <NA>
the <NA>
annual <NA>
meeting <NA>
of <NA>
the <NA>
American_Society_of_Clinical_Oncology <ORGANIZATION>
. <NA>
Bonadonna <NA>
predicted <NA>
that <NA>
by <NA>
1994 <DATE>
, <NA>
the <NA>
100th <NA>
anniversary <NA>
of <NA>
the <NA>
radical <NA>
mastectomy, <NA>
this <NA>
common <NA>
operation <NA>
``will <NA>
be <NA>
very, <NA>
very <NA>
rare. <NA>
So <NA>
far, <NA>
Bonadonna <PERSON>
and <NA>
colleagues <NA>
in <NA>
Italy <LOCATION>
have <NA>
used <NA>
the <NA>
new <NA>
procedure <NA>
on <NA>
97 <NA>
patients <NA>
beginning <NA>
in <NA>
January_1988 <DATE>
. <NA>
Hendre <NA>
Falkson <NA>
of_the_<ORGANIZATION>University_of_Pretoria </PERSON>
in <NA>
South_Africa <LOCATION>
. <NA>
While <NA>
cautious, <NA>
some <NA>
other <NA>
physicians <NA>
said <NA>
they <NA>
found <NA>
Bonadonna <PERSON>
's <NA>
findings <NA>
intriguing. <NA>
Nikolay <NA>
Dimitrov <NA>
of_<ORGANIZATION>Michigan_State_University </PERSON>
. <NA>
Jules <NA>
Harris <NA>
of_Rush_Cancer_in_<LOCATION>Chicago </PERSON>
: <NA>
``I <NA>
think <NA>
it's <NA>
interesting <NA>
and <NA>
exciting <NA>
and <NA>
will <NA>
give <NA>
rise <NA>
to <NA>
a <NA>
great <NA>
deal <NA>
of <NA>
clinical <NA>
investigation. <NA>
'' <NA>
Breast <NA>
cancer <NA>
is <NA>
the <NA>
leading <NA>
cancer <NA>
killer <NA>
of <NA>
women <NA>
in <NA>
the <NA>
United_States <LOCATION>
. <NA>
In <NA>
Bonadonna <PERSON>
's <NA>
study, <NA>
chemotherapy <NA>
was <NA>
given <NA>
to <NA>
women <NA>
whose <NA>
breast <NA>
tumors <NA>
were <NA>
bigger <NA>
than <NA>
three <NA>
centimeters, <NA>
or <NA>
just <NA>
over <NA>
one <NA>
inch. <NA>
The <NA>
drugs <NA>
could <NA>
bring <NA>
them <NA>
down <NA>
below <NA>
three <NA>
centimeters <NA>
in <NA>
87_percent <PERCENT>
of <NA>
the <NA>
women. <NA>
AP890105-0004 <DOCNO>
The <NA>
study <NA>
results <NA>
were <NA>
being <NA>
presented <NA>
today <NA>
at <NA>
a <NA>
hearing <NA>
of <NA>
the <NA>
Food_and_Drug_Administration <ORGANIZATION>
. <NA>
Researchers <NA>
at <NA>
the <NA>
Boston_University_School_of_Medicine <ORGANIZATION>
found <NA>
that <NA>
women <NA>
who <NA>
used <NA>
oral <NA>
contraceptives <NA>
had <NA>
twice <NA>
the <NA>
risk <NA>
of <NA>
breast <NA>
cancer <NA>
compared <NA>
to <NA>
women <NA>
who <NA>
have <NA>
never <NA>
used <NA>
the <NA>
pill. <NA>
The <NA>
issue <NA>
is <NA>
of <NA>
particular <NA>
concern <NA>
because <NA>
oral <NA>
contraceptives <NA>
are <NA>
the <NA>
most <NA>
popular <NA>
form <NA>
of <NA>
birth <NA>
control <NA>
in <NA>
the <NA>
United_States <LOCATION>
, <NA>
and <NA>
breast <NA>
cancer <NA>
is <NA>
the <NA>
second <NA>
most <NA>
common <NA>
fatal <NA>
cancer <NA>
in <NA>
women. <NA>
An <NA>
estimated <NA>
13.2 <NA>
million <NA>
American <NA>
women <NA>
take <NA>
birth <NA>
control <NA>
pills, <NA>
according <NA>
to <NA>
the <NA>
Alan_Guttmacher_Institute <ORGANIZATION>
, <NA>
which <NA>
specializes <NA>
in <NA>
reproductive <NA>
biology. <NA>
About <NA>
42,000 <NA>
women <NA>
die <NA>
of <NA>
breast <NA>
cancer <NA>
each <NA>
year, <NA>
according <NA>
to <NA>
the <NA>
American_Cancer_Society <ORGANIZATION>
. <NA>
The <NA>
Boston_University <ORGANIZATION>
findings <NA>
were <NA>
based <NA>
on <NA>
a <NA>
study <NA>
of <NA>
407 <NA>
women <NA>
with <NA>
breast <NA>
cancer <NA>
and <NA>
a <NA>
cancer-free <NA>
control <NA>
group <NA>
of <NA>
424. <NA>
All <NA>
were <NA>
patients <NA>
in <NA>
hospitals <NA>
in <NA>
Boston <LOCATION>
, <NA>
New_York <LOCATION>
, <NA>
Philadelphia <LOCATION>
and <NA>
Baltimore <LOCATION>
. <NA>
Dr. <NA>
Samuel_Shapiro <PERSON>
, <NA>
director <NA>
of <NA>
the <NA>
Slone_Epidemiology_Unit <ORGANIZATION>
at <NA>
Boston_University <ORGANIZATION>
, <NA>
said <NA>
in <NA>
a <NA>
news <NA>
release <NA>
the <NA>
new <NA>
study <NA>
contradicts <NA>
findings <NA>
in <NA>
earlier <NA>
studies, <NA>
which <NA>
indicated <NA>
there <NA>
was <NA>
no <NA>
association <NA>
between <NA>
use <NA>
of <NA>
the <NA>
pill <NA>
and <NA>
development <NA>
of <NA>
breast <NA>
cancer. <NA>
``Whereas <NA>
early <NA>
studies, <NA>
including <NA>
our <NA>
own, <NA>
were <NA>
reassuring <NA>
about <NA>
the <NA>
use <NA>
of <NA>
oral <NA>
contraceptives <NA>
and <NA>
the <NA>
risk <NA>
of <NA>
breast <NA>
cancer, <NA>
recent <NA>
studies <NA>
reopen <NA>
the <NA>
question, <NA>
but <NA>
do <NA>
not, <NA>
by <NA>
any <NA>
means, <NA>
answer <NA>
it,'' <NA>
said <NA>
Shapiro <PERSON>
. <NA>
Clifford <NA>
R. <NA>
Kay <NA>
and_<PERSON>Philip_C._Hannaford </PERSON>
of <NA>
Manchester <LOCATION>
, <NA>
England <LOCATION>
, <NA>
found <NA>
no <NA>
overall <NA>
increase <NA>
in <NA>
breast <NA>
cancer <NA>
among <NA>
women <NA>
who <NA>
had <NA>
taken <NA>
birth <NA>
control <NA>
pills, <NA>
but <NA>
did <NA>
find <NA>
a <NA>
threefold <NA>
increase <NA>
in <NA>
breast <NA>
cancers <NA>
in <NA>
women <NA>
30 <NA>
to <NA>
34 <NA>
years <NA>
old <NA>
who <NA>
were <NA>
former <NA>
pill <NA>
users. <NA>
The <NA>
Boston_University <ORGANIZATION>
researchers <NA>
said <NA>
it <NA>
is <NA>
possible <NA>
the <NA>
results <NA>
of <NA>
their <NA>
study <NA>
were <NA>
biased <NA>
and <NA>
the <NA>
association <NA>
between <NA>
oral <NA>
contraceptives <NA>
and <NA>
breast <NA>
cancer <NA>
``may <NA>
not <NA>
be <NA>
one <NA>
of <NA>
cause <NA>
and <NA>
effect. <NA>
'' <NA>
Further <NA>
details <NA>
of <NA>
the <NA>
study <NA>
were <NA>
to <NA>
be <NA>
revealed <NA>
at <NA>
the <NA>
FDA <ORGANIZATION>
hearing <NA>
and <NA>
will <NA>
be <NA>
published <NA>
next <NA>
month <NA>
in <NA>
the <NA>
American_Journal_of_Epidemiology <ORGANIZATION>
. <NA>
LA100490-0179 <DOCNO>
Chemotherapy_undergone_before_radiation_treatment_doubled_the_survival_rate_of_a_group_of_patients_with_the_most_common_type_of_inoperable_lung_cancer,_according_to_a_national_study_released_<DATE>today <P>
in <NA>
the <NA>
New_England_Journal_of_Medicine <ORGANIZATION>
. <NA>
<P>_Of_the_patients_who_underwent_only_radiation_therapy,_<PERCENT>11% </P>
survived <NA>
three <NA>
years <NA>
after <NA>
treatment, <NA>
contrasted <NA>
with <NA>
23% <PERCENT>
who <NA>
underwent <NA>
five <NA>
weeks <NA>
of <NA>
chemotherapy <NA>
followed <NA>
by <NA>
six <NA>
weeks <NA>
of <NA>
daily <NA>
radiation <NA>
therapy, <NA>
according <NA>
to <NA>
the <NA>
lead <NA>
author <NA>
of <NA>
the <NA>
study, <NA>
Robert <NA>
O. <NA>
Dillman <NA>
,_medical_director_of_the_<ORGANIZATION>Hoag_Cancer_Center </PERSON>
in <NA>
Newport_Beach <LOCATION>
. <NA>
<P>_"The_good_news_is_that_just_by_adding_that_little_bit_of_chemotherapy,_there_was_a_doubling_in_the_survival_rate,"_<PERSON>Dillman </P>
said. <NA>
"The <NA>
bad <NA>
news <NA>
is <NA>
that <NA>
still <NA>
didn't <NA>
help <NA>
about <NA>
75% <PERCENT>
of <NA>
the <NA>
patients. <NA>
" <NA>
<P>_Dr._<PERSON>John_Glaspy </P>
, <NA>
director <NA>
of <NA>
UCLA <ORGANIZATION>
's <NA>
joint <NA>
oncology <NA>
clinic, <NA>
said <NA>
the <NA>
study <NA>
proves <NA>
there <NA>
are <NA>
benefits <NA>
to <NA>
chemotherapy. <NA>
<P>_"The_big_point_to_the_reader_is,_you'd_better_quit_smoking_--_quick,"_<PERSON>Glaspy </P>
said. <NA>
" <NA>
<P>_The_three-year_study_began_in_<DATE>1984 </P>
and <NA>
examined <NA>
155 <NA>
patients <NA>
with <NA>
inoperable <NA>
non-small-cell <NA>
lung <NA>
cancer, <NA>
which <NA>
affects <NA>
as <NA>
many <NA>
as <NA>
40,000 <NA>
Americans, <NA>
Dillman <PERSON>
said. <NA>
<P>_It_was_sponsored_by_the_<ORGANIZATION>National_Cancer_Institute </P>
and <NA>
conducted <NA>
by <NA>
a <NA>
cooperative <NA>
group <NA>
of <NA>
oncologists <NA>
from <NA>
Hoag <PERSON>
, <NA>
Massachusetts_General_Hospital <ORGANIZATION>
in <NA>
Boston <LOCATION>
, <NA>
Dartmouth_College <ORGANIZATION>
in <NA>
New_Hampshire <LOCATION>
, <NA>
UC_San_Diego <LOCATION>
Medical <NA>
Center, <NA>
McGill_University <ORGANIZATION>
in <NA>
Montreal <LOCATION>
and <NA>
the <NA>
University_of_Missouri <ORGANIZATION>
in <NA>
Columbia <ORGANIZATION>
. <NA>
The <NA>
duration <NA>
was <NA>
short <NA>
enough <NA>
so <NA>
that <NA>
patients <NA>
were <NA>
able <NA>
to <NA>
tolerate <NA>
the <NA>
side <NA>
effects <NA>
of <NA>
the <NA>
chemotherapy <NA>
and <NA>
still <NA>
benefit <NA>
from <NA>
radiation <NA>
treatment, <NA>
Dillman <PERSON>
said. <NA>
<P>_This_was_followed_by_six_weeks_of_daily_treatments_of_high-dose_radiation_therapy,_concentrated_on_the_chest_area_where_the_cancer_was_visible,_<PERSON>Dillman </P>
said. <NA>
<P>_Major_tumor_shrinkage_was_seen_in_<PERCENT>44% </P>
of <NA>
the <NA>
patients <NA>
who <NA>
got <NA>
both <NA>
chemotherapy <NA>
and <NA>
radiation, <NA>
contrasted <NA>
with <NA>
35% <PERCENT>
in <NA>
patients <NA>
who <NA>
received <NA>
only <NA>
radiation, <NA>
the <NA>
study <NA>
said. <NA>
<P>_After_one_year_of_treatment,_<PERCENT>55% </P>
of <NA>
those <NA>
who <NA>
underwent <NA>
chemotherapy <NA>
and <NA>
radiation <NA>
therapy <NA>
survived, <NA>
contrasted <NA>
with <NA>
40% <PERCENT>
among <NA>
the <NA>
radiation-only <NA>
group. <NA>
Three <NA>
years <NA>
after <NA>
treatment, <NA>
23% <PERCENT>
of <NA>
the <NA>
chemotherapy-radiation <NA>
group <NA>
had <NA>
survived, <NA>
contrasted <NA>
with <NA>
11% <PERCENT>
for <NA>
the <NA>
radiation-only <NA>
group. <NA>
<P>_The_three-year_study_was_followed_by_three_more_years_of_tracking_the_patients_and_analyzing_the_data,_<PERSON>Dillman </P>
said. <NA>
Two <NA>
were <NA>
from <NA>
Massachusetts_General_Hospital <ORGANIZATION>
and <NA>
one <NA>
from <NA>
McGill_University <ORGANIZATION>
. <NA>
<P>_A_confirming_study_sponsored_by_the_<ORGANIZATION>National_Cancer_Institute </P>
is <NA>
under <NA>
way <NA>
across <NA>
the <NA>
country. <NA>
<P>_<PERSON>Dillman </P>
said <NA>
the <NA>
key <NA>
finding <NA>
is <NA>
that <NA>
chemotherapy, <NA>
especially <NA>
in <NA>
earlier <NA>
stages, <NA>
is <NA>
more <NA>
effective <NA>
in <NA>
lung <NA>
cancer <NA>
than <NA>
many <NA>
doctors <NA>
realize. <NA>
<P>_"Most_patients_with_lung_cancer_are_diagnosed_by_family_practitioners_or_general_internists,_and_they_often_have_their_initial_care_and_treatment_decisions_made_by_those_physicians,"_<PERSON>Dillman </P>
said. <NA>
FBIS4-20345 <DOCNO>
BFN <NA>
[By_<PERSON>Susie_Weldon <FÊP=106>
] <NA>
[Text]_Viral_hepatitis_infections_surged_in_<DATE>1992 </F>
, <NA>
with <NA>
more <NA>
than <NA>
twice <NA>
as <NA>
many <NA>
cases <NA>
recorded <NA>
as <NA>
in <NA>
the <NA>
previous <NA>
year, <NA>
according <NA>
to <NA>
statistics <NA>
just <NA>
released <NA>
by <NA>
the <NA>
Department_of_Health <ORGANIZATION>
. <NA>
The <NA>
department's <NA>
annual <NA>
report <NA>
for <NA>
1992-93 <NA>
shows <NA>
that <NA>
4,357 <NA>
hepatitis <NA>
cases <NA>
were <NA>
reported <NA>
in <NA>
1992 <DATE>
compared <NA>
with <NA>
1,801 <NA>
in <NA>
1991 <DATE>
. <NA>
The <NA>
report <NA>
said <NA>
the <NA>
infections <NA>
were <NA>
due <NA>
to <NA>
eating <NA>
raw <NA>
or <NA>
badly <NA>
cooked <NA>
seafood <NA>
from <NA>
Hong_Kong <LOCATION>
's <NA>
polluted <NA>
waters. <NA>
Other <NA>
figures <NA>
in <NA>
the <NA>
report <NA>
show <NA>
Hong_Kong <LOCATION>
people <NA>
died <NA>
from <NA>
the <NA>
same <NA>
serious <NA>
diseases, <NA>
in <NA>
about <NA>
the <NA>
same <NA>
proportions, <NA>
in <NA>
1992 <DATE>
as <NA>
in <NA>
the <NA>
previous <NA>
year. <NA>
As <NA>
in <NA>
the <NA>
previous <NA>
year, <NA>
lung <NA>
cancer <NA>
killed <NA>
more <NA>
men <NA>
and <NA>
women <NA>
than <NA>
any <NA>
other <NA>
tumour, <NA>
causing <NA>
2,761 <NA>
deaths <NA>
in <NA>
1992 <DATE>
. <NA>
Although <NA>
slightly <NA>
fewer <NA>
people <NA>
died <NA>
of <NA>
a <NA>
heart <NA>
attack <NA>
in <NA>
1992 <DATE>
-- <NA>
1,785 <NA>
men <NA>
and <NA>
women <NA>
-- <NA>
overall <NA>
deaths <NA>
from <NA>
heart <NA>
disease <NA>
rose <NA>
by <NA>
about <NA>
400, <NA>
to <NA>
5,359. <NA>
Almost <NA>
24_percent <PERCENT>
(83 <NA>
deaths) <NA>
of <NA>
infant <NA>
mortalities <NA>
in <NA>
1992 <DATE>
were <NA>
blamed <NA>
on <NA>
immaturity, <NA>
compared <NA>
with <NA>
about <NA>
15_percent <PERCENT>
(67 <NA>
deaths) <NA>
the <NA>
previous <NA>
year. <NA>
A <NA>
staggering <NA>
82,800 <NA>
patients <NA>
were <NA>
treated <NA>
in <NA>
hospital <NA>
because <NA>
of <NA>
injury <NA>
and <NA>
poisoning <NA>
in <NA>
1992 <DATE>
, <NA>
making <NA>
the <NA>
category <NA>
the <NA>
leading <NA>
cause <NA>
of <NA>
hospital <NA>
admission. <NA>
Of <NA>
the <NA>
1,693 <NA>
deaths <NA>
from <NA>
injury <NA>
and <NA>
poisoning <NA>
-- <NA>
the <NA>
fifth <NA>
biggest <NA>
cause <NA>
of <NA>
death <NA>
in <NA>
1992 <DATE>
-- <NA>
almost <NA>
45_percent <PERCENT>
were <NA>
self <NA>
inflicted <NA>
or <NA>
due <NA>
to <NA>
suicide. <NA>
Nearly <NA>
3,000 <NA>
more <NA>
people <NA>
were <NA>
diagnosed <NA>
with <NA>
sexually <NA>
transmitted <NA>
diseases <NA>
in <NA>
1992 <DATE>
, <NA>
making <NA>
a <NA>
total <NA>
of <NA>
13,257 <NA>
cases. <NA>
Almost <NA>
60_percent <PERCENT>
of <NA>
these <NA>
were <NA>
in <NA>
men <NA>
aged <NA>
between <NA>
2040 <NA>
years. <NA>
One <NA>
person <NA>
died <NA>
because <NA>
of <NA>
injuries <NA>
resulting <NA>
from <NA>
"operation <NA>
of <NA>
war" <NA>
in <NA>
1992 <DATE>
, <NA>
the <NA>
report <NA>
says. <NA>
WSJ880311-0012 <DOCNO>
A <NA>
woman <NA>
who <NA>
undergoes <NA>
an <NA>
X-ray <NA>
breast <NA>
examination <NA>
every <NA>
year <NA>
during <NA>
her <NA>
40s <NA>
would <NA>
cut <NA>
her <NA>
risk <NA>
of <NA>
dying <NA>
of <NA>
breast <NA>
cancer <NA>
by <NA>
26% <PERCENT>
. <NA>
But <NA>
urging <NA>
annual <NA>
mammography <NA>
for <NA>
all <NA>
women <NA>
between <NA>
ages <NA>
40 <NA>
and <NA>
50 <NA>
years <NA>
would <NA>
boost <NA>
the <NA>
nation's <NA>
medical <NA>
bill <NA>
by <NA>
more <NA>
than <NA>
$400_million <MONEY>
for <NA>
the <NA>
year <NA>
2000 <DATE>
while <NA>
saving <NA>
373 <NA>
women <NA>
from <NA>
dying <NA>
of <NA>
breast <NA>
cancer <NA>
that <NA>
year. <NA>
So <NA>
concluded <NA>
an <NA>
unusual <NA>
cost-benefit <NA>
analysis <NA>
of <NA>
X-ray <NA>
mammography <NA>
by <NA>
researchers <NA>
from <NA>
Duke_University <ORGANIZATION>
and <NA>
the <NA>
American_Medical_Association <ORGANIZATION>
, <NA>
published <NA>
this <NA>
week <NA>
in <NA>
the <NA>
association's <NA>
journal. <NA>
Breast <NA>
cancer <NA>
is <NA>
most <NA>
common <NA>
among <NA>
older <NA>
women, <NA>
and <NA>
a <NA>
variety <NA>
of <NA>
studies <NA>
show <NA>
that <NA>
such <NA>
annual <NA>
exams <NA>
can <NA>
reduce <NA>
the <NA>
number <NA>
of <NA>
breast-cancer <NA>
deaths <NA>
among <NA>
women <NA>
over <NA>
50 <NA>
by <NA>
50% <PERCENT>
over <NA>
a <NA>
five-year <NA>
period. <NA>
The <NA>
American_Cancer_Society <ORGANIZATION>
and <NA>
the <NA>
American_Medical_Association <ORGANIZATION>
urge <NA>
women <NA>
to <NA>
have <NA>
at <NA>
least <NA>
one <NA>
mammogram <NA>
taken <NA>
between <NA>
age <NA>
35 <NA>
and <NA>
40 <NA>
and <NA>
have <NA>
additional <NA>
mammograms <NA>
every <NA>
year <NA>
or <NA>
two <NA>
through <NA>
age <NA>
49. <NA>
But <NA>
the <NA>
federal <NA>
government's <NA>
National_Cancer_Institute <ORGANIZATION>
, <NA>
the <NA>
American_College_of_Obstetricians <ORGANIZATION>
and <NA>
Gynecologists <NA>
and <NA>
others <NA>
have <NA>
declined <NA>
to <NA>
recommend <NA>
mammography <NA>
in <NA>
this <NA>
age <NA>
group <NA>
except <NA>
for <NA>
women <NA>
with <NA>
a <NA>
family <NA>
history <NA>
of <NA>
breast <NA>
cancer. <NA>
However, <NA>
these <NA>
odds <NA>
are <NA>
reduced <NA>
to <NA>
60 <NA>
out <NA>
of <NA>
10,000 <NA>
if <NA>
she <NA>
undergoes <NA>
annual <NA>
mammography <NA>
during <NA>
her <NA>
40s, <NA>
a <NA>
26% <PERCENT>
reduction <NA>
in <NA>
the <NA>
risk <NA>
of <NA>
dying <NA>
of <NA>
a <NA>
breast <NA>
cancer <NA>
that <NA>
develops <NA>
before <NA>
age <NA>
50. <NA>
For <NA>
society <NA>
as <NA>
a <NA>
whole, <NA>
the <NA>
researchers <NA>
assumed <NA>
that, <NA>
if <NA>
it <NA>
were <NA>
formally <NA>
recommended, <NA>
about <NA>
4.5 <NA>
million <NA>
women <NA>
in <NA>
their <NA>
40s, <NA>
or <NA>
25% <PERCENT>
of <NA>
women <NA>
in <NA>
this <NA>
age <NA>
group, <NA>
would <NA>
be <NA>
following <NA>
this <NA>
annual <NA>
practice <NA>
in <NA>
the <NA>
year <NA>
2000 <DATE>
. <NA>
The <NA>
cost <NA>
of <NA>
annual <NA>
mammography <NA>
in <NA>
the <NA>
year <NA>
2000 <DATE>
for <NA>
4.5 <NA>
million <NA>
women <NA>
would <NA>
be <NA>
$361_million <MONEY>
in <NA>
1984 <DATE>
dollars, <NA>
they <NA>
estimated. <NA>
The <NA>
cost <NA>
of <NA>
biopsies <NA>
for <NA>
women <NA>
who <NA>
turn <NA>
out <NA>
to <NA>
be <NA>
"false-positives" <NA>
would <NA>
add <NA>
almost <NA>
$41_million <MONEY>
to <NA>
the <NA>
annual <NA>
medical <NA>
bill <NA>
without <NA>
helping <NA>
to <NA>
reduce <NA>
the <NA>
death <NA>
rate. <NA>
The <NA>
annual-mammography <NA>
policy <NA>
would <NA>
save <NA>
about <NA>
$5.2_million <MONEY>
in <NA>
expensive <NA>
terminal <NA>
care <NA>
that <NA>
year <NA>
for <NA>
women <NA>
who <NA>
otherwise <NA>
would <NA>
have <NA>
died <NA>
of <NA>
breast <NA>
cancer. <NA>
However, <NA>
this <NA>
would <NA>
be <NA>
more <NA>
than <NA>
offset <NA>
by <NA>
almost <NA>
$5.9_million <MONEY>
spent <NA>
on <NA>
trying <NA>
to <NA>
cure <NA>
those <NA>
women <NA>
who <NA>
were <NA>
found <NA>
by <NA>
mammography <NA>
to <NA>
have <NA>
cancer. <NA>
The <NA>
net <NA>
cost <NA>
of <NA>
the <NA>
annual-mammography <NA>
policy <NA>
for <NA>
this <NA>
age <NA>
group, <NA>
after <NA>
taking <NA>
into <NA>
account <NA>
other <NA>
medical <NA>
costs, <NA>
would <NA>
be <NA>
$402_million <MONEY>
in <NA>
the <NA>
year_2000 <DATE>
, <NA>
they <NA>
calculated. <NA>
Put <NA>
another <NA>
way, <NA>
it <NA>
requires <NA>
more <NA>
than <NA>
12,000 <NA>
mammography <NA>
exams <NA>
in <NA>
the <NA>
year_2000 <DATE>
, <NA>
at <NA>
a <NA>
cost <NA>
of <NA>
more <NA>
than <NA>
$1_million <MONEY>
, <NA>
to <NA>
reduce <NA>
the <NA>
number <NA>
of <NA>
breast-cancer <NA>
deaths <NA>
by <NA>
one, <NA>
they <NA>
calculated. <NA>
" <NA>
A <NA>
survey <NA>
of <NA>
21 <NA>
medical <NA>
centers <NA>
found <NA>
the <NA>
cost <NA>
of <NA>
a <NA>
mammography <NA>
exam <NA>
ranges <NA>
between <NA>
$35 <MONEY>
and <NA>
$182 <MONEY>
. <NA>
A <NA>
biopsy <NA>
resulting <NA>
from <NA>
a <NA>
suspicious <NA>
mammogram <NA>
cost <NA>
about <NA>
$900 <MONEY>
in <NA>
1984 <DATE>
, <NA>
they <NA>
noted. <NA>
FBIS4-67666 <DOCNO>
BFN <NA>
[Article_by_<PERSON>Susie_Weldon <FÊP=106>
] <NA>
[Text]_Viral_hepatitis_infections_surged_in_<DATE>1992 </F>
, <NA>
with <NA>
more <NA>
than <NA>
twice <NA>
as <NA>
many <NA>
cases <NA>
recorded <NA>
as <NA>
in <NA>
the <NA>
previous <NA>
year, <NA>
according <NA>
to <NA>
statistics <NA>
just <NA>
released <NA>
by <NA>
the <NA>
Department_of_Health <ORGANIZATION>
. <NA>
The <NA>
department's <NA>
annual <NA>
report <NA>
for <NA>
1992-93 <NA>
shows <NA>
that <NA>
4,357 <NA>
hepatitis <NA>
cases <NA>
were <NA>
reported <NA>
in <NA>
1992 <DATE>
compared <NA>
with <NA>
1,801 <NA>
in <NA>
1991 <DATE>
. <NA>
The <NA>
report <NA>
said <NA>
the <NA>
infections <NA>
were <NA>
due <NA>
to <NA>
eating <NA>
raw <NA>
or <NA>
badly <NA>
cooked <NA>
seafood <NA>
from <NA>
Hong_Kong <LOCATION>
's <NA>
polluted <NA>
waters. <NA>
Other <NA>
figures <NA>
in <NA>
the <NA>
report <NA>
show <NA>
Hong_Kong <LOCATION>
people <NA>
died <NA>
from <NA>
the <NA>
same <NA>
serious <NA>
diseases, <NA>
in <NA>
about <NA>
the <NA>
same <NA>
proportions, <NA>
in <NA>
1992 <DATE>
as <NA>
in <NA>
the <NA>
previous <NA>
year. <NA>
As <NA>
in <NA>
the <NA>
previous <NA>
year, <NA>
lung <NA>
cancer <NA>
killed <NA>
more <NA>
men <NA>
and <NA>
women <NA>
than <NA>
any <NA>
other <NA>
tumour, <NA>
causing <NA>
2,761 <NA>
deaths <NA>
in <NA>
1992 <DATE>
. <NA>
Although <NA>
slightly <NA>
fewer <NA>
people <NA>
died <NA>
of <NA>
a <NA>
heart <NA>
attack <NA>
in <NA>
1992 <DATE>
-- <NA>
1,785 <NA>
men <NA>
and <NA>
women <NA>
-- <NA>
overall <NA>
deaths <NA>
from <NA>
heart <NA>
disease <NA>
rose <NA>
by <NA>
about <NA>
400, <NA>
to <NA>
5,359. <NA>
Almost <NA>
24_percent <PERCENT>
(83 <NA>
deaths) <NA>
of <NA>
infant <NA>
mortalities <NA>
in <NA>
1992 <DATE>
were <NA>
blamed <NA>
on <NA>
immaturity, <NA>
compared <NA>
with <NA>
about <NA>
15_percent <PERCENT>
(67 <NA>
deaths) <NA>
the <NA>
previous <NA>
year. <NA>
A <NA>
staggering <NA>
82,800 <NA>
patients <NA>
were <NA>
treated <NA>
in <NA>
hospital <NA>
because <NA>
of <NA>
injury <NA>
and <NA>
poisoning <NA>
in <NA>
1992 <DATE>
, <NA>
making <NA>
the <NA>
category <NA>
the <NA>
leading <NA>
cause <NA>
of <NA>
hospital <NA>
admission. <NA>
Of <NA>
the <NA>
1,693 <NA>
deaths <NA>
from <NA>
injury <NA>
and <NA>
poisoning <NA>
-- <NA>
the <NA>
fifth <NA>
biggest <NA>
cause <NA>
of <NA>
death <NA>
in <NA>
1992 <DATE>
-- <NA>
almost <NA>
45_percent <PERCENT>
were <NA>
self <NA>
inflicted <NA>
or <NA>
due <NA>
to <NA>
suicide. <NA>
Nearly <NA>
3,000 <NA>
more <NA>
people <NA>
were <NA>
diagnosed <NA>
with <NA>
sexually <NA>
transmitted <NA>
diseases <NA>
in <NA>
1992 <DATE>
, <NA>
making <NA>
a <NA>
total <NA>
of <NA>
13,257 <NA>
cases. <NA>
Almost <NA>
60_percent <PERCENT>
of <NA>
these <NA>
were <NA>
in <NA>
men <NA>
aged <NA>
between <NA>
20 <NA>
to <NA>
40 <NA>
years. <NA>
One <NA>
person <NA>
died <NA>
because <NA>
of <NA>
injuries <NA>
resulting <NA>
from <NA>
"operation <NA>
of <NA>
war" <NA>
in <NA>
1992 <DATE>
. <NA>
AP900316-0097 <DOCNO>
Genetic <NA>
tests <NA>
on <NA>
women <NA>
with <NA>
breast <NA>
cancer <NA>
could <NA>
determine <NA>
the <NA>
risk <NA>
of <NA>
recurrence <NA>
for <NA>
some <NA>
patients, <NA>
improving <NA>
the <NA>
chance <NA>
of <NA>
treating <NA>
women <NA>
generally <NA>
thought <NA>
to <NA>
be <NA>
safe, <NA>
a <NA>
researcher <NA>
said <NA>
Friday <DATE>
. <NA>
The <NA>
scientists' <NA>
findings <NA>
are <NA>
being <NA>
presented <NA>
this <NA>
week <NA>
at <NA>
the <NA>
American_College_of_Radiology <ORGANIZATION>
's <NA>
24th <NA>
annual <NA>
National_Conference_on_Breast_Cancer <ORGANIZATION>
. <NA>
Eva <NA>
Rubin <NA>
,_chief_of_the_mammography_section_at_the_<ORGANIZATION>University_of_Alabama </PERSON>
in <NA>
Birmingham <LOCATION>
. <NA>
But <NA>
a <NA>
new <NA>
study <NA>
shows <NA>
that <NA>
similar <NA>
genetic <NA>
irregularities <NA>
indicating <NA>
aggressive <NA>
cancer <NA>
show <NA>
up <NA>
in <NA>
large <NA>
and <NA>
small <NA>
tumors, <NA>
a <NA>
finding <NA>
that <NA>
could <NA>
signal <NA>
doctors <NA>
to <NA>
begin <NA>
additional <NA>
treatment <NA>
to <NA>
fight <NA>
recurrence, <NA>
Rubin <PERSON>
said. <NA>
Currently, <NA>
women <NA>
with <NA>
small <NA>
cancerous <NA>
breast <NA>
tumors <NA>
that <NA>
have <NA>
not <NA>
spread <NA>
to <NA>
the <NA>
lymph <NA>
nodes <NA>
have <NA>
surgery <NA>
or <NA>
a <NA>
lumpectomy <NA>
with <NA>
radiation <NA>
therapy, <NA>
Rubin <PERSON>
said. <NA>
But <NA>
30_percent <PERCENT>
of <NA>
those <NA>
patients <NA>
later <NA>
die <NA>
from <NA>
recurring <NA>
cancer, <NA>
she <NA>
said. <NA>
The <NA>
Birmingham <LOCATION>
test <NA>
was <NA>
designed <NA>
to <NA>
determine <NA>
if <NA>
DNA <NA>
test <NA>
results <NA>
were <NA>
different <NA>
for <NA>
larger <NA>
tumors <NA>
that <NA>
can <NA>
be <NA>
felt, <NA>
and <NA>
non-palpable <NA>
cancerous <NA>
tumors, <NA>
she <NA>
said. <NA>
``Of <NA>
the <NA>
21 <NA>
palpable <NA>
and <NA>
24 <NA>
non-palpable <NA>
cancers <NA>
we <NA>
reviewed, <NA>
we <NA>
found <NA>
that <NA>
DNA <NA>
characteristics <NA>
of <NA>
small <NA>
tumors <NA>
are <NA>
the <NA>
same <NA>
as <NA>
larger <NA>
tumors,'' <NA>
Rubin <PERSON>
said. <NA>
If <NA>
the <NA>
tumor <NA>
is <NA>
growing <NA>
and <NA>
the <NA>
DNA <NA>
test <NA>
is <NA>
abnormal, <NA>
the <NA>
patient's <NA>
cancer <NA>
is <NA>
likely <NA>
to <NA>
be <NA>
aggressive, <NA>
Rubin <PERSON>
said. <NA>
The <NA>
study <NA>
does <NA>
not <NA>
mean <NA>
that <NA>
all <NA>
patients <NA>
with <NA>
breast <NA>
cancer <NA>
should <NA>
have <NA>
the <NA>
DNA <NA>
test <NA>
to <NA>
find <NA>
out <NA>
whether <NA>
the <NA>
tumor <NA>
is <NA>
aggressive, <NA>
Rubin <PERSON>
said, <NA>
adding <NA>
that <NA>
more <NA>
research <NA>
and <NA>
tests <NA>
are <NA>
needed <NA>
before <NA>
recommendations <NA>
are <NA>
made. <NA>
Yale_University <ORGANIZATION>
researchers, <NA>
meanwhile, <NA>
said <NA>
they <NA>
found <NA>
that <NA>
a <NA>
lumpectomy <NA>
_ <NA>
removing <NA>
a <NA>
cancerous <NA>
tumor <NA>
and <NA>
some <NA>
surrounding <NA>
tissue <NA>
_ <NA>
combined <NA>
with <NA>
radiation <NA>
therapy <NA>
can <NA>
be <NA>
a <NA>
good <NA>
alternative <NA>
to <NA>
a <NA>
mastectomy. <NA>
Bruce <NA>
Haffty <NA>
of_<ORGANIZATION>Yale </PERSON>
's <NA>
department <NA>
of <NA>
therapeutic <NA>
radiology. <NA>
But <NA>
a <NA>
study <NA>
of <NA>
58 <NA>
patients <NA>
at <NA>
New_Haven_Hospital <ORGANIZATION>
shows <NA>
a <NA>
high <NA>
success <NA>
rate <NA>
using <NA>
the <NA>
less <NA>
radical <NA>
surgical <NA>
procedure, <NA>
he <NA>
said. <NA>
If <NA>
the <NA>
cancer <NA>
returns <NA>
after <NA>
a <NA>
breast-saving <NA>
lumpectomy <NA>
is <NA>
performed, <NA>
a <NA>
mastectomy <NA>
could <NA>
still <NA>
be <NA>
an <NA>
option, <NA>
Haffty <PERSON>
said. <NA>
The <NA>
Yale <ORGANIZATION>
study <NA>
so <NA>
far <NA>
does <NA>
not <NA>
bear <NA>
out <NA>
this <NA>
concern, <NA>
Haffty <PERSON>
said. <NA>
AP881229-0052 <DOCNO>
I. <NA>
Craig <NA>
Henderson <NA>
of_the_<ORGANIZATION>Dana-Farber_Cancer_Institute </PERSON>
in <NA>
Boston <LOCATION>
. <NA>
Henderson <PERSON>
, <NA>
one <NA>
of <NA>
79 <NA>
co-authors <NA>
of <NA>
the <NA>
analysis, <NA>
said <NA>
that <NA>
while <NA>
the <NA>
treatments <NA>
do <NA>
not <NA>
necessarily <NA>
cure <NA>
the <NA>
cancer, <NA>
the <NA>
review <NA>
shows <NA>
that <NA>
``they <NA>
substantially <NA>
delay <NA>
death. <NA>
Nicholas <NA>
Robert <NA>
of_<ORGANIZATION>New_England_Medical_Center </PERSON>
. <NA>
An <NA>
estimated <NA>
135,000 <NA>
new <NA>
cases <NA>
of <NA>
breast <NA>
cancer <NA>
were <NA>
diagnosed <NA>
in <NA>
the <NA>
United_States <LOCATION>
this <NA>
year, <NA>
and <NA>
42,300 <NA>
women <NA>
died <NA>
of <NA>
the <NA>
disease. <NA>
William <NA>
Wood <NA>
of_<ORGANIZATION>Massachusetts_General_Hospital </PERSON>
. <NA>
The <NA>
data <NA>
were <NA>
reviewed <NA>
by <NA>
a <NA>
consensus <NA>
panel <NA>
of <NA>
the <NA>
National_Institutes_of_Health <ORGANIZATION>
before <NA>
it <NA>
recommended <NA>
in <NA>
1985 <DATE>
that <NA>
tamoxifen <NA>
and <NA>
chemotherapy <NA>
be <NA>
used <NA>
for <NA>
breast <NA>
cancer <NA>
that <NA>
has <NA>
spread <NA>
to <NA>
the <NA>
lymph <NA>
nodes. <NA>
Last <NA>
May <DATE>
, <NA>
the <NA>
National_Cancer_Institute <ORGANIZATION>
told <NA>
doctors <NA>
that <NA>
the <NA>
treatment <NA>
could <NA>
be <NA>
extended <NA>
to <NA>
women <NA>
in <NA>
the <NA>
earliest <NA>
stages <NA>
of <NA>
breast <NA>
cancer <NA>
that <NA>
is <NA>
not <NA>
yet <NA>
evident <NA>
in <NA>
the <NA>
lymph <NA>
nodes. <NA>
Richard <NA>
Peto <NA>
of_<ORGANIZATION>Oxford_University </PERSON>
and <NA>
combined <NA>
the <NA>
results <NA>
of <NA>
61 <NA>
comparison <NA>
studies, <NA>
conducted <NA>
mostly <NA>
in <NA>
Europe <LOCATION>
and <NA>
North_America <LOCATION>
, <NA>
on <NA>
28,896 <NA>
women. <NA>
WSJ870424-0126 <DOCNO>
Since <NA>
1980 <DATE>
, <NA>
the <NA>
National_Cancer_Institute <ORGANIZATION>
aggressively <NA>
has <NA>
supported <NA>
research <NA>
into <NA>
whether <NA>
diet <NA>
and <NA>
the <NA>
use <NA>
of <NA>
drugs <NA>
derived <NA>
from <NA>
natural <NA>
nutrients <NA>
can <NA>
protect <NA>
people <NA>
from <NA>
cancer. <NA>
The <NA>
government's <NA>
arbiter <NA>
of <NA>
established <NA>
cancer <NA>
science, <NA>
NCI <ORGANIZATION>
has <NA>
assembled <NA>
a <NA>
list <NA>
of <NA>
550 <NA>
substances <NA>
believed <NA>
to <NA>
be <NA>
potentially <NA>
protective <NA>
against <NA>
cancer. <NA>
The <NA>
NCI <ORGANIZATION>
decided <NA>
to <NA>
throw <NA>
its <NA>
scientific <NA>
weight <NA>
behind <NA>
the <NA>
research <NA>
because, <NA>
it <NA>
says, <NA>
"mounting <NA>
evidence" <NA>
from <NA>
laboratory <NA>
studies <NA>
and <NA>
surveys <NA>
of <NA>
large <NA>
groups <NA>
of <NA>
people <NA>
found <NA>
that <NA>
"various <NA>
agents <NA>
could <NA>
halt <NA>
or <NA>
reverse <NA>
cancer <NA>
progression <NA>
in <NA>
animals <NA>
or <NA>
reduce <NA>
the <NA>
incidence <NA>
or <NA>
risk <NA>
of <NA>
cancer <NA>
in <NA>
humans. <NA>
In <NA>
a <NA>
study <NA>
expected <NA>
to <NA>
end <NA>
in <NA>
1990 <DATE>
, <NA>
scientists <NA>
are <NA>
giving <NA>
vitamin <NA>
A <NA>
and <NA>
two <NA>
other <NA>
nutrients, <NA>
vitamin <NA>
E <NA>
and <NA>
selenium, <NA>
to <NA>
tin <NA>
miners <NA>
at <NA>
risk <NA>
of <NA>
developing <NA>
lung <NA>
cancer, <NA>
to <NA>
determine <NA>
if <NA>
the <NA>
nutrients <NA>
cut <NA>
the <NA>
incidence <NA>
of <NA>
disease. <NA>
One <NA>
study <NA>
found <NA>
that <NA>
Japanese <NA>
who <NA>
migrated <NA>
to <NA>
Hawaii <LOCATION>
had <NA>
a <NA>
lower <NA>
rate <NA>
of <NA>
stomach <NA>
cancer <NA>
than <NA>
would <NA>
have <NA>
been <NA>
expected <NA>
if <NA>
they <NA>
stayed <NA>
in <NA>
Japan <LOCATION>
. <NA>
The <NA>
reason <NA>
was <NA>
that <NA>
fresh <NA>
fruits <NA>
and <NA>
vegetables <NA>
are <NA>
readily <NA>
available <NA>
in <NA>
Hawaii <LOCATION>
, <NA>
but <NA>
not <NA>
in <NA>
Japan <LOCATION>
. <NA>
A <NA>
study <NA>
at <NA>
Johns_Hopkins_School_of_Hygiene_and_Public_Health <ORGANIZATION>
in <NA>
Baltimore <LOCATION>
also <NA>
found <NA>
that <NA>
among <NA>
a <NA>
group <NA>
of <NA>
men <NA>
who <NA>
were <NA>
smokers, <NA>
those <NA>
with <NA>
low <NA>
levels <NA>
of <NA>
vitamin <NA>
E <NA>
in <NA>
their <NA>
blood <NA>
had <NA>
a <NA>
2.5 <NA>
times <NA>
greater <NA>
risk <NA>
of <NA>
developing <NA>
lung <NA>
cancer <NA>
than <NA>
those <NA>
with <NA>
higher <NA>
levels <NA>
of <NA>
the <NA>
vitamin. <NA>
Population <NA>
studies <NA>
in <NA>
the <NA>
U.S. <LOCATION>
, <NA>
especially <NA>
in <NA>
the <NA>
Northeast <LOCATION>
, <NA>
suggest <NA>
that <NA>
people <NA>
with <NA>
low <NA>
selenium <NA>
in <NA>
their <NA>
diets <NA>
have <NA>
higher <NA>
rates <NA>
of <NA>
colon, <NA>
breast <NA>
and <NA>
prostate <NA>
cancer. <NA>
The <NA>
studies <NA>
are <NA>
following <NA>
people <NA>
who <NA>
live <NA>
in <NA>
areas <NA>
of <NA>
the <NA>
country, <NA>
such <NA>
as <NA>
South_Dakota <LOCATION>
, <NA>
where <NA>
selenium <NA>
intake <NA>
is <NA>
high. <NA>
One <NA>
population <NA>
study <NA>
reported <NA>
in <NA>
1983 <DATE>
found <NA>
that <NA>
people <NA>
in <NA>
England <LOCATION>
and <NA>
Wales <LOCATION>
whose <NA>
consumption <NA>
of <NA>
sugar, <NA>
meat <NA>
and <NA>
fat <NA>
were <NA>
sharply <NA>
reduced <NA>
during <NA>
World <NA>
War <NA>
II <NA>
had <NA>
a <NA>
marked <NA>
reduction <NA>
of <NA>
cancer <NA>
of <NA>
the <NA>
breast <NA>
and <NA>
colon. <NA>
The <NA>
NCI <ORGANIZATION>
also <NA>
is <NA>
supporting <NA>
research <NA>
looking <NA>
at <NA>
the <NA>
combined <NA>
effects <NA>
in <NA>
the <NA>
diet <NA>
of <NA>
many <NA>
nutrients. <NA>
A <NA>
researcher <NA>
at <NA>
Memorial_Sloan-Kettering_Hospital <ORGANIZATION>
in <NA>
New_York <LOCATION>
is <NA>
testing <NA>
whether <NA>
a <NA>
combination <NA>
of <NA>
beta-carotene <NA>
and <NA>
vitamins <NA>
C <NA>
and <NA>
E <NA>
can <NA>
prevent <NA>
the <NA>
development <NA>
of <NA>
skin <NA>
cancer <NA>
lesions <NA>
in <NA>
people <NA>
who <NA>
previously <NA>
had <NA>
a <NA>
tumor <NA>
growth. <NA>
AP900622-0042 <DOCNO>
The <NA>
committee <NA>
of <NA>
15 <NA>
experts <NA>
was <NA>
assembled <NA>
by <NA>
the <NA>
National_Institutes_of_Health <ORGANIZATION>
to <NA>
consider <NA>
research <NA>
on <NA>
the <NA>
survival <NA>
of <NA>
women <NA>
with <NA>
early <NA>
stages <NA>
of <NA>
breast <NA>
cancer <NA>
and <NA>
to <NA>
develop <NA>
a <NA>
consensus <NA>
on <NA>
what <NA>
therapy <NA>
should <NA>
be <NA>
used <NA>
to <NA>
treat <NA>
the <NA>
disease. <NA>
William <NA>
C. <NA>
Wood <NA>
,_a_<ORGANIZATION>Harvard_Medical_School </PERSON>
surgeon <NA>
and <NA>
chairman <NA>
of <NA>
the <NA>
committee. <NA>
'' <NA>
Mastectomy <NA>
is <NA>
still <NA>
the <NA>
most <NA>
commonly <NA>
used <NA>
therapy <NA>
for <NA>
early <NA>
stage <NA>
breast <NA>
cancer, <NA>
Wood <ORGANIZATION>
said. <NA>
A <NA>
lumpectomy <NA>
is <NA>
followed <NA>
with <NA>
radiation <NA>
therapy, <NA>
and <NA>
Wood <ORGANIZATION>
said <NA>
some <NA>
patients <NA>
choose <NA>
mastectomy <NA>
because <NA>
they <NA>
``prefer <NA>
to <NA>
lose <NA>
a <NA>
breast <NA>
instead <NA>
of <NA>
have <NA>
six <NA>
weeks <NA>
of <NA>
radiation <NA>
therapy. <NA>
If <NA>
these <NA>
nodes <NA>
are <NA>
cancer-free <NA>
and <NA>
the <NA>
primary <NA>
tumor <NA>
is <NA>
smaller <NA>
than <NA>
one <NA>
centimeter, <NA>
both <NA>
methods <NA>
of <NA>
treatment <NA>
have <NA>
about <NA>
a <NA>
90_percent <PERCENT>
chance <NA>
of <NA>
cure. <NA>
Between <NA>
75_percent <PERCENT>
and <NA>
80_percent <PERCENT>
of <NA>
this <NA>
group <NA>
will <NA>
have <NA>
Stage <NA>
I <NA>
or <NA>
Stage <NA>
II <NA>
disease, <NA>
and <NA>
about <NA>
two-thirds <NA>
of <NA>
these <NA>
will <NA>
have <NA>
cancer-free <NA>
lymph <NA>
nodes. <NA>
During <NA>
the <NA>
past_two_decades <DATE>
, <NA>
there <NA>
have <NA>
been <NA>
a <NA>
number <NA>
of <NA>
studies <NA>
comparing <NA>
the <NA>
survival <NA>
results <NA>
of <NA>
less <NA>
extensive <NA>
breast <NA>
surgery, <NA>
including <NA>
lumpectomy. <NA>
WSJ910315-0104 <DOCNO>
"The <NA>
potential <NA>
for <NA>
using <NA>
this <NA>
gene <NA>
in <NA>
early <NA>
detection <NA>
of <NA>
the <NA>
cancer <NA>
is <NA>
very <NA>
exciting <NA>
to <NA>
us," <NA>
said <NA>
Bert_Vogelstein <PERSON>
, <NA>
the <NA>
molecular <NA>
biologist <NA>
whose <NA>
laboratory <NA>
made <NA>
the <NA>
discovery. <NA>
The <NA>
three <NA>
genes <NA>
found <NA>
by <NA>
the <NA>
Johns_Hopkins <PERSON>
group <NA>
are <NA>
dubbed <NA>
tumor <NA>
suppressors <NA>
because <NA>
scientists <NA>
believe <NA>
in <NA>
their <NA>
normal <NA>
state <NA>
they <NA>
govern <NA>
cell <NA>
growth. <NA>
In <NA>
1989 <DATE>
, <NA>
In <NA>
January_1990 <DATE>
, <NA>
Vogelstein <NA>
's_lab_found_another_suppressor_gene_called_<ORGANIZATION>DCC </PERSON>
, <NA>
deleted <NA>
in <NA>
colorectal <NA>
cancer. <NA>
The <NA>
most <NA>
recent <NA>
discovery <NA>
is <NA>
a <NA>
gene <NA>
being <NA>
called <NA>
MCC <ORGANIZATION>
, <NA>
for <NA>
mutated <NA>
in <NA>
colorectal <NA>
cancer. <NA>
The <NA>
MCC <ORGANIZATION>
gene <NA>
appears <NA>
to <NA>
be <NA>
the <NA>
same <NA>
gene <NA>
that <NA>
researchers <NA>
at <NA>
the <NA>
University_of_Utah <ORGANIZATION>
and <NA>
in <NA>
London <LOCATION>
believe <NA>
can <NA>
be <NA>
inherited <NA>
in <NA>
a <NA>
mutant <NA>
form <NA>
and <NA>
cause <NA>
a <NA>
rare <NA>
familial <NA>
form <NA>
of <NA>
colon <NA>
cancer. <NA>
The <NA>
Utah <LOCATION>
and <NA>
British <NA>
scientists <NA>
have <NA>
been <NA>
studying <NA>
the <NA>
genetic <NA>
material <NA>
of <NA>
several <NA>
families <NA>
where <NA>
numerous <NA>
relatives <NA>
have <NA>
a <NA>
tendency <NA>
to <NA>
grow <NA>
dozens <NA>
of <NA>
polyps <NA>
in <NA>
their <NA>
colon, <NA>
tiny <NA>
clumps <NA>
of <NA>
mushroom-sized <NA>
growth <NA>
which <NA>
under <NA>
certain <NA>
circumstances <NA>
can <NA>
become <NA>
cancerous. <NA>
At <NA>
about <NA>
the <NA>
same <NA>
time, <NA>
researchers <NA>
at <NA>
Johns_Hopkins <PERSON>
had <NA>
found <NA>
evidence <NA>
in <NA>
sifting <NA>
through <NA>
genetic <NA>
material <NA>
taken <NA>
from <NA>
colon <NA>
cancer <NA>
cells <NA>
suggesting <NA>
that <NA>
a <NA>
tumor <NA>
suppressor <NA>
gene <NA>
also <NA>
existed <NA>
on <NA>
chromosome <NA>
5. <NA>
Believing <NA>
the <NA>
two <NA>
genes <NA>
might <NA>
be <NA>
the <NA>
same, <NA>
about <NA>
two <NA>
years <NA>
ago <NA>
the <NA>
Johns_Hopkins <PERSON>
researchers <NA>
joined <NA>
forces <NA>
with <NA>
the <NA>
Utah <LOCATION>
team <NA>
and <NA>
another <NA>
group <NA>
from <NA>
Tokyo <LOCATION>
's <NA>
Cancer_Institute <ORGANIZATION>
to <NA>
pinpoint <NA>
the <NA>
gene's <NA>
exact <NA>
identity. <NA>
In <NA>
a <NA>
report <NA>
in <NA>
the <NA>
journal <NA>
Science, <NA>
the <NA>
three <NA>
labs <NA>
say <NA>
they <NA>
have <NA>
isolated <NA>
the <NA>
gene, <NA>
calling <NA>
it <NA>
MCC <ORGANIZATION>
. <NA>
Vogelstein <NA>
said_he_and_his_colleagues_are_convinced_that_the_loss_of_two_copies_of_a_cell's_<ORGANIZATION>MCC </PERSON>
gene <NA>
is <NA>
what <NA>
makes <NA>
a <NA>
normal <NA>
cell <NA>
begin <NA>
growing <NA>
into <NA>
a <NA>
polyp. <NA>
People <NA>
who <NA>
inherit <NA>
one <NA>
or <NA>
two <NA>
copies <NA>
of <NA>
MCC <ORGANIZATION>
already <NA>
in <NA>
damaged <NA>
form <NA>
are <NA>
at <NA>
very <NA>
high <NA>
risk <NA>
of <NA>
developing <NA>
colon <NA>
cancer, <NA>
the <NA>
researchers <NA>
said. <NA>
As <NA>
a <NA>
result <NA>
of <NA>
the <NA>
finding, <NA>
the <NA>
researchers <NA>
said <NA>
that <NA>
someday <NA>
doctors <NA>
will <NA>
be <NA>
able <NA>
to <NA>
test <NA>
patients' <NA>
blood <NA>
to <NA>
detect <NA>
if <NA>
some <NA>
of <NA>
their <NA>
cells <NA>
have <NA>
somehow <NA>
-- <NA>
perhaps <NA>
through <NA>
exposure <NA>
to <NA>
some <NA>
environmental <NA>
agent <NA>
-- <NA>
collected <NA>
damaged <NA>
versions <NA>
of <NA>
MCC <ORGANIZATION>
. <NA>
A <NA>
patient <NA>
found <NA>
to <NA>
have <NA>
a <NA>
damaged <NA>
MCC <ORGANIZATION>
"would <NA>
be <NA>
closely <NA>
monitored <NA>
for <NA>
any <NA>
suspicious <NA>
polyp <NA>
growths," <NA>
" <NA>
The <NA>
gene <NA>
was <NA>
pinpointed <NA>
in <NA>
the <NA>
Johns_Hopkins <PERSON>
lab <NA>
by <NA>
Kenneth_Kinzler <PERSON>
and <NA>
Mef_Nilbert <ORGANIZATION>
. <NA>
Vogelstein <NA>
believe_the_<ORGANIZATION>MCC </PERSON>
gene <NA>
in <NA>
its <NA>
normal <NA>
state <NA>
produces <NA>
a <NA>
protein <NA>
that <NA>
acts <NA>
as <NA>
a <NA>
curb <NA>
for <NA>
a <NA>
certain <NA>
kind <NA>
of <NA>
cell <NA>
growth. <NA>
WSJ891102-0191 <DOCNO>
Lorillard_Inc. <ORGANIZATION>
, <NA>
the <NA>
unit <NA>
of <NA>
New <NA>
York-based <NA>
Loews_Corp. <ORGANIZATION>
that <NA>
makes <NA>
Kent <NA>
cigarettes, <NA>
stopped <NA>
using <NA>
crocidolite <NA>
in <NA>
its <NA>
Micronite <NA>
cigarette <NA>
filters <NA>
in <NA>
1956 <DATE>
. <NA>
A <NA>
Lorillard <ORGANIZATION>
spokewoman <NA>
said, <NA>
"This <NA>
is <NA>
an <NA>
old <NA>
story. <NA>
" <NA>
Neither <NA>
Lorillard <ORGANIZATION>
nor <NA>
the <NA>
researchers <NA>
who <NA>
studied <NA>
the <NA>
workers <NA>
were <NA>
aware <NA>
of <NA>
any <NA>
research <NA>
on <NA>
smokers <NA>
of <NA>
the <NA>
Kent <NA>
cigarettes. <NA>
"We <NA>
have <NA>
no <NA>
useful <NA>
information <NA>
on <NA>
whether <NA>
users <NA>
are <NA>
at <NA>
risk," <NA>
said <NA>
James_A._Talcott <PERSON>
of <NA>
Boston <LOCATION>
's <NA>
Dana-Farber_Cancer_Institute <ORGANIZATION>
. <NA>
Talcott <NA>
led_a_team_of_researchers_from_the_<ORGANIZATION>National_Cancer_Institute </PERSON>
and <NA>
the <NA>
medical <NA>
schools <NA>
of <NA>
Harvard_University <ORGANIZATION>
and <NA>
Boston_University <ORGANIZATION>
. <NA>
The <NA>
Lorillard <ORGANIZATION>
spokeswoman <NA>
said <NA>
asbestos <NA>
was <NA>
used <NA>
in <NA>
"very <NA>
modest <NA>
amounts" <NA>
in <NA>
making <NA>
paper <NA>
for <NA>
the <NA>
filters <NA>
in <NA>
the <NA>
early <NA>
1950s <DATE>
and <NA>
replaced <NA>
with <NA>
a <NA>
different <NA>
type <NA>
of <NA>
filter <NA>
in <NA>
1956 <DATE>
. <NA>
From <NA>
1953 <DATE>
to <NA>
1955 <DATE>
, <NA>
9.8 <NA>
billion <NA>
Kent <NA>
cigarettes <NA>
with <NA>
the <NA>
filters <NA>
were <NA>
sold, <NA>
the <NA>
company <NA>
said. <NA>
The <NA>
percentage <NA>
of <NA>
lung <NA>
cancer <NA>
deaths <NA>
among <NA>
the <NA>
workers <NA>
at <NA>
the <NA>
West_Groton <LOCATION>
, <NA>
Mass. <LOCATION>
, <NA>
paper <NA>
factory <NA>
appears <NA>
to <NA>
be <NA>
the <NA>
highest <NA>
for <NA>
any <NA>
asbestos <NA>
workers <NA>
studied <NA>
in <NA>
Western <LOCATION>
industrialized <NA>
countries, <NA>
he <NA>
said. <NA>
The <NA>
plant, <NA>
which <NA>
is <NA>
owned <NA>
by <NA>
Hollingsworth_&amp;_Vose_Co. <ORGANIZATION>
, <NA>
was <NA>
under <NA>
contract <NA>
with <NA>
Lorillard <ORGANIZATION>
to <NA>
make <NA>
the <NA>
cigarette <NA>
filters. <NA>
The <NA>
finding <NA>
probably <NA>
will <NA>
support <NA>
those <NA>
who <NA>
argue <NA>
that <NA>
the <NA>
U.S. <LOCATION>
should <NA>
regulate <NA>
the <NA>
class <NA>
of <NA>
asbestos <NA>
including <NA>
crocidolite <NA>
more <NA>
stringently <NA>
than <NA>
the <NA>
common <NA>
kind <NA>
of <NA>
asbestos, <NA>
chrysotile, <NA>
found <NA>
in <NA>
most <NA>
schools <NA>
and <NA>
other <NA>
buildings, <NA>
The <NA>
U.S. <LOCATION>
is <NA>
one <NA>
of <NA>
the <NA>
few <NA>
industrialized <NA>
nations <NA>
that <NA>
doesn't <NA>
have <NA>
a <NA>
higher <NA>
standard <NA>
of <NA>
regulation <NA>
for <NA>
the <NA>
smooth, <NA>
needle-like <NA>
fibers <NA>
such <NA>
as <NA>
crocidolite <NA>
that <NA>
are <NA>
classified <NA>
as <NA>
amphobiles, <NA>
according <NA>
to <NA>
Brooke_T._Mossman <PERSON>
, <NA>
a <NA>
professor <NA>
of <NA>
pathlogy <NA>
at <NA>
the <NA>
University_of_Vermont_College_of_Medicine <ORGANIZATION>
. <NA>
In <NA>
July <DATE>
, <NA>
the <NA>
Environmental_Protection_Agency <ORGANIZATION>
imposed <NA>
a <NA>
gradual <NA>
ban <NA>
on <NA>
virtually <NA>
all <NA>
uses <NA>
of <NA>
asbestos. <NA>
By <NA>
1997 <DATE>
, <NA>
almost <NA>
all <NA>
remaining <NA>
uses <NA>
of <NA>
cancer-causing <NA>
asbestos <NA>
will <NA>
be <NA>
outlawed. <NA>
About <NA>
160 <NA>
workers <NA>
at <NA>
a <NA>
factory <NA>
that <NA>
made <NA>
paper <NA>
for <NA>
the <NA>
Kent <NA>
filters <NA>
were <NA>
exposed <NA>
to <NA>
asbestos <NA>
in <NA>
the <NA>
1950s <DATE>
. <NA>
"There's <NA>
no <NA>
question <NA>
that <NA>
some <NA>
of <NA>
those <NA>
workers <NA>
and <NA>
managers <NA>
contracted <NA>
asbestos-related <NA>
diseases," <NA>
said <NA>
Darrell_Phillips <PERSON>
, <NA>
vice <NA>
president <NA>
of <NA>
human <NA>
resources <NA>
for <NA>
Hollingsworth_&amp;_Vose <ORGANIZATION>
. <NA>
FT944-3521 <DOCNO>
Sally_Macintyre <PERSON>
, <NA>
director <NA>
of <NA>
the <NA>
Medical_Research_Council's_Medical_Sociology_Unit <ORGANIZATION>
in <NA>
Glasgow <LOCATION>
, <NA>
says <NA>
the <NA>
mechanism <NA>
of <NA>
this <NA>
effect <NA>
is <NA>
far <NA>
from <NA>
clear, <NA>
though <NA>
it <NA>
appears <NA>
that <NA>
'repeated <NA>
psycho-social <NA>
stress' <NA>
somehow <NA>
depresses <NA>
the <NA>
immune <NA>
system. <NA>
'One <NA>
of <NA>
the <NA>
biggest <NA>
myths <NA>
in <NA>
recent <NA>
years <NA>
is <NA>
that <NA>
there <NA>
is <NA>
a <NA>
cancer <NA>
epidemic <NA>
caused <NA>
by <NA>
exposure <NA>
to <NA>
radiation, <NA>
pollution, <NA>
pesticides <NA>
and <NA>
food <NA>
additives,' <NA>
says <NA>
Sir <NA>
Richard_Doll <PERSON>
of <NA>
the <NA>
Imperial_Cancer_Research_Fund <ORGANIZATION>
's <NA>
cancer <NA>
studies <NA>
unit <NA>
in <NA>
Oxford <LOCATION>
. <NA>
' <NA>
Epidemiologists <NA>
are <NA>
confident <NA>
tobacco <NA>
is <NA>
implicated <NA>
in <NA>
about <NA>
30 <NA>
per <NA>
cent <NA>
of <NA>
cancer <NA>
deaths <NA>
in <NA>
Europe <LOCATION>
and <NA>
North_America <LOCATION>
. <NA>
Because <NA>
there <NA>
can <NA>
be <NA>
a <NA>
delay <NA>
of <NA>
several <NA>
decades <NA>
between <NA>
starting <NA>
to <NA>
smoke <NA>
and <NA>
the <NA>
onset <NA>
of <NA>
disease, <NA>
the <NA>
big <NA>
rise <NA>
in <NA>
lung <NA>
cancer <NA>
did <NA>
not <NA>
begin <NA>
until <NA>
the <NA>
1940s <DATE>
among <NA>
men <NA>
and <NA>
the <NA>
1970s <DATE>
among <NA>
women <NA>
(see <NA>
chart). <NA>
The <NA>
male <NA>
lung <NA>
cancer <NA>
rate <NA>
is <NA>
falling <NA>
in <NA>
countries <NA>
such <NA>
as <NA>
the <NA>
US <LOCATION>
and <NA>
UK <NA>
where <NA>
large <NA>
numbers <NA>
of <NA>
men <NA>
gave <NA>
up <NA>
smoking <NA>
in <NA>
the <NA>
1960s <DATE>
and <NA>
1970s <DATE>
, <NA>
but <NA>
it <NA>
is <NA>
rising <NA>
throughout <NA>
the <NA>
developing <NA>
world. <NA>
On <NA>
the <NA>
contrary, <NA>
the <NA>
most <NA>
striking <NA>
trend <NA>
is <NA>
the <NA>
long-term <NA>
decline <NA>
in <NA>
stomach <NA>
cancer <NA>
in <NA>
Europe <LOCATION>
and <NA>
North_America <LOCATION>
- <NA>
a <NA>
fall <NA>
widely <NA>
attributed <NA>
to <NA>
modern <NA>
methods <NA>
of <NA>
food <NA>
preservation <NA>
and <NA>
storage <NA>
which <NA>
prevent <NA>
the <NA>
formation <NA>
of <NA>
carcinogenic <NA>
decay <NA>
products. <NA>
Although <NA>
colo-rectal <NA>
cancer <NA>
rates <NA>
have <NA>
remained <NA>
steady <NA>
for <NA>
several <NA>
decades <NA>
in <NA>
the <NA>
west, <NA>
those <NA>
in <NA>
Japan <LOCATION>
have <NA>
risen <NA>
rapidly <NA>
to <NA>
European <NA>
levels <NA>
- <NA>
probably <NA>
because <NA>
the <NA>
Japanese <NA>
diet <NA>
has <NA>
become <NA>
westernised <NA>
with <NA>
more <NA>
meat <NA>
and <NA>
fat <NA>
eaten. <NA>
The <NA>
next <NA>
stage, <NA>
according <NA>
to <NA>
speakers <NA>
at <NA>
the <NA>
UK_Biochemical_Society_Conference <ORGANIZATION>
this <NA>
week, <NA>
will <NA>
be <NA>
genetic <NA>
engineering <NA>
of <NA>
crops <NA>
to <NA>
make <NA>
more <NA>
of <NA>
these <NA>
protective <NA>
nutrients. <NA>
Catherine_Rice-Evans <PERSON>
, <NA>
a <NA>
biochemistry <NA>
professor <NA>
at <NA>
Guy's_Hospital <ORGANIZATION>
, <NA>
London <LOCATION>
, <NA>
predicts: <NA>
'The <NA>
introduction <NA>
of <NA>
plants <NA>
that <NA>
have <NA>
been <NA>
manipulated <NA>
to <NA>
produce <NA>
more <NA>
effective <NA>
anti-oxidants <NA>
should <NA>
be <NA>
possible <NA>
within <NA>
five <NA>
years. <NA>
' <NA>
IN <NA>
THIS <NA>
SERIES: <NA>
NOVEMBER_29 <DATE>
Introduction. <NA>
AP900327-0127 <DOCNO>
Preliminary <NA>
studies <NA>
in <NA>
mice <NA>
suggest <NA>
that <NA>
an <NA>
air <NA>
pollutant <NA>
may <NA>
hasten <NA>
the <NA>
spread <NA>
of <NA>
cancer <NA>
within <NA>
the <NA>
body, <NA>
a <NA>
researcher <NA>
said <NA>
Tuesday <DATE>
. <NA>
Mice <NA>
with <NA>
cancer <NA>
that <NA>
breathed <NA>
air <NA>
containing <NA>
nitrogen <NA>
dioxide, <NA>
which <NA>
is <NA>
found <NA>
in <NA>
smog, <NA>
showed <NA>
higher <NA>
numbers <NA>
of <NA>
cancer-cell <NA>
colonies <NA>
in <NA>
their <NA>
lungs <NA>
than <NA>
mice <NA>
than <NA>
breathed <NA>
purified <NA>
air, <NA>
said <NA>
Arnis_Richters <PERSON>
. <NA>
``It <NA>
is <NA>
very <NA>
difficult <NA>
to <NA>
say <NA>
at <NA>
this <NA>
point, <NA>
what <NA>
does <NA>
it <NA>
mean <NA>
for <NA>
human <NA>
populations,'' <NA>
said <NA>
Richters <PERSON>
, <NA>
an <NA>
associate <NA>
professor <NA>
of <NA>
pathology <NA>
at <NA>
the <NA>
University_of_Southern_California_School_of_Medicine <ORGANIZATION>
in <NA>
Los_Angeles <LOCATION>
. <NA>
He <NA>
spoke <NA>
at <NA>
a <NA>
science <NA>
writers <NA>
seminar <NA>
sponsored <NA>
by <NA>
the <NA>
American_Cancer_Society <ORGANIZATION>
. <NA>
Such <NA>
levels <NA>
can <NA>
be <NA>
reached <NA>
in <NA>
Los_Angeles <LOCATION>
' <NA>
notoriously <NA>
dirty <NA>
air, <NA>
Richters <PERSON>
said. <NA>
The <NA>
mice <NA>
were <NA>
particularly <NA>
prone <NA>
to <NA>
get <NA>
lung <NA>
colonies <NA>
from <NA>
the <NA>
skin <NA>
cancer, <NA>
Richters <ORGANIZATION>
said. <NA>
Lance_Liotta <PERSON>
, <NA>
chief <NA>
of <NA>
the <NA>
National_Cancer_Institute <ORGANIZATION>
's <NA>
section <NA>
of <NA>
tumor <NA>
invasion <NA>
and <NA>
metastasis, <NA>
said <NA>
the <NA>
concept <NA>
of <NA>
Richters <ORGANIZATION>
' <NA>
paper <NA>
``makes <NA>
sense. <NA>
Arthur <NA>
Mashberg <NA>
of_the_<ORGANIZATION>Veterans_Administration_Medical_Center </PERSON>
in <NA>
East_Orange <LOCATION>
, <NA>
N.J. <LOCATION>
, <NA>
said <NA>
dentists <NA>
and <NA>
doctors <NA>
often <NA>
overlook <NA>
an <NA>
early <NA>
sign <NA>
of <NA>
cancer <NA>
of <NA>
the <NA>
mouth. <NA>
Only <NA>
about <NA>
11_percent <PERCENT>
of <NA>
leukoplakias <NA>
are <NA>
cancerous, <NA>
but <NA>
some <NA>
64_percent <PERCENT>
of <NA>
red <NA>
lesions <NA>
called <NA>
mucosal <NA>
erythroplasias <NA>
are <NA>
cancerous, <NA>
he <NA>
said. <NA>
Lawrence <NA>
Coia <NA>
of_the_<ORGANIZATION>University_of_Pennsylvania_School_of_Medicine </PERSON>
reported <NA>
on <NA>
a <NA>
combined <NA>
treatment <NA>
of <NA>
chemotherapy <NA>
and <NA>
radiation, <NA>
without <NA>
surgery. <NA>
Being <NA>
able <NA>
to <NA>
avoid <NA>
surgery <NA>
is <NA>
an <NA>
advantage, <NA>
because <NA>
the <NA>
operation <NA>
itself <NA>
is <NA>
dangerous <NA>
and <NA>
survival <NA>
from <NA>
the <NA>
disease <NA>
still <NA>
is <NA>
low, <NA>
commented <NA>
Roy_Sessions_of_Georgetown_University <ORGANIZATION>
. <NA>
Coia <PERSON>
said <NA>
half <NA>
of <NA>
patients <NA>
whose <NA>
disease <NA>
had <NA>
been <NA>
confined <NA>
to <NA>
the <NA>
esophagus <NA>
lived <NA>
more <NA>
than <NA>
18 <NA>
months <NA>
after <NA>
the <NA>
experimental <NA>
treatment, <NA>
with <NA>
a <NA>
corresponding <NA>
figure <NA>
of <NA>
eight <NA>
months <NA>
for <NA>
those <NA>
with <NA>
more <NA>
advanced <NA>
disease. <NA>
AP890825-0068 <DOCNO>
The <NA>
annual <NA>
death <NA>
rate <NA>
from <NA>
breast <NA>
cancer <NA>
in <NA>
the <NA>
United_States <LOCATION>
in <NA>
1986 <DATE>
, <NA>
the <NA>
latest <NA>
year <NA>
available, <NA>
was <NA>
32.8 <NA>
per <NA>
100,000 <NA>
women, <NA>
up <NA>
5_percent <PERCENT>
from <NA>
1979 <DATE>
's <NA>
31.1, <NA>
the <NA>
national <NA>
Centers_for_Disease_Control <ORGANIZATION>
reported <NA>
Thursday <DATE>
. <NA>
The <NA>
mortality <NA>
rate <NA>
in <NA>
1986 <DATE>
was <NA>
12_percent <PERCENT>
higher <NA>
for <NA>
black <NA>
women <NA>
than <NA>
for <NA>
white <NA>
women. <NA>
Breast <NA>
cancer <NA>
killed <NA>
40,534 <NA>
women <NA>
in <NA>
the <NA>
United_States <LOCATION>
in <NA>
1986 <DATE>
, <NA>
the <NA>
CDC <ORGANIZATION>
said. <NA>
The <NA>
National_Cancer_Institute <ORGANIZATION>
estimates <NA>
that <NA>
75_percent <PERCENT>
of <NA>
breast <NA>
cancer <NA>
patients <NA>
live <NA>
at <NA>
least <NA>
another <NA>
five <NA>
years. <NA>
The <NA>
CDC <ORGANIZATION>
said <NA>
Delaware <LOCATION>
, <NA>
with <NA>
an <NA>
annual <NA>
breast <NA>
cancer <NA>
death <NA>
rate <NA>
of <NA>
41 <NA>
per <NA>
100,000 <NA>
women, <NA>
had <NA>
a <NA>
rate <NA>
nearly <NA>
double <NA>
that <NA>
of <NA>
Hawaii <LOCATION>
, <NA>
which <NA>
was <NA>
lowest <NA>
at <NA>
23 <NA>
per <NA>
100,000. <NA>
In <NA>
contrast, <NA>
all <NA>
but <NA>
three <NA>
of <NA>
the <NA>
bottom <NA>
dozen <NA>
were <NA>
in <NA>
the <NA>
South <NA>
or <NA>
Southwest <ORGANIZATION>
. <NA>
Robert <NA>
Hahn <NA>
,_a_cancer_specialist_with_the_Atlanta-based_<ORGANIZATION>CDC </PERSON>
. <NA>
For <NA>
example, <NA>
Hahn <PERSON>
said, <NA>
women <NA>
born <NA>
in <NA>
the <NA>
1930s <DATE>
are <NA>
showing <NA>
a <NA>
higher <NA>
rate <NA>
than <NA>
those <NA>
born <NA>
in <NA>
the <NA>
'20s, <NA>
whose <NA>
rate <NA>
was <NA>
higher <NA>
than <NA>
those <NA>
born <NA>
in <NA>
the <NA>
teens. <NA>
That <NA>
trend <NA>
is <NA>
apparently <NA>
continuing, <NA>
Hahn <PERSON>
said, <NA>
although <NA>
many <NA>
women <NA>
born <NA>
in <NA>
this <NA>
century <NA>
are <NA>
just <NA>
entering <NA>
_ <NA>
or <NA>
haven't <NA>
yet <NA>
entered <NA>
_ <NA>
their <NA>
years <NA>
of <NA>
greatest <NA>
risk <NA>
for <NA>
breast <NA>
cancer. <NA>
The <NA>
CDC <ORGANIZATION>
said <NA>
more <NA>
than <NA>
half <NA>
of <NA>
all <NA>
breast <NA>
cancer <NA>
deaths <NA>
occur <NA>
in <NA>
women <NA>
65 <NA>
or <NA>
older. <NA>
Another <NA>
possible <NA>
risk <NA>
factor <NA>
is <NA>
a <NA>
diet <NA>
high <NA>
in <NA>
animal <NA>
fat, <NA>
Hahn <PERSON>
said, <NA>
although <NA>
some <NA>
researchers <NA>
question <NA>
that. <NA>
CDC <ORGANIZATION>
researchers <NA>
believe <NA>
at <NA>
least <NA>
19_percent <PERCENT>
of <NA>
the <NA>
deaths <NA>
attributed <NA>
to <NA>
breast <NA>
cancer <NA>
could <NA>
have <NA>
been <NA>
prevented <NA>
if <NA>
the <NA>
victims <NA>
had <NA>
undergone <NA>
recommended <NA>
mammograms, <NA>
which <NA>
screen <NA>
for <NA>
breast <NA>
cancer. <NA>
Women <NA>
are <NA>
seven <NA>
times <NA>
more <NA>
likely <NA>
to <NA>
have <NA>
mammograms <NA>
if <NA>
their <NA>
doctor <NA>
urges <NA>
it, <NA>
but <NA>
Hahn <PERSON>
said <NA>
that <NA>
as <NA>
many <NA>
as <NA>
nine <NA>
out <NA>
of <NA>
10 <NA>
doctors <NA>
don't <NA>
follow <NA>
the <NA>
American_Cancer_Society <ORGANIZATION>
's <NA>
advice <NA>
and <NA>
recommend <NA>
the <NA>
procedure. <NA>
The <NA>
American_Cancer_Society <ORGANIZATION>
recommends <NA>
that <NA>
women <NA>
40 <NA>
and <NA>
over <NA>
have <NA>
a <NA>
breast <NA>
exam <NA>
every <NA>
year. <NA>
Previous <NA>
studies <NA>
cited <NA>
by <NA>
the <NA>
CDC <ORGANIZATION>
have <NA>
indicated <NA>
that <NA>
fewer <NA>
than <NA>
three <NA>
in <NA>
10 <NA>
eligible <NA>
women <NA>
reported <NA>
having <NA>
a <NA>
mammogram <NA>
in <NA>
the <NA>
previous <NA>
year, <NA>
and <NA>
nearly <NA>
half <NA>
of <NA>
women <NA>
surveyed <NA>
said <NA>
no <NA>
professional <NA>
had <NA>
ever <NA>
recommended <NA>
they <NA>
get <NA>
a <NA>
mammogram. <NA>
WSJ900521-0110 <DOCNO>
Lupro <NA>
,_38_years_old,_believes_a_new_treatment,_involving_an_"autologous_bone_marrow_transplant,"_or_<ORGANIZATION>ABMT </PERSON>
, <NA>
could <NA>
kill <NA>
lingering <NA>
tumor <NA>
cells <NA>
and <NA>
buy <NA>
her <NA>
a <NA>
lot <NA>
of <NA>
time. <NA>
But <NA>
her <NA>
health <NA>
insurer, <NA>
Travelers_Corp. <ORGANIZATION>
, <NA>
says <NA>
the <NA>
procedure <NA>
is <NA>
still <NA>
experimental, <NA>
hence <NA>
not <NA>
covered. <NA>
Lupro <NA>
,_who_says_she_may_sue_<ORGANIZATION>Travelers </PERSON>
to <NA>
get <NA>
an <NA>
ABMT <ORGANIZATION>
. <NA>
" <NA>
A <NA>
Travelers <ORGANIZATION>
spokeswoman <NA>
says <NA>
the <NA>
Lupro <PERSON>
case <NA>
is <NA>
"being <NA>
reviewed <NA>
with <NA>
an <NA>
outside <NA>
oncologist. <NA>
Preliminary <NA>
studies <NA>
on <NA>
ABMT <ORGANIZATION>
for <NA>
breast <NA>
cancer <NA>
indicate <NA>
it <NA>
may <NA>
work <NA>
better <NA>
than <NA>
conventional <NA>
alternatives <NA>
for <NA>
some <NA>
women. <NA>
A <NA>
recent <NA>
report <NA>
in <NA>
Tokyo <LOCATION>
showed <NA>
that <NA>
about <NA>
one-third <NA>
of <NA>
258 <NA>
metastatic <NA>
breast-cancer <NA>
patients <NA>
treated <NA>
with <NA>
ABMT <ORGANIZATION>
after <NA>
standard <NA>
chemotherapy <NA>
showed <NA>
no <NA>
signs <NA>
of <NA>
the <NA>
disease <NA>
in <NA>
follow-up <NA>
periods <NA>
of <NA>
12 <NA>
to <NA>
42 <NA>
months, <NA>
according <NA>
to <NA>
Bristol-Myers_Squibb_Co. <ORGANIZATION>
, <NA>
which <NA>
sponsored <NA>
the <NA>
meeting. <NA>
Karen_Antman <PERSON>
, <NA>
a <NA>
researcher <NA>
at <NA>
the <NA>
Dana-Farber_Cancer_Institute <ORGANIZATION>
in <NA>
Boston <LOCATION>
, <NA>
told <NA>
the <NA>
meeting <NA>
that <NA>
the <NA>
frequency <NA>
of <NA>
tumor <NA>
disappearance <NA>
in <NA>
certain <NA>
patients <NA>
is <NA>
"much <NA>
higher" <NA>
than <NA>
with <NA>
standard <NA>
chemotherapy. <NA>
But <NA>
the <NA>
treatment, <NA>
which <NA>
typically <NA>
costs <NA>
$100,000 <MONEY>
or <NA>
more, <NA>
is <NA>
risky. <NA>
About <NA>
9% <PERCENT>
of <NA>
patients <NA>
with <NA>
various <NA>
stages <NA>
of <NA>
breast <NA>
cancer <NA>
have <NA>
died <NA>
from <NA>
complications <NA>
after <NA>
the <NA>
therapy, <NA>
according <NA>
to <NA>
Most <NA>
doctors <NA>
say <NA>
that <NA>
more <NA>
data <NA>
on <NA>
ABMT <ORGANIZATION>
is <NA>
needed <NA>
to <NA>
establish <NA>
whether <NA>
it's <NA>
better <NA>
than <NA>
alternative <NA>
treatments. <NA>
ABMT <ORGANIZATION>
is <NA>
very <NA>
experimental <NA>
for <NA>
breast <NA>
cancer," <NA>
says <NA>
Subhash_Gulati <PERSON>
, <NA>
chief <NA>
of <NA>
the <NA>
ABMT <ORGANIZATION>
team <NA>
at <NA>
New_York <LOCATION>
's <NA>
Memorial <NA>
Sloan-Kettering <NA>
Cancer <NA>
Center. <NA>
Based <NA>
on <NA>
available <NA>
data, <NA>
"I <NA>
certainly <NA>
can't <NA>
conclude <NA>
that <NA>
{breast-cancer} <NA>
patients <NA>
are <NA>
better <NA>
off <NA>
with <NA>
ABMT <ORGANIZATION>
," <NA>
says <NA>
David_Eddy <PERSON>
, <NA>
a <NA>
Duke_University <ORGANIZATION>
health-policy <NA>
professor <NA>
and <NA>
a <NA>
consultant <NA>
to <NA>
the <NA>
Blue_Cross_&amp;_Blue_Shield_Association <ORGANIZATION>
. <NA>
The <NA>
stakes <NA>
in <NA>
the <NA>
ABMT <ORGANIZATION>
debate <NA>
are <NA>
large. <NA>
The <NA>
rate <NA>
of <NA>
breast-cancer <NA>
incidence <NA>
in <NA>
the <NA>
U.S. <LOCATION>
has <NA>
risen <NA>
sharply <NA>
in <NA>
the <NA>
past <NA>
decade, <NA>
though <NA>
the <NA>
mortality <NA>
rate <NA>
has <NA>
held <NA>
steady. <NA>
The <NA>
metastatic <NA>
form <NA>
will <NA>
develop <NA>
in <NA>
about <NA>
30% <PERCENT>
of <NA>
those <NA>
women, <NA>
with <NA>
most <NA>
patients <NA>
dying <NA>
within <NA>
two <NA>
years. <NA>
Doctors <NA>
testing <NA>
ABMT <ORGANIZATION>
for <NA>
breast <NA>
cancer <NA>
estimate <NA>
that <NA>
one-fourth <NA>
to <NA>
one-half <NA>
of <NA>
metastatic <NA>
cases <NA>
may <NA>
be <NA>
good <NA>
candidates <NA>
for <NA>
the <NA>
procedure <NA>
-- <NA>
if <NA>
it's <NA>
proved <NA>
effective. <NA>
Physicians <NA>
also <NA>
are <NA>
testing <NA>
ABMT <ORGANIZATION>
to <NA>
treat <NA>
high-risk <NA>
patients <NA>
before <NA>
metastasis, <NA>
as <NA>
well <NA>
as <NA>
people <NA>
with <NA>
testicular <NA>
cancer <NA>
and <NA>
melanoma. <NA>
For <NA>
certain <NA>
other <NA>
cancers, <NA>
such <NA>
as <NA>
leukemia, <NA>
ABMT <ORGANIZATION>
already <NA>
is <NA>
an <NA>
accepted <NA>
treatment <NA>
covered <NA>
by <NA>
insurers. <NA>
"It's <NA>
too <NA>
early <NA>
to <NA>
say <NA>
this <NA>
approach <NA>
is <NA>
right <NA>
for <NA>
public <NA>
consumption," <NA>
says <NA>
Jacob_Bitran <PERSON>
, <NA>
a <NA>
University_of_Chicago <ORGANIZATION>
cancer <NA>
researcher <NA>
testing <NA>
ABMT <ORGANIZATION>
. <NA>
"But <NA>
I've <NA>
never <NA>
seen <NA>
metastatic <NA>
breast <NA>
cancer <NA>
patients <NA>
respond <NA>
as <NA>
frequently" <NA>
as <NA>
they <NA>
do <NA>
with <NA>
ABMT <ORGANIZATION>
, <NA>
he <NA>
says. <NA>
Its <NA>
promise <NA>
appears <NA>
greatest <NA>
with <NA>
breast-cancer <NA>
patients <NA>
whose <NA>
cancers <NA>
respond <NA>
to <NA>
conventional <NA>
chemotherapy, <NA>
says <NA>
Nancy_Davidson <PERSON>
, <NA>
a <NA>
Johns_Hopkins_University <ORGANIZATION>
researcher. <NA>
To <NA>
prevent <NA>
that, <NA>
doctors <NA>
using <NA>
ABMT <ORGANIZATION>
extract <NA>
marrow <NA>
cells <NA>
from <NA>
patients' <NA>
pelvic <NA>
bones <NA>
through <NA>
needles <NA>
before <NA>
giving <NA>
them <NA>
anti-cancer <NA>
drugs. <NA>
Unlike <NA>
conventional <NA>
chemotherapy, <NA>
which <NA>
requires <NA>
shots <NA>
over <NA>
months <NA>
or <NA>
years, <NA>
anti-cancer <NA>
drugs <NA>
with <NA>
ABMT <ORGANIZATION>
are <NA>
administered <NA>
in <NA>
intense <NA>
doses <NA>
over <NA>
several <NA>
days. <NA>
But <NA>
the <NA>
advent <NA>
of <NA>
"colony <NA>
stimulating <NA>
factors" <NA>
-- <NA>
experimental <NA>
drugs <NA>
to <NA>
speed <NA>
immune-cell <NA>
growth <NA>
-- <NA>
and <NA>
other <NA>
recent <NA>
advances <NA>
"are <NA>
knocking <NA>
four <NA>
or <NA>
five <NA>
days <NA>
off" <NA>
that <NA>
period, <NA>
says <NA>
Chicago <LOCATION>
's <NA>
Deaths <NA>
from <NA>
the <NA>
treatment <NA>
now <NA>
occur <NA>
in <NA>
about <NA>
4% <PERCENT>
to <NA>
9% <PERCENT>
of <NA>
patients <NA>
who <NA>
are <NA>
treated <NA>
by <NA>
doctors <NA>
experienced <NA>
with <NA>
it, <NA>
compared <NA>
with <NA>
20% <PERCENT>
in <NA>
one <NA>
early <NA>
study, <NA>
says <NA>
Andrew_Dorr <PERSON>
, <NA>
a <NA>
National_Cancer_Institute <ORGANIZATION>
researcher. <NA>
Dorr <NA>
adds_that_the_<ORGANIZATION>NCI </PERSON>
plans <NA>
this <NA>
fall <NA>
to <NA>
organize <NA>
a <NA>
large <NA>
clinical <NA>
study <NA>
of <NA>
the <NA>
new <NA>
therapy <NA>
and <NA>
breast <NA>
cancer. <NA>
One <NA>
is <NA>
Pam_Pirozzi <PERSON>
, <NA>
a <NA>
35-year-old <NA>
mother <NA>
in <NA>
Tracy <LOCATION>
's <NA>
Landing, <NA>
Md. <LOCATION>
, <NA>
diagnosed <NA>
with <NA>
breast <NA>
cancer <NA>
last <NA>
year. <NA>
She <NA>
sued <NA>
her <NA>
insurer, <NA>
Blue_Cross/Blue_Shield <ORGANIZATION>
of <NA>
Virginia <LOCATION>
, <NA>
to <NA>
force <NA>
it <NA>
to <NA>
pay <NA>
for <NA>
an <NA>
ABMT <ORGANIZATION>
. <NA>
Last <NA>
month, <NA>
a <NA>
federal <NA>
judge <NA>
in <NA>
Alexandria <LOCATION>
, <NA>
Va. <LOCATION>
, <NA>
ruled <NA>
in <NA>
her <NA>
favor, <NA>
potentially <NA>
setting <NA>
an <NA>
important <NA>
precedent. <NA>
Now <NA>
she's <NA>
undergoing <NA>
conventional <NA>
therapy, <NA>
hoping <NA>
to <NA>
follow <NA>
it <NA>
up <NA>
with <NA>
ABMT <ORGANIZATION>
this <NA>
fall <DATE>
. <NA>
SJMN91-06051091 <DOCNO>
Among <NA>
California <LOCATION>
's <NA>
15 <NA>
largest <NA>
counties <NA>
in <NA>
1988 <DATE>
, <NA>
only <NA>
San_Francisco <LOCATION>
exceeded <NA>
the <NA>
overall <NA>
cancer <NA>
rate <NA>
in <NA>
the <NA>
nation <NA>
for <NA>
males, <NA>
officials <NA>
said. <NA>
; <NA>
State_Department_of_Health_Services <ORGANIZATION>
Director <NA>
Ken_Kizer <PERSON>
said <NA>
during <NA>
a <NA>
news <NA>
conference <NA>
that <NA>
the <NA>
state's <NA>
significant <NA>
populations <NA>
of <NA>
Hispanics <NA>
and <NA>
Asians <NA>
have <NA>
lower <NA>
rates <NA>
than <NA>
other <NA>
ethnic <NA>
groups, <NA>
which <NA>
may <NA>
explain <NA>
California <LOCATION>
's <NA>
overall <NA>
ranking <NA>
below <NA>
the <NA>
national <NA>
rate. <NA>
; <NA>
A <NA>
report <NA>
on <NA>
the <NA>
1987 <DATE>
and <NA>
1988 <DATE>
incidence <NA>
of <NA>
cancer <NA>
shows <NA>
that <NA>
rates <NA>
for <NA>
the <NA>
Los_Angeles <LOCATION>
region <NA>
were <NA>
the <NA>
lowest <NA>
in <NA>
the <NA>
state, <NA>
while <NA>
those <NA>
for <NA>
the <NA>
San_Francisco <LOCATION>
, <NA>
Sacramento <LOCATION>
and <NA>
Orange <NA>
county <NA>
areas <NA>
nearly <NA>
matched <NA>
those <NA>
of <NA>
the <NA>
nation. <NA>
; <NA>
The_American_Cancer_Society <ORGANIZATION>
hailed <NA>
the <NA>
news <NA>
of <NA>
the <NA>
lower <NA>
rates <NA>
in <NA>
California <LOCATION>
and <NA>
Los_Angeles <LOCATION>
, <NA>
but <NA>
University_of_Southern_California <ORGANIZATION>
cancer <NA>
experts <NA>
cautioned <NA>
that <NA>
the <NA>
report <NA>
may <NA>
provide <NA>
a <NA>
distorted <NA>
picture. <NA>
; <NA>
Leslie_Bernstein <PERSON>
, <NA>
scientific <NA>
director <NA>
of <NA>
the <NA>
USC-Los_Angeles_County_Cancer_Surveillance_Program <ORGANIZATION>
, <NA>
said <NA>
the <NA>
report <NA>
does <NA>
not <NA>
take <NA>
into <NA>
account <NA>
how <NA>
populations <NA>
vary <NA>
across <NA>
the <NA>
state <NA>
in <NA>
its <NA>
region-to-region <NA>
comparisons. <NA>
; <NA>
" <NA>
Los_Angeles_County <LOCATION>
appears <NA>
to <NA>
have <NA>
low <NA>
cancer <NA>
rates <NA>
because <NA>
it <NA>
has <NA>
more <NA>
Asians <NA>
and <NA>
Latinos <NA>
than <NA>
other <NA>
counties. <NA>
The <NA>
cancer <NA>
rates <NA>
of <NA>
Asians <NA>
and <NA>
Latinos <NA>
are <NA>
known <NA>
to <NA>
be <NA>
30_percent <PERCENT>
to <NA>
40_percent <PERCENT>
lower <NA>
than <NA>
those <NA>
of <NA>
blacks <NA>
and <NA>
whites," <NA>
Bernstein <PERSON>
said. <NA>
; <NA>
Among <NA>
the <NA>
major <NA>
findings <NA>
of <NA>
the <NA>
report:; <NA>
(check) <NA>
Breast <NA>
cancer <NA>
was <NA>
the <NA>
most <NA>
frequently <NA>
diagnosed <NA>
cancer <NA>
in <NA>
California <LOCATION>
. <NA>
In <NA>
1988 <DATE>
, <NA>
there <NA>
were <NA>
16,342 <NA>
cases <NA>
among <NA>
California <LOCATION>
women. <NA>
Overall, <NA>
the <NA>
California <LOCATION>
rate <NA>
was <NA>
lower <NA>
in <NA>
both <NA>
years <NA>
than <NA>
the <NA>
rate <NA>
for <NA>
the <NA>
nation. <NA>
; <NA>
(check) <NA>
Lung <NA>
cancer <NA>
was <NA>
the <NA>
second <NA>
most <NA>
frequently <NA>
diagnosed <NA>
cancer <NA>
in <NA>
1988 <DATE>
, <NA>
with <NA>
9,469 <NA>
cases <NA>
among <NA>
men <NA>
and <NA>
6,579 <NA>
cases <NA>
among <NA>
women. <NA>
AP900110-0062 <DOCNO>
Rose <NA>
Kushner <PERSON>
, <NA>
a <NA>
medical <NA>
writer <NA>
and <NA>
psychologist <NA>
and <NA>
forceful <NA>
advocate <NA>
for <NA>
women <NA>
with <NA>
breast <NA>
cancer, <NA>
has <NA>
died <NA>
of <NA>
the <NA>
disease <NA>
at <NA>
age <NA>
60. <NA>
Kushner <PERSON>
, <NA>
who <NA>
resided <NA>
in <NA>
Kensington <LOCATION>
, <NA>
Md. <LOCATION>
, <NA>
died <NA>
Sunday <DATE>
, <NA>
The <NA>
New_York_Times <ORGANIZATION>
reported <NA>
today. <NA>
She <NA>
gained <NA>
national <NA>
fame <NA>
in <NA>
1975 <DATE>
, <NA>
with <NA>
the <NA>
publication <NA>
of <NA>
``Why <NA>
Me? <NA>
Kushner <NA>
focused <NA>
her <NA>
energies <NA>
on <NA>
the <NA>
breast <NA>
cancer <NA>
crusade <NA>
in <NA>
1974 <DATE>
, <NA>
when <NA>
she <NA>
discovered <NA>
a <NA>
lump <NA>
in <NA>
her <NA>
breast <NA>
but <NA>
refused <NA>
to <NA>
submit <NA>
to <NA>
the <NA>
then-routine <NA>
``one-step'' <NA>
procedure. <NA>
Chabner <NA>
is <NA>
the <NA>
director <NA>
of <NA>
the <NA>
division <NA>
of <NA>
cancer <NA>
treatment <NA>
at <NA>
the <NA>
National_Cancer_Institute <ORGANIZATION>
in <NA>
Bethesda <LOCATION>
, <NA>
Md. <LOCATION>
``I <NA>
don't <NA>
think <NA>
the <NA>
public <NA>
would <NA>
have <NA>
accepted <NA>
it <NA>
or <NA>
even <NA>
known <NA>
about <NA>
it <NA>
if <NA>
she <NA>
had <NA>
not <NA>
been <NA>
so <NA>
persistent <NA>
in <NA>
her <NA>
efforts. <NA>
'' <NA>
Kushner <PERSON>
founded <NA>
and <NA>
was <NA>
director <NA>
of <NA>
the <NA>
Breast_Cancer_Advisory_Center <ORGANIZATION>
, <NA>
through <NA>
which <NA>
she <NA>
provided <NA>
women <NA>
with <NA>
information <NA>
about <NA>
their <NA>
options <NA>
when <NA>
faced <NA>
with <NA>
the <NA>
disease. <NA>
This <NA>
year, <NA>
she <NA>
was <NA>
scheduled <NA>
to <NA>
be <NA>
awarded <NA>
the <NA>
James_Ewing <PERSON>
award <NA>
from <NA>
the <NA>
Society <NA>
of <NA>
Surgical <NA>
Oncology <NA>
for <NA>
the <NA>
outstanding <NA>
contribution <NA>
by <NA>
a <NA>
non-physician <NA>
to <NA>
the <NA>
fight <NA>
against <NA>
cancer. <NA>
Her <NA>
husband, <NA>
Harvey_Kushner <PERSON>
, <NA>
called <NA>
this <NA>
``poetic <NA>
justice. <NA>
'' <NA>
In <NA>
1975 <DATE>
the <NA>
society's <NA>
members <NA>
had <NA>
booed <NA>
her <NA>
off <NA>
the <NA>
stage <NA>
after <NA>
she <NA>
challenged <NA>
their <NA>
standard <NA>
procedures. <NA>
Kushner <NA>
is <NA>
survived <NA>
by <NA>
her <NA>
husband; <NA>
her <NA>
sons, <NA>
Gantt_of_Silver_Spring <ORGANIZATION>
, <NA>
Md, <NA>
and <NA>
Todd_of_Rockville_Md. <ORGANIZATION>
; <NA>
a <NA>
daughter, <NA>
Lesley_Kushner <PERSON>
of <NA>
San_Francisco <LOCATION>
, <NA>
and <NA>
three <NA>
brothers. <NA>
FT932-12525 <DOCNO>
Death <NA>
rates <NA>
are <NA>
dropping <NA>
in <NA>
England <LOCATION>
, <NA>
Wales <LOCATION>
, <NA>
Finland <LOCATION>
and <NA>
Sweden <LOCATION>
, <NA>
have <NA>
plateaued <NA>
in <NA>
Australia <LOCATION>
, <NA>
Austria <LOCATION>
, <NA>
the <NA>
US <LOCATION>
, <NA>
Belgium <LOCATION>
, <NA>
Germany <LOCATION>
, <NA>
the <NA>
Netherlands <LOCATION>
, <NA>
New_Zealand <LOCATION>
and <NA>
Switzerland <LOCATION>
, <NA>
and <NA>
are <NA>
still <NA>
rising <NA>
in <NA>
Spain <LOCATION>
, <NA>
France <LOCATION>
, <NA>
Hungary <LOCATION>
, <NA>
Italy <LOCATION>
, <NA>
Ireland <LOCATION>
and <NA>
Poland <LOCATION>
. <NA>
Once <NA>
diagnosed, <NA>
less <NA>
than <NA>
30_per_cent <MONEY>
of <NA>
patients <NA>
are <NA>
eligible <NA>
for <NA>
curative <NA>
surgery, <NA>
explaining <NA>
in <NA>
part <NA>
the <NA>
dismal <NA>
chances <NA>
of <NA>
survival, <NA>
less <NA>
than <NA>
10_per_cent <MONEY>
five <NA>
years <NA>
after <NA>
diagnosis. <NA>
With <NA>
the <NA>
help <NA>
of <NA>
a <NA>
qualified <NA>
nutritionist, <NA>
also <NA>
try <NA>
limiting <NA>
saturated <NA>
(animal) <NA>
fats <NA>
to <NA>
less <NA>
than <NA>
25_per_cent <MONEY>
of <NA>
your <NA>
diet. <NA>
It <NA>
appears <NA>
to <NA>
be <NA>
on <NA>
the <NA>
increase <NA>
even <NA>
in <NA>
areas <NA>
where <NA>
it <NA>
was <NA>
previously <NA>
uncommon, <NA>
such <NA>
as <NA>
east <NA>
and <NA>
southeast <NA>
Asia <LOCATION>
. <NA>
Prostate <NA>
cancer <NA>
is <NA>
frequent <NA>
in <NA>
North_America <LOCATION>
and <NA>
Europe <LOCATION>
. <NA>
Incidence <NA>
and <NA>
mortality <NA>
increase <NA>
in <NA>
Chinese <NA>
and <NA>
Japanese <NA>
after <NA>
migrating <NA>
to <NA>
the <NA>
US <LOCATION>
. <NA>
When <NA>
it <NA>
comes <NA>
to <NA>
screening, <NA>
a <NA>
combination <NA>
of <NA>
Digital_Rectal_Exam <ORGANIZATION>
and <NA>
a <NA>
relatively <NA>
inexpensive <NA>
blood <NA>
test <NA>
is <NA>
probably <NA>
the <NA>
best <NA>
balance <NA>
between <NA>
cost, <NA>
benefit <NA>
and <NA>
efficacy. <NA>
The <NA>
author <NA>
is <NA>
medical <NA>
director <NA>
of <NA>
the <NA>
Insead_Business_Health <ORGANIZATION>
course. <NA>
